Vittorio Cristini

Top Italian Scientist in Mathematics

Modeling and Simulation to Support Drug Development and Optimize Treatment Outcomes

Poetry and Other Writings

Society

Vittorio CristiniPh.D.

• Citation metrics (h-index > 60; i10-index > 125)^[1]: https://scholar.google.com/citations?user=uwl5tw0AAAAJ&hl=en&oi=ao

• Top 0.5% in mathematics 2022. https://scholargps.com/scholars/80178551571443/vittorio-cristini

• ISI Highly-Cited Researcher in the Mathematics category 2014 (Thomson Reuters). http://highlycited.com

• Stanford—Scopus Top 2% Scholars List 2023. https://data.mendeley.com/datasets/btchxktzyw/6

• Top Italian Scientists List. https://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Mathematics.htm

• Websites (in progress): https://www.houstonmethodist.org/faculty/1mmune1o-cristini/ https://www.houstonmethodist.org/math-in-medicine/

PRESENT TITLES

• Professor of Computational Biology and Mathematics in Medicine2022-present

Department of MedicineThe Houston Methodist Research Institute

• Professor and ChairmanMathematics in Medicine Program2018-present

The Houston Methodist Research Institute

• ProfessorPopulation Health Sciences2021-present

Weill Cornell MedicineCornell University

• ProfessorPhysiologyBiophysics and Systems Biology2021-present

Weill Cornell MedicineCornell University2017-present

• Adjunct ProfessorDepartment of Imaging Physics

The University of Texas MD Anderson Cancer Center

Business Address: Houston Methodist Research InstituteR8-1236670 Bertner AvenueHouston Texas- 77030Email: [email protected] 505-934-1813

SHORT BIOGRAPHY AND PERSONAL STATEMENT

Since July 2018he has been with the Houston Methodist Research Institute (HMRI) as Professor and Chairman of the Mathematics in Medicine Programwhile his academic appointments are as Professor of PhysiologyBiophysics and Systems Biology at Cornell University Medical School and Professor of Computational Biology and Mathematics in Medicine at the Department of Medicine of Houston Methodist. He is also member of the graduate program and of the promotion and tenure committee at both institutions. Finallyhe is currently an Adjunct Professor of Imaging Physics at the MD Anderson Cancer Center. In the past decadesby focusing on clinical translation of mathematical and biophysical modelshe has established multiple localnationaland international collaborationsin order to combine forces and work towards multi-faceted and multi-disciplinary studies. More recentlyhis team has established several collaborations with research scientists and clinicians at the HMRI in different fields of interestincluding immunoncology (Dr. Shu-hsia Chen)and clinical translational cancer research (Drs. Jenny ChangEsnaola Kai and BernickerHouston Methodist Cancer Center). These collaborative efforts have resulted in the development of several successful grant applications. Over the yearsHe's also served as consultant or independent contractor for a number of pharma and biomedical device companies and as CFO for a neuroimaging society.^[2]

Scientific recognition

The collaborations and scientific output throughout the years have brought him international recognition as a “thought leader” of research excellence and leadership in the fields of mathematical and computational biologyapplied and computational mathematicsphysical oncologycomplex fluids and microfluidicsand multidisciplinary (bio)materials science. In 2014He was honored to be recognized ISI Highly-Cited Researcher in Mathematicsand had the privilege to be named one of the World’s “most influential scientific minds,” shared with less than 100 mathematicians worldwide. In his 27 years in researchhe has also had the privilege to serve as editor for several scientific journalsincluding Cancer ResearchNeuroImageFrontiersand PLOS Computational Biologyhe has published over 100 peer-reviewed journal articlesand two book monographs with Cambridge University Press in 2010 and with CRC Press in 2017. He has served as consultant and board member for a number of private companies^[3]and on several faculty committees at various academic institutions.

His work has been recognized through various awardsnationally and internationally. He was the first recipient of the “Andreas Acrivos Dissertation Award in Fluid Dynamics” by the American Physical Society in 2000 for my PhD thesis in Chemical Engineering at Yale University. His 2005 paper in the Bulletin of Mathematical Biology was in the top 0.1% of citations in the field of Mathematics and has been designated as a “New Hot Paper in the field of Mathematics” by the Institute for Scientific Information (ISI) Web of Knowledge; two articles have been featured in the Cancer Research Highlights of the American Association for Cancer Research. His research has been highly recognized internationally and by the media and several science museums in the USand has been supported by the Cullen Trust for Health CareArtidis corporationthe National Science Foundationthe National Institutes of Healththe Department of Defenseand the States of CaliforniaTexasand New Mexicoamong others.

Funding and strategic development

Over the past 20 yearshe has continually served in PI roles on several NSFNIHand DoD grants focused on the development of predictive multi-scalepatient-specific computational models of tumor growth and mechanistic mathematical models of tumor response to chemo/immunotherapytargeted therapyand nano-therapeuticsmost notably as part of multi-institutional grants including two NSF and joint NSF/NIGMS grants (funded in September 2017 and 2013respectively)two R01s beginning in April and July 2018two U01 NCI grants on pancreatic and gynecological cancers (funded in August 2015 and July 2017respectively)two NCI Physical Sciences in Oncology Centers (PS-OC)one NCI Center for Excellence in Cancer Nanotechnology (CCNE)of which he also served as the overall PI in 2015-2016one NCI Integrative Cancer Biology Program (ICBP) center grantand one NIGMS P50 grant in systems biologyseveral additional R01s and one SPORE grant. At UCIUNMUTHealthand HMRI he has developed and taught novel courses in Computational and Precision Biomedicineand have mentored and trained graduate studentspostdocsand junior facultyincluding mentees in the NIGMS Spatio-Temporal Modeling Center (STMC UNM) and the NIGMS-IRACDA Academic Science Education and Research Training (ASERT) programWeil-Cornell Graduate Schooland Rice University Applied Physics. He has also established important collaborations with industrial partners as wellincluding ARTIDIS (a company based in BaselSwitzerland)and AstraZeneca. One of the major goals behind this type of strategic network of preclinical and clinical collaborations with mathematicalphysical scientistsand engineers is to develop new intellectual property (IP) centered around mathematical interpretation of clinically relevant data methods to predict and optimize therapy outcome.

Modeling-supported clinical translation

He pioneered the field of “Physical Oncology”which aims at using mathematical modelingphysical theoriesand engineering approaches to describe and quantify biological mechanisms that play important roles in the growth of cancer and in response to therapies. With a solid background and experience in Applied Mathematics and Chemical Engineeringand specifically in the development of theories and numerical methods in Complex Fluids and MaterialsHe is dedicated to applying and adapting engineering and physical sciences approaches to the modeling of complex normal and pathologic biological tissue. One important approach he has been leading is focused on investigating the effects of diffusionperfusionand transport phenomena on cancer growth and dissemination rateand on the development of resistance to drug or other systemic therapies. All the models and approaches developed within this framework integrate input from patient and experimental data (ACS Nano 2013PLOS Computational Biology 20132016PLOS One 20132016Scientific Reports 2018Nature Communications 2018JCI Insight 2019). These efforts have been supported by the National Cancer Institute’s (NCI) Physical Science in Oncology (PS-OC) and the Center for Excellence in Cancer Nanotechnology funding mechanisms (three U54s funded) and regular R01-type funding from the National Science Foundation and National Institutes of Health. In line with this type of workI have also made important discoveries on the role of physical transport in drug resistance in patients (JCI 2014PNAS 20132016Clin Cancer Res 2018Science Advances 2020Nature BME 2021ELife 2022). Currentlya first-of-kind effort is underway at the MD Anderson Cancer Centerthe Baylor College of Medicineand the Houston Methodist Cancer Centertowards the development of prospective clinical trials (and retrospective clinical studies) based on my mathematical models of physical transport in tumors to elucidate the role of physics in overall resistance to cancer chemotherapy and immunotherapy drugs.

His translational modeling effort is part of an ongoing collaboration with biologistsoncologistsand nanotechnologists at MD Anderson Cancer Center (Drs. Anirban MaitraGabriel Lopez-BeresteinAnil SoodDavid HongJen WargoGeorge CalinBulent OzpolatEugene KoaySubrata SenJames WelshMary EdgertonJohn HazleAhmed Kaseband Christopher Crane among the others)Moffitt Cancer Center (Drs. Jason FlemingDaniel Anaya)Baylor College of Medicine (Drs. Alastair ThompsonMichael Lewisand Jeff Rosen)UNM (Drs. Jeffrey BrinkerElaine BearerCheryl Willman)Rutgers University (Drs. Wadih ArapRenata PasqualiniDaniela Staquicini)Stanford University School of Medicine (Dr. Sam Gambhir)USC School of Medicine (Dr. David Agus)and Houston Methodist (Drs. Haifa ShenShu-hsia ChenAlessandro Grattoniand others). To properly account for the purely biological phenomena affecting this tissue physicsthey developed data-driven cell signaling and molecular interaction modelsincluding under the umbrella of the NCI ICBP program (one additional U54 funded) in collaboration with the Baylor College of Medicine and also in collaboration with UNM (Cancer Res 2009a,bPhysical Biology 2012PLOS Comput Biol 2016).

Education and outreach

As a scientific leaderhe also contributed to developing outreach and education initiatives to promote novel approaches and results coming from the field of physical oncology. In particularwith the support of the NCIthey have developed a series of educational workshops (most notably: The Ohio State University workshop on “The role of biomedical informatics in overcoming current barriers in cancer research” 2008; and the National Cancer Institute meeting: “Integrating and Leveraging the Physical Sciences to Open a New Frontier in Oncology” 2008). These efforts led to the creation of the PS-OC program by the NCI. An introduction to this new field was developed in my book monograph on multiscale mathematical modeling of tumor growthCambridge University Press (2010). A second monographtitled “An Introduction to Physical Oncology”was published by CRC Press in 2017where new mathematical models of physical transport processes (including our recent modeling work) that use patient tissue and imaging data to predict the efficacy of 6mmune/chemotherapy and radiation therapy are introduced and discussed.

In his careerhe has also had the pleasure to serve as mentor to ca. 100 traineesincluding graduate studentspostdocs and junior facultyand many of them have gone on to successful research and academic careers (e.g.Dr. Paul MacklinIndiana University; Dr. Steven WiseThe University of Tennessee; Dr. Hermann FrieboesUniversity of Louisville; Dr. Jennifer PascalUniversity of ConnecticutDrs. WangDograNizzero and ButnerHMRI). His current research group is highly interdisciplinaryand includes undergraduate studentsgraduate studentspost-doctoral fellowsresearch associatesand junior faculty in the field of biophysicsapplied physicsengineeringstatisticsmathematical modelingimagingand immunology.

Citizenship

United States of AmericaItaly

Undergraduate Education

1989 – 1994 University of Rome – La SapienzaLaurea DegreeSumma cum LaudeNuclear Engineering

Graduate Education

1995 – 1996 Yale UniversityNew HavenConnecticutM.S.Chemical Engineering

1996 – 1998 Yale UniversityNew HavenConnecticutM.Phil.Chemical Engineering

1998 – 2000 Yale UniversityNew HavenConnecticutPh.D.Chemical EngineeringThesis: “Drop dynamics in viscous flow”

Postgraduate Training

2000 – 2002 University of MinnesotaMinneapolisMinnesotaPostdoctoral AssociateChemical Engineering and Materials Science

2001 – 2002 University of MinnesotaMinneapolisMinnesotaPostdoctoral AssociateInstitute for Mathematics and its Applications

Academic and Administrative Appointments

2022-present Houston Methodist Department of MedicineProfessor of Computational Biology and Mathematics in Medicine

2021-present Weill Cornell MedicineCornell UniversityProfessor of Population Health Sciences

2020-present Weill Cornell MedicineCornell UniversityProfessorGraduate School of Medical Sciences

2018-present The Houston Methodist Research Institute (HMRI)Professor & DirectorMathematics in Medicine Program

2017-2018 The University of Texas Health Science Center at Houston McGovern Medical SchoolCo-director of the Nanochemistry and 3D-printing Service Center Institute for Molecular Medicine; Co-director of the Proteomics Service CenterInstitute for Molecular Medicine

2017-present The University of Texas MD Anderson Cancer CenterAdjunct ProfessorDepartment of Imaging Physics

2016–2018 The University of Texas Health Science Center at Houston McGovern Medical SchoolProfessor with tenure and DirectorCenter for Precision BiomedicineThe Brown Institute of Molecular Medicine

2015–2016 The University of Texas Health Science Center at Houston McGovern Medical SchoolVisiting Professor and ChairmanDepartment of Nanomedicine and Biomedical Engineering; ProfessorCenter for Proteomics and Systems BiologyThe Brown Institute of Molecular Medicine

2015-2018 Department of NanomedicineFull Affiliate MemberHMRI

2014 – 2015 King Abdulaziz UniversityJeddahSaudi ArabiaDistinguished Adjunct ProfessorDepartment of Mathematics

2012 – 2018 The Methodist Hospital Research InstituteSenior Scientist Fellow

2010 – 2015 University of New MexicoAlbuquerqueNew MexicoProfessorDepartment of Chemical and Nuclear Engineering; ProfessorCenter for Biomedical EngineeringThe Victor and Ruby Hansen Surface Professor in the Molecular Modeling of CancerUNM Cancer Center; Director of Computational BiologyDepartment of Pathology; Professor with TenureDepartment of Pathology

2009 – 2010 University of Texas Health Science Center at HoustonTexasProfessorDepartment of Biomedical Engineering; DirectorCenter for Computational BiomedicineSchool of Biomedical Informatics; Professor with TenureSchool of Biomedical Informatics

2009 – 2010 University of Texas MD Anderson Cancer CenterHoustonTexasAssociate ProfessorDepartment of Systems BiologyDivision of Cancer Medicine

2009 – 2010 University of Texas at AustinTexasProfessorDepartment of Biomedical Engineering

2009 – present University of DundeeScotlandUKHonorary ProfessorDepartment of Mathematics

2009 – 2010 Scottish Universities Life Sciences AllianceScotlandUKProfessor

2009 Auvergne UniversityClermont-FerrandFranceChair of Excellence in Neurosurgery

2007 – 2009 University of Texas MD Anderson Cancer CenterHoustonTexasAssociate ProfessorDepartment of Systems BiologyDivision of Cancer Medicine

2007 – 2009 University of Texas at AustinTexasAssociate ProfessorDepartment of Biomedical Engineering

2006 – 2009 University of Texas Health Science Center at HoustonTexasAssociate ProfessorDepartment of Biomedical EngineeringAssociate ProfessorSchool of Biomedical Informatics

2006 – 2007 University of CaliforniaIrvineCaliforniaAssociate ProfessorDepartment of Mathematics

2005 University of NaplesItalyVisiting Assistant ProfessorDepartment of Chemical Engineering

2002 – 2006 University of CaliforniaIrvineCaliforniaAssistant ProfessorDepartment of Biomedical Engineering; Assistant ProfessorDepartment of Mathematics

2002 University of MinnesotaMinneapolisMinnesotaMentor FacultyNIH-National Institute of Dental Craniofacial Res.T32 Training Grant; Visiting Assistant ProfessorSchool of Mathematics

Positions at National/International Professional Organizations

2018 – present Consulting History Information available upon request

2016 – 2017 Society for Brain Mapping & Therapeutics (SBMT)Science Committee Member

2006 – 2007 International Brain Mapping and Intra-operative Surgical Planning FoundationChief Financial Officer

2005 – 2007 Centre for Molecular (Bio) MedicineTriesteItalyScientific Advisory Board Member

2004 – 2006 Orqis Medical/Edwards LifesciencesConsultant

2004 – 2007 International Brain Mapping and Intra-operative Surgical Planning SocietyBoard of Directors

2004 – 2007 American Institute of Chemical EngineersFluids Programming Committee Member

HONORS AND AWARDS

• EnMed Capstone Innovator AwardTexas A&M U & Houston Methodist2023/9. (Award recipient: Gayatri PrakashMentor: Zhihui Wang)

• Wolfram Innovators Award (an International award by Wolfram Technology); for using Mathematica for mathematical modeling to predict cancer patient response to immune checkpoint inhibitor immunotherapy on a per-patient basisusing only current standard-of-care clinical measuresand at times earlier after start of treatment than current response assessment standards are able to provide2021/10. (with Joseph D. Butner and Zhihui Wang)

• Career Cornerstone Award2021/4Houston Methodist. (with Zhihui Wang)

• President’s Award for Excellence in Peer-Reviewed Publication for “A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden,” in Nature Biomedical Engineering2021/1Houston Methodist (with Joseph D. Butner and Zhihui Wang)

• The Cockrell Foundation Professorship Award to support mathematical modeling efforts in infectious diseases research at HMRI. 2021-2024. (with Prashant Dogra)

• News press featuring paper Dogra et al.ACS Pharmacology & Translational Science 2021DOI: 10.1021/acsptsci.0c00183: New York Times Medical SciencesNews Medical

• News press featuring paper Butner et al.Sci Adv 2020PMC7190324: AAAS EurekAlert!Medical XpressScience Magazine7th floorNews MedicalNew BreakBright SurfAdvanced Science NewsMJH Life ScienceX-MOLNews Break

• Featured article: “A Multiscale Agent-Based Model of Ductal Carcinoma in Situ,” by Butner et al.IEEE TBME 2020 May.

• Excellence in Mentoring Award 2019. Methodist Association for Postdoctoral and Trainee Affairs. (Postdoc: Sara Nizzero)

• Award for Excellence in Peer-Reviewed Publication for “Establishing the Effects of Mesoporous Silica Nanoparticle Properties on in vivo Disposition Using Imaging-Based Pharmacokinetics,” in Nature Communications 2018Houston Methodist

• Government of Mexico CONACYT Fellowship2018-Present (Student: Maria Jose Pelaez SoniRice University)

• Ph.D. Thesis “with distinction” (Student: J. ButnerCenter for Biomedical EngineeringUNM)July 2017. · Invited feature in Global Health & Pharma 2016www.ghp-magazine.com

• Invited contributions to Open Access Government2015-2021

• Endowed Chair – Rochelle and Max Levit Chair in the NeurosciencesThe University of Texas Health Science Center at Houston McGovern Medical School. 2016-2018

• UT STAR award – The University of Texas System – Science and Technology Acquisition and Retention (STARS). 2015 “Mathematical modeling integrated with experiments and clinical trials to understand tumor heterogeneitydrug delivery and treatment outcome” ($1,000,000)

• V CristiniEJ KoayZ Wang. Taking cancer out of the equation. International Innovation 2015 (September) 191: 38-40.

• Named as one of the “World’s Most Influential Scientific Minds” in 2014 by Thomson Reuters. http://highlycited.com

• Named in 2014 by the Institute for Scientific Information (ISI)Thomson Reutersas one of 99 Highly-Cited Researchers in Mathematics worldwide. http://highlycited.com

• Endowed Professorship – The Victor and Ruby Hansen Surface Professor of Molecular Modeling of CancerUniversity of New Mexico Cancer Center2010-2015.

• Recent Articles and News Reportsfeaturing Dr. Cristini’s latest research have appeared in 2013-2015including in: The Business Journals; ABC News and local TV and radio shows; several daily newspapers; The Morning Brew; AdvanceWeb; Newswise; The Stanford Biomedical Computation Review (see below for detailed media coverage links)

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship2013-2014 (Student: Romica KerkettaUNM)

• 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship (Student: Terisse BrocatoUNM)

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship2014-2016 (Student: Terisse BrocatoUNM)

• The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship2014-2016. (Student: Prashant DograBiomedical SciencesUniversity of New Mexico)

• NIGMS-IRACDA Academic Science Education and Research Training (ASERT) K12GM088021 postdoctoral fellowship (Jennifer Pascal)

• PS-OC Newsletter 2014“Physical Transport Properties Could Predict Outcomes for Patients with Cancer”

• Young Oncologist Essay AwardAmerican Radium Society’s 95th Annual MeetingApril 27 – May 12013ScottsdaleArizona (E Koay)

• Front cover of Physical BiologyOctober 2012

• Articles by van de Ven et alAIP Advances 2012and by Chauviere et al.AIP Advances 2012selected for inclusion in the Virtual Journal of Nanoscale Science & TechnologyApril 2012

• Chair of Excellence in NeurosurgeryAuvergne UniversityClermont-FerrandFrance2009

• Highly Accessed BioMed Central Paper (SangaS. et al.BMC Medical Genomics 20092:59)

• SULSA Professor 2009-2010 (Scottish Universities Life Sciences Alliance)

• Front cover of Nonlinearity 2010

• Honorary Professor of MathematicsUniversity of DundeeScotland UK2009-present

• Founding Member of International Academy of Nanomedicine (IANM)2009-present

• Active Member (by invitation) of American Association for Cancer Research (AACR)2009-present

• Cancer Research HighlightsMay 15 2009: “Multi-parameter Computational Modeling of Tumor Invasion.” (Cancer Research 2009 69: 4493-4501)

• Interview on National Public RadioMay 25 2009“Math Could Help Solve Cancer Tumor Mysteries,” by Jack Williams.

• Special Feature of article: “Prediction of drug response in breast cancer using integrative experimental/computational modeling,” by Frieboes et al.Cancer Research 2009at the American Association for Cancer Research annual meetingDenverCO 2009.

• Special Feature of article: “Multi-parameter Computational Modeling of Tumor Invasion,” by Bearer et al.Cancer Research 2009at the American Association for Cancer Research annual meetingDenverCO 2009.

• Special feature of Dr. Cristini’s project “Virtual Cancer” at the event “Gratias Dono” – Gifts that change lifeorganized by the University of Texas Health Science Center to honor medical philanthropy. Houston Country ClubFebruary 4 2009.

• 2008 STEP-UP Clinical and Research Internship Award for Research Excellence—MD Anderson Cancer Center (Undergraduate student: Deepa Raghunathan)

• Featured in Forbes magazine – “Can Mathematics Cure Cancer?” 27 October2008

• Video exhibit of Cristini’s cancer simulations in the Boston Museum of Science2008

• Front cover of Journal of Mathematical Biology 2008

• Featured in the Cancer Bulletin of the National Cancer Institute (“The mathematics of cancer”Cancer Bulletin July 102007 – Vol. 4 / Number 21)

• FellowAmerican Academy of Nanomedicine2006-present

• Front cover of Bulletin of Mathematical Biology 2006-2009

• Cancer Research HighlightsFeb 1 2006: “Simulation model predicts tumor invasion in marginal environmental conditions.” (Cancer Res 2006; 66(3):1597-604)

• UNCF-MERCK Graduate Science Research Dissertation Fellowship2006-2008 (Student: N DeMagalhaes).

• NIH Graduate Fellowship2006-2008 (Student: N DeMagalhaes)

• Biomedical Engineer of the yearThe Henry Samueli School of EngineeringUniversity of California at Irvine2006 (Student: K. Velasco)

• New Hot Paper in the field of MathematicsJul 2006Thomson-Scientific Essential Science Indicators (Bull Math Biol. 2005; 67(2):211-59)

• B. S. Honors ThesisU. of Minnesota 2004 (Student: A. Anderson)

• · Physical Sciences Faculty Endowed AwardU.C. Irvine2003-4 (Student: X. Zheng,)

• Research ScholarshipMinnesota Supercomputing InstituteUniv of Minnesota2001

• Andreas Acrivos Dissertation Award in Fluid DynamicsAmerican Physical Society—Division of Fluid Dynamics 2000“For important theoretical and numerical contributions to the description and understanding of drop dynamics and breakup in laminar and turbulent flows”

• Henry Prentiss Becton Dissertation AwardYale 2000“For exceptional achievements in the field of Engineering and Appl. Sci.”

• Outstanding Paper AwardAmerican Institute of Chemical Eng 1997

• Harold Cheel Fund Graduate FellowshipYale U. 1995

• Ente Nazionale Energia Atomica (ENEA) FellowshipItaly1994-1995

• University of Rome – La Sapienza. Laurea DegreeSumma cum LaudeNuclear Engineering1994

Media coverage (selected)

DograP. et al. JCI Insight 2023 PMC10371350 DOI: 10.1172/jci.insight.169860

Newswise: https://www.newswise.com/coronavirus/study-suggests-longer-time-between-covid-19-vaccines-more-effective-for-some/?article_id=790807

Becker’s Hospital Review: https://www.beckershospitalreview.com/public-health/new-covid-19-bivalent-booster-may-require-customized-dosing-study.html

Houston Methodist Newsroom: https://www.houstonmethodist.org/newsroom/study-suggests-longer-time-between-covid-19-vaccines-more-effective-for-some/

Medical Xpress: https://medicalxpress.com/news/2023-04-longer-covid-vaccines-effective.html

Butner et al.eLife2021 PMID: 34749885 DOI: 10.7554/eLife.70130.

eLife Press ReleaseModel predicts early response to cancer immunotherapy https://elifesciences.org/for-the-press/4e89e409/model-predicts-early-response-to-cancer-immunotherapy

X-MOL https://en.x-mol.com/paper/article/1392261663514148864

Society https://sciety.org/articles/meta/10.1101/2021.05.10.21256419

Technology Networks Mathematical Model Designed to Predict Early Response to Immunotherapy https://www.technologynetworks.com/cancer-research/news/mathematical-model-designed-to-predict-early-response-to-immunotherapy-355667

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2021-02/hm-mmd020121.php

ScienceNet.cn by China Science Daily

http://news.sciencenet.cn/htmlpaper/2021/1/202111116585021860733.shtm?id=60733

https://mp.weixin.qq.com/s/vO0S5yqUJEAPW0HusY0z-g

X-MOL

https://www.x-mol.com/paper/1346548820336594944

NewsBreak

https://www.newsbreak.com/news/2138602865734-a-mathematical-model-for-the-quantification-of-a-patients-sensitivity-to-checkpoint-inhibitors-and-long-term-tumour-burden

Nonur.com

https://nonur.com/2021/02/02/mathematical-method-developed-to-predict-cancer-and-drug-specific-immunotherapy-efficacy/

Nature in Facebook

https://m.facebook.com/nature/posts/10158296561028167

Nature Bioengineering Community

Towards providing physicians with a quantitative tool for optimizing immunotherapy treatment protocols for each individual patient https://bioengineeringcommunity.nature.com/posts/towards-providing-physicians-with-a-quantitative-tool-for-optimizing-immunotherapy-treatment-protocols-for-each-individual-patient

Diagnostics World

Mathematical Model of Treatment Response ‘Designed For Clinical Translation’ https://www.diagnosticsworldnews.com/news/2021/03/04/mathematical-model-of-treatment-response-designed-for-clinical-translation

The Naked Scientist (BBC)

https://www.bbc.co.uk/sounds/play/p0915r4r

Science Daily

https://www.sciencedaily.com/releases/2020/12/201210112118.htm

AP News

https://apnews.com/press-release/pr-newswire/business-pandemics-public-health-products-and-services-coronavirus-pandemic-d69af76f4657a6cce42b7600a67fdb39

News Medical

https://www.news-medical.net/news/20201210/Researchers-find-new-method-for-safe-and-effective-delivery-of-medicines-to-the-lungs.aspx

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2020-12/cp-ivi120320.php https://www.youtube.com/watch?v=wLi0LciskaY&t=13s https://twitter.com/Gut_BMJ/status/1338527208718131206

Social Media

https://www.youtube.com/watch?v=wLi0LciskaY&t=13s

https://twitter.com/Gut_BMJ/status/1338527208718131206

https://www.facebook.com/permalink.php?id=123423901047095&story_fbid=3718876078168508

News Medical

https://www.news-medical.net/news/20201108/Innate-immunity-key-to-limiting-viral-load-in-COVID-19-cases.aspx

AAAS EurekAlert!

https://www.eurekalert.org/pub_releases/2020-04/hm-cmm042920.php

Medical Press

https://medicalxpress.com/news/2020-04-clinically-applicable-math-patient-outcomes.html

Science Magazine

https://scienmag.com/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy/

7th floor

http://7thspace.com/headlines/1180408/clinically_applicable_math_model_predicts_patient_outcomes_to_cancer_immunotherapy.html

News Medical

https://www.news-medical.net/news/20200430/New-math-model-predicts-clinical-outcomes-in-cancer-patients-treated-with-immunotherapy.aspx

NewsBreak

https://www.newsbreak.com/texas/houston/news/0Ov2e42o/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy

Bright Surf

https://www.brightsurf.com/news/article/043020508630/clinically-applicable-math-model-predicts-patient-outcomes-to-cancer-immunotherapy.html

Advanced Science News

https://www.advancedsciencenews.com/a-mathematical-model-to-predict-patient-response-in-cancer-immunotherapy/

The Business Journals

http://www.bizjournals.com/albuquerque/print-edition/2013/08/23/vittorio-cristini-everything-clicked.html

ABC News

http://www.koat.com/news/new-mexico/albuquerque/Cancer-Math/-/9153728/21512452/-/14irq94z/-/index.html

AdvanceWeb

http://laboratory-manager.advanceweb.com/Archives/Article-Archives/Perspectives-in-Pathology-19.aspx

Newswise

http://www.newswise.com/articles/unm-cancer-center-scientist-develops-a-numbers-approach-to-treatment

The Stanford Biomedical Computation Review

http://biomedicalcomputationreview.org/content/cancer%E2%80%99s-crystal-ball-personalized-tumor-models-guide-treatment

Santa Fe New Mexican

http://www.santafenewmexican.com/news/health_and_science/article_905465f9-5772-5c7d-a99e-d73fa07aca41.html

UNM Cancer Center Press Release

http://cancer.unm.edu/files/2013/08/FINAL_20130812_Predictive-Modeling-DrCristini_PR.pdf

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-uses-physics-again-to-fight-cancer/

KSFR SF (radio interview)

http://cancer.unm.edu/newsroom/dr-cristini-fights-cancer-using-an-unconventional-approach/

Albuquerque The Magazine

http://cancer.unm.edu/files/2014/07/Albuquerque-The-Magazine-Dr.-Cristini_2.pdf

The Morning Brew

https://www.youtube.com/watch?v=p9fxhWKnD0g

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-develops-a-numbers-approach-to-treatment/

UNM HSCTV

https://www.youtube.com/watch?v=k-TalZh8y0s

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/dr-cristini-named-influential-scientific-mind/

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/dr-cristini-uses-math-customize-breast-cancer-therapy/

UNM Cancer Center Press Release

http://cancer.unm.edu/newsroom/unm-cancer-center-scientist-recognized-one-influential-scientific-minds/

International Innovation

http://www.internationalinnovation.com/taking-cancer-out-of-the-equation/

American Physiological Society

https://www.newswise.com/articles/fighting-cancer-with-math

Open Access Government

1. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14
2. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics-2/21536/
3. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics/21432/
4. https://www.openaccessgovernment.org/profile-combining-biology-physics-solve-cancer-problem/22371/
5. https://www.openaccessgovernment.org/mathematical-relationship-immune-system-cancer-implications-cancer-therapy/22262/
6. https://www.openaccessgovernment.org/profile-mathematical-pathology-determining-surgical-volume-breast-cancer-treatment/23968/
7. https://www.openaccessgovernment.org/cancer-diagnosis-and-treatment/25598/
8. https://www.openaccessgovernment.org/understanding-cancer-physics/25938/
9. https://www.openaccessgovernment.org/spatio-temporal-mathematical-model-cancer/28963/
10. https://www.openaccessgovernment.org/integrated-non-invasive-cancer-diagnosis/31174/
11. https://www.openaccessgovernment.org/tissue-scale-factors-predicting-cancer-treatment-outcome/32302/
12. https://www.openaccessgovernment.org/stem-cell-transdifferentiation/36169/
13. https://www.openaccessgovernment.org/dilemma-diagnosis-pancreatic-cysts/35088/
14. https://www.openaccessgovernment.org/identifying-pancreatic-cysts-might-turn-cancer/34409/
15. https://www.openaccessgovernment.org/multimodal-feedback-control-can-lead-self-organizing-morphogenesis/34429/
16. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=558600cb-8de9-4616-9242-f8f3b41da315&pnum=78
17. https://www.openaccessgovernment.org/regenerative-medicine-to-trump-cancer/53150/
18. https://www.openaccessgovernment.org/mathematical-modelling-nanoparticle-pharmacokinetics/68801/
19. https://www.openaccessgovernment.org/wp-content/uploads/2019/10/OAG24-WEB.pdf
20. https://www.openaccessgovernment.org/oncology/78946/
21. Nizzero SPlodinec MWang ZCristini. Giving oncology its power back: A clinical technology revolution is conquering the US from Texas (December 2019). https://www.openaccessgovernment.org/oncology/78946/
22. https://www.openaccessgovernment.org/graph-theory-in-the-study-of-alzheimers-disease-progression/83621/
23. https://www.openaccessgovernment.org/body-dynamics-of-sars-cov-2-treatment-of-covid-19/86929/
24. Butner et al.“Personalized prediction of immunotherapy efficacy: improving clinical approaches via mechanistic mathematical modeling”Open Access GovernmentJanuary 2021: p. 116-117. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=abe4b9c2-2198-40d4-9b41-c05d7aaff94f
25. DograP.CristiniV.“Is the Pandemic Obeying the Elliott Wave Principle of Financial Markets?” (April 2021). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14
26. PeláezM.J.DograP.CristiniV. “Impact of mathematical modeling in understanding and controlling the COVID-19 pandemic” (October 2021) https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=eaaa2691-f2e2-4ecd-9e5e-f2985210b663

Open Access Government

1. eBook: http://www.adjacentgovernment.co.uk/wp-content/uploads/2016/01/Uni-of-Texas-ebook-web.pdf
2. eBook: https://www.openaccessgovernment.org/mathematical-modeling-drug-delivery-via-nanoparticles-cancer-treatment/27830/

Global Health & Pharma

Invited e-book: “Mathematical Pathology” in Global Health & Pharma 2016www.ghp-magazine.com

Editorial Board (selected)

2023 – present Cancers (Guest Editor)

2022 – present Frontiers in Physiology (Guest Editor)

2021 – present Nanomaterials (Guest Editor)

2013 – present PLOS Computational Biology (Guest Editor)

2011 – present Frontiers in Computational Physiology and Medicine

2010 – present World Journal of Clinical Oncology

2009 – present Open Journal of Neuroscience (Ross Science Publishers)

2008 – present Cancer Research (American Association of Cancer Research)

2007 – present Open Biomedical Engineering Journal (Bentham Science)

2007 – present Journal of Serbian Society for Computational Mechanics

2006 – 2007 NeuroImage (Elsevier)

2004 – present Journal of Biomedical Nanotechnology (American Scientific Publishers)

2004 – present Biomedical Microdevices (Springer)

Selected: Invitations for Service on National Grant Review PanelsStudy SectionsCommittees (mentee involved)

• Early Career Fellowship reviewThe India Alliance5/2023 (Z Wang)

• NIH/NCI Clinical and Translational Cancer Research review meeting on breast cancer (R03/R21)5/2023 (Z Wang)

• NIH special emphasis panel BBBT for Biodata and Biomodeling2/2023 (Z Wang)

• DOD Breast Cancer Program (BCRP) Clinical and Experimental Therapeutics 1 (CET-1) review panel7/2022 (Z Wang)

• NIH/NCI Program Project V (P01) Special Emphasis Panel (SEP) for PAR-20-077 (National Cancer Institute Program Project ApplicationsP01)6/2022 (Z Wang)

• NIH Modeling and Analysis of Biological Systems (MABS) study section2/8-92022 panel member · The Research Foundation Flanders (FWO)Review College. 2022-present

• NIH special emphasis panel for Academic-Industrial Partnerships for Translation of Medical TechnologiesZRG1 SBIB,10/25-26 (Z Wang)

• NIH Modeling and Analysis of Biological Systems (MABS) study section panel on October 21-222021

• European Science foundation reviewer: Research Foundation Flanders call for Junior and Senior Research Projects2021

• NIH/NCI Program Project V (P01) Special Emphasis Panel (SEP)for PAR-20-077 (National Cancer Institute Program Project ApplicationsP01)6/10-112021 (Z Wang)

• RFS/SRFSScienceTechnologyEngineering and Mathematics Selection Panel (STEM Panel)The Research Grants Council (RGC) of Hong Kong4/2021 (Z Wang)

• NIH Special Emphasis Panel ZCA1 RPRB-H (M2)3/19/21 (P Dogra)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment2/22-232021 (Z Wang)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment6/292020 (Z Wang)

• NIH Small Business Innovation Research (SBIR) review panelco-chair2/122021

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment2/32020 (Z Wang)

• European Science foundation: I-SITE ULNE (Université Lille Nord-Europe)Program for Early-stage Researchers in Lille (PEARL). 19-Lille-PEARL-007

• Appel A Projects 2019:Inserm – Département de l’Evaluation et du Suivi des Programmes (DESP)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment10/10-112019 (Z Wang)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment6/24-252019 (Z Wang)

• NIH MABS Study SectionSpecial Emphasis Panel/Scientific Review Group2/14-152019.

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment2/82019 (Z Wang)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment10/15-162018 (Z Wang)

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment6/152018 (Z Wang)

• NIH Special Emphasis Panel2018/05 ZRG1 BST-H (2)Bioengineering Sciences and Technologies4/4 2018

• NIH special emphasis panelZRG1 SBIB-Q 57Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment2/22-232018 (Z Wang)

• The Dutch Cancer Society (KWF Kankerbestrijding)external reviewer 2018

• The Netherlands Organisation for Scientific Research (Ithe Dutch Research Council)external reviewer 2018

• Cancer TMOIFrench National Alliance for Life and Health Sciences (AVIESAN) jointly with the French National Cancer Institute (INCa) – mail reviewer in the field of multidisciplinary approaches in modeling complex biological processes applied to cancer2017

• Sinergia funding instrumentSwiss National Science Foundation (SNSF) external reviewer 2018

• Science Committee – Multidisciplinary Project Award 2018Cancer Research UK

• BSF (United States-Israel Binational Science Foundation)external reviewer 2018

• Medical Research Council (MRC)UK2017. Mail reviewer invitation

• Office of Sponsored Research (OSR) Competitive Research Grants (CRG)Mail review 2017King Abdullah University of Science and Technology (KAUST)Saudi Arabia

• Netherlands Organisation for Scientific Research (Ithe Dutch Research Council)Innovational Research Incentives Scheme (Veni)I-Interdivisional Veni round2017. Mail reviewer.

• Breakthrough Award Levels 1 and 2 (BTA) peer review panel member invitation2017 Breast Cancer Research Program (BCRP)the Department of Defense Congressionally Directed Medical Research Programs (CDMRP).

• NIH special emphasis panel for U01 Multiscale Modeling (MSM) program20162017 (Z Wang)

• NCI Provocative Questions PQ8: What cancer models or other approaches can be developed to study clinically stable disease and the subsequent transition to progressive disease? 2017. Ad hoc reviewer.

• Cancer Research UK mail reviewer2015-2016.

• Army Medical Research and Material Command (MRMC) Online Reviewer2016.

• Pathobiology – 2 (PB-2) peer review panel member2016 Breast Cancer Research Program (BCRP)the Department of Defense Congressionally Directed Medical Research Programs (CDMRP).

• NIH reviewer2016.

• The Wellcome trust/DBT India Alliance Fellowship application reviewer2016.

• NIGMS special panel to review a number of “Support of Competitive Research (SCORE)”. BethesdaMarylandon June 30 – July 12015.

• NIH special emphasis panel for Mathematical ModelingCancers and Cell Signaling systemsFebruary 262015.

• Mail and Panel ReviewerNIH CSR Oncology 1-Basic Translational Integrated Review Group2013-2015.

• Mail and Panel ReviewerNIH ZRG1 OTC-X(80) AREA: Oncological Sciences study section2013-2015.

• Mail ReviewerAIRC Italian Association for Cancer Research2013.

• Center Advisory Committee (CAC): NCI Physical Sciences in Oncology Center (PSOC) U54: “The Center for Transport Onco-Physics”.

• Senior Investigator Committee: NCI Physical Sciences in Oncology Center (PS-OC) U54: “The Center for Multiscale Complex Systems Transdisciplinary Analysis of Response to Therapy”.

• Senior Leadership Committee; Pilot Grant Review Committee: Integrative Cancer Biology Program (ICBP) NCI U54: “The Center for Systematic Modeling of Tumor Development”.

• OSU Mathematical Biosciences (MBI) program review2012.

• Reviewer for German and French government grant funding agencies2012.

• Mail Reviewer for several EU agencies2011-2013.

• UNM Cancer Center P30 Senior Leadership Committee2011-2012.

• ReviewerTexas Center for Cancer Nanomedicine – Pilot Projects2011.

• ReviewerCenter for Systematic Modeling of Cancer Development (Methodist Hospital Research InstituteHoustonTX and Baylor College of MedicineHoustonTX) – Pilot Projects2011.

• European Partnership for Alternatives Approaches to Animal Testing – Annual WorkshopBrusselsJuly 5-72010.

• Panel Member2010 DoD Congressionally Directed Medical Research Program (CDMRP)Breast Cancer Research Program (BCRP); Clinical and Experimental Therapeutics 5 (CET-5).

• NIH mail reviewer (SBIR)2010.

• Panel MemberEuropean Commission Research Directorate General Unit F5: Biotechnology for HealthFP7-Health-2010-single-stage – Alternative Testing StrategiesBrusselsMarch 15-192010.

• DoD Breast Cancer Idea Award review panel member20092010.

• DoD Breast Cancer Concept Award review panel member20092010.

• ReviewerMedical Research CouncilUnited Kingdom2010.

• NIH review panel member2009.

• ReviewerIsrael Science Foundation2009.

• Department of Defense—Congressionally Directed Medical Research Program (CDMRP)Concept awards2008 Breast Cancer funding cycle.

• Joint National Science Foundation-DMS/National Institutes of Health-NIGMS panel member 2008. Mathematical Biology.

• NIH review panel member 2008. R01: Multi-scale modeling of physiome in health and disease.

• National Cancer Institute—The Ohio State University: workshop on “The role of biomedical informatics in overcoming current barriers in cancer research”2008.

• National Cancer Institute meeting – “Integrating and Leveraging the Physical Sciences to Open a New Frontier in Oncology”2008.

• ReviewerU.S. – Israel Bi-National Science Foundation2008.

• ReviewerAmerican Chemical Society2007.

• ReviewerWWTF Vienna Science and Technology Fund 07. Program: Mathematics and Cancer Nanotechnology.

• ReviewerDept of Energy-Office of Science 03. Program: Innovative and Novel Computational Impact on Theory and Experiments.

• Panel memberTelemedicine and Advanced Technology Research Command (TATRC)/American Institute of Biological Sciences (AIBS) panel to conduct independent scientific review to the Alliance for NanoHealth (ANH) program. HoustonTX2006.

• ReviewerDepartment of Energy-Office of Science2005. Program: Basic Energy Sciences.

• ReviewerNational Science Foundation-Division of Mathematical Sciences2005.

EDUCATION AND OUTREACH

Service on Graduate School Committees

2022 – Present Houston Methodist Academic Institute and University of Naples Federico II (Italy) International Academic Affiliation

2021 – Present Weill Cornell MedicineCornell UniversityProfessorGraduate School of Medical Sciences

2017 – 2018 Regular MemberGraduate School of Biomedical Sciences (GSBS) Medical Physics ProgramThe University of Texas Health Science Center at Houston

2003 – 2006 University of CaliforniaIrvineCaliforniaMember and Co-FounderMathematical and Computational Graduate Program

Service to the Community

Selected: Conference Organization Invitations (mentee involved)

• Conference Program Co-ChairThe 6th International Conference on Computational Biology and Bioinformatics (ICCBB 2023)December 2023 (Z Wang)

• Editorial group discussion on Research IntegritySpringer NatureJuly 2023 (Z Wang)

• Editorial meeting on how to improve IEEE publicationsIEEEJune 2023 (Z Wang)

• Discussion LeaderGordon Research Seminar (Physical Science of Cancer)GalvestonTXFebruary 2023 (P Dogra)

• Gordon Research Seminar on Physics of CancerElected Chair (S Nizzero)

• Scientific and Health Care outreach platform in support of Covid-19 vaccination (90k members; S Nizzero Founder and Administratorsee Media coverage) https://www.facebook.com/groups/433459851127376/

• 5th International Conference on Computational Biology and Bioinformatics (ICCBB 2021)December 2021Technical Program Committee Member (Z Wang)

• NCI-DOE Collaboration 2021 Virtual Workshops: Accelerating Precision Radiation Oncology Through Advanced Computing and Artificial Intelligence. Discussion Leader (DL) for “Multimodal Patient Trajectories: Individual Predictive Modeling,” March 2021 (Z Wang)

• Abstract Screening Committee Track LeaderAmerican Association of Pharmaceutical Scientists PharmSci 360 Conference 2021Track: Clinical Pharmacology (P Dogra)

• Guest EditorNanomaterials. Special issue: Delivery of Nanoformulations for Cancer Diagnosis and Treatment2021. With Z Wang and P Dogra)

• Translational Engineering and Healthcare Innovation (TEHI) committee electionIEEE EMBS2019 (Z Wang)

• Symposium on “Imaging in Tumor Modeling,” American Association of Physicists in Medicine (AAPM) Annual Meeting (Nashville TN | July 29 – August 22018)

• Symposium on “Imaging in Tumor ModelingWorld Molecular Imaging Congress (WMIC)2018.

• Organizing Committee Member“2nd International Conferences on Clinical Oncology and Molecular Diagnostics,” June 11-132018DublinIreland. Theme: Enlightening the Future Panorama of Clinical Oncology

• Organizing Committee member“28th Euro congress on Cancer Science and Therapy,” August 09-102018MadridSpain. Theme: To codify a responsive discussion on cancer science and therapy

• Innovate Cancer Research 2017International Colloquium on Cancer Researchadvisory board memberNovember 29-30BrisbaneAustralia.

• World Brain Mapping 2017Society for Brain Mapping & Therapeutics (SBMT)Science Committee Member.

• National Science Foundation (NSF) merit review survey 2016 “Satisfaction of Investigators and Reviewers with the Merit Review Process.”

• Los Alamos National LabsNew Mexico Consortium Workshop to launch NMC/LANL joint initiatives in Biomedical TechnologyMay 92013.

• Co-organized the U54 NCI-ICBP Center for Systematic Modeling of Tumor Development symposium at The Methodist Hospital Research InstituteHoustonTXFebruary 122012.

• Session OrganizerSandia / UNM Cancer Center Symposium on Nanoparticle Human InteractionsJune 2-32011.

• OrganizerNIMBioS Investigative Workshop on Solid Tumor Modeling. University of TennesseeKnoxvilleJanuary 19-212011.

• Mini-symposium on Tumor Growth Modeling.

• Chair and OrganizerWorld Congress on Computational MechanicsSydney2010.

• Joint EU & US Workshop on Virtual Tissues in RTP. Focus: modeling tissue level outcomes from molecular and cellular scalesApril 21-242009.

• Chair and OrganizerEducational Session: “Mathematical Models in Pharmacology,” American Association for Cancer Research (AACR) Annual MeetingBoulderColoradoApril 182009.

• Program Committee Memberjoint BME symposium UT AustinUT Health Science Center HoustonUT MD Anderson Cancer Center; Directorcomputational bioengineering session. Institute for Molecular MedicineHoustonTXJanuary152009.

• 15th US National Congress on Theoretical & Applied Mechanics (USNCTAM06)Biomechanics of Tissues Mini-symposiumUniversity of ColoradoBoulder2006.

Session Chair“Cells and Materials: At the Interface between MathematicsBiology and Engineering,” Microfluidics symposiumInstitute for Pure and Applied MathematicsUCLA2006.

• Program Committee MemberCells and Materials ConferenceInstitute for Pure and Applied MathUCLA2006.

• Program Committee MemberInternational Brain Mapping and Intra-operative Surgical Planning SymposiumUniversity of Southern California2005-2007.

• Session ChairInternational Brain Mapping and Intra-operative Surgical Planning SymposiumUniversity of Southern California2005-2006.

• Editor of the conference proceedingsEuropean Conference on Mathematics and Theoretical Biology (ECMTB)2005.

• Session ChairStability and Non-linear HydrodynamicsAmerican Institute of Chemical Engineers Annual Meeting2005

• Session ChairDynamics DaysUniversity of California at Irvine2005.

• Program Committee MemberDynamics DaysUniversity of California at Irvine2005.

• Program Committee Member4th IEEE International Symposium on Bioinformatics and BioengineeringTaichungTaiwan2004.

• Session ChairInternational Biofluid Mechanics ConferenceCaltech2003.

Sponsorship and Mentorship of Candidates for Postgraduate Degrees

1. Gayatri PrakashMD studentEnMed ProgramTexas A& University. April 2023-Present (not primary advisor; with Z Wang)

2. Joseph CavePhD studentWeill Cornell-Houston campus. August 2022-Present. (primary advisorwith Prashant Dogra and Z Wang)

3. Carmine SchiavonePhD student in Chemical EngineeringUniversità degli Studi di Napoli Federico IINaplesItaly. 2022-Present. (Co-advisor)

4. Rishi RameshMD studentEnMed ProgramTexas A& University. March 2023-Present (not primary advisor; with Z Wang and Prashant Dogra)

5. Gregory ZauggMasters student in NanoscienceUniversity of BaselBaselSwitzerland. August 2022-Present. (primary advisor with S Nizzero)

6. Giacomo DoglioMasters student in PhysicsUniversità degli Studi di MilanoMilanItaly. 2022-Present. (Not primary advisor)

7. Meitham AmerehPhD studentUniversity of VictoriaBritish ColumbiaCanada2022-Present (not primary advisor).

8. Verya Gavili KilanehMSUniversity of KurdistanIran. 2022 (not primary advisor)

9. Yu ShenPhD studentJohns Hopkins University2022 (not primary advisor)

10. Nithin Kumar GoonaPhD studentNational Institute of TechnologyGoaIndia2022 (not primary advisor)

11. Maria Jose Pelaez SoniPhD student in Applied Physics at Rice University. 2021-Present. (primary advisor)

12. Akash AwasthiPhD student in Electrical and Computer EngineeringUniversity of Houston. 2021-2022. (not primary advisor)

13. Ishaan DuggalPhD student in Pharmaceutical Sciences at The University of Texas at Austin. 2021-2022. (not primary advisor)

14. Bandita KarkiMasters student in StatisticsUniversity of Idaho. 2021-2022. (not primary advisor)

15. Garima KhannaMasters student in Nanomedicine at Université de ParisFrance. 2021-2022. (not primary advisor)

16. Carmine SchiavoneMasters student in Chemical EngineeringUniversità degli Studi di Napoli Federico IINaplesItaly. 2021-Present. (Not primary advisor)

17. Maria Jose Pelaez SoniMasters in Applied Physics at Rice University. Graduated May 2021. Title: Mechanistic modeling of pathological biomarkers to study Alzheimer’s disease progression. (primary advisor)

18. Giorgia MigliaccioMasters in BioengineeringUniversità degli Studi di Napoli Federico IINaplesItaly. Graduated January 2021. Title: Calibration of wound healing assay in silico lattice model with experimental data. (Not primary advisor)

19. Luca MessinaMasters in BioengineeringUniversità degli Studi di Napoli Federico IINaplesItaly. Graduated January 2021. Title: A hybrid cellular automata for cancer cells growth and chemotaxis. (Not primary advisor)

20. Mingee KimUndergraduate in Biochemistry at Rice University. 2018-2021. (Not primary advisor)

21. Si Qi TongUndergraduate in Kinesiology at Rice University. 2018-2021. (Not primary advisor)

22. Sara NizzeroPhD in Applied Physics at Rice University. 2018-2019. (Not primary advisor)

23. Rosalia FerraroPhD ,Department of Industrial Engineeringat University of Naples Federico II. (Not primary advisor)

24. Naomi HasegawaM.D.McGovern Medical SchoolUTHealth1st year2017-present. Webber award candidate

25. Terisse BrocatoPh.D. Center for Biomedical EngineeringUniversity of New MexicoAugust 2012-December 2017. 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship; The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship2014-Present. Graduated in December 2017. Title: “Mathematical Modeling for the Use of Predicting Chemotherapy and Nanoparticle Treatment Efficacy in Breast Cancer”

26. Prashant DograPh.D. Biomedical SciencesUniversity of New MexicoAugust 2012-December 2017; The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship2014-2016. Graduated in May 2018. Title: “Multiscale Modeling of Nanoparticle Biodistribution”

27. Joseph ButnerPh.D. (Center for Biomedical EngineeringUNM)August 2012-July 2017. Graduated in July 2017 with distinction. Title: “A Multiscale Modeling Study of the Mammary Gland: Using mathematical modeling and computer simulation to study the roles of cell phenotypic dynamics and molecular signaling in the pubertal end bud and postmenopausal DCIS initiation”

28. Romica KerkettaPh.D. (Biomedical SciencesUNM)October 2012-May 2017 (Co-Advisor). The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship2013-2014. Graduated in May 2017. Title: “Exploring biological heterogeneity and its consequences at tissue and cellular scales through mathematical and computational modeling"

29. Kuan FengPh.D. Biomedical SciencesUniversity of New MexicoJanuary 2014-2015 (not primary mentor)

30. Neelima ShresthaUndergraduate researcherBiochemistryUniversity of IdahoSummer 2012 (not primary advisor)

31. Armin DayJoint B.A. / M.D. ProgramUNM 2011-2015

32. Nzola DeMagalhaesPh.D. Biomedical EngineeringUniversity of California at Irvine 2009 — UNCF-MERCK Graduate Science Research Dissertation Fellow –NIH graduate Dissertation Fell

33. Xiaoqin YuanPhDMD Anderson Cancer Center2009-2010 (not primary advisor)

34. Srimahita KalikiPh.D. studentBiomed EngineeringThe University of Texas at Austin2009-2010

35. Sandeep SangaPh.D. Biomed EngineeringThe University of Texas at Austin2009

36. Deepa RaghunathanB.S. MD Anderson Cancer Center2008; STEP-UP Clinical and Research Internship Award for Research Excellence (not primary advisor)

37. Xiangrong LiPh.D. Applied MathematicsUniversity of California at Irvine2008 (not primary advisor)

38. Jahun KimPh.D. StudentSchool of Health Information SciencesThe University of Texas Health Science Center2007-2010

39. Kaveh AzartashM.S. Biomedical EngineeringUniversity of California at Irvine2006

40. Hermann FrieboesPh.D. Biomedical EngineeringU.C. Irvine2006

41. Shuwang LiPh.D. Aerospace Engineering and MechanicsUniversity of Minnesota2005 (not primary advisor)

42. Ryan HainleyM.S. Biomedical EngineeringUniversity of California at Irvine 2005

43. Balakrishnan SivaramanM.S. Chemical Engineering and Materials ScienceU.C. Irvine 2005

44. John SinekPh.D. Applied MathematicsUniversity of California at Irvine2005

45. Xiaoming ZhengPh.D. Applied MathematicsUniversity of California at Irvine2005 – Physical Sciences Faculty Endowed Award2003-2004

Sponsorship and Mentorship of Postdoctoral Fellows and Faculty

1. Vrushaly ShinglotPh.DPostdoctoral FellowMathematics In Medicine ProgramHMRIJuly 2022- June 2023

2. Maguy FarhatPostdoctoral Fellow in Radiology and Computational ImagingDepartment of Gastrointestinal (GI) Radiation OncologyMD Anderson Cancer Center2021-Present. (With JD Butner and Z Wang)

3. Arturas ZyemisNon-Tenure-Track Assistant ProfessorMathematics in Medicine ProgramHMRI2018-2022.

4. Sara NizzeroPh.D.ConsultantARTIDISINC2021-present.

5. Sara NizzeroPh.D.Faculty FellowMathematics in Medicine ProgramHMRI2021-present.

6. Joseph ButnerPh.D.Faculty FellowMathematics in Medicine ProgramHMRI2021-present.

7. Prashant DograPh.D.Non-Tenure-Track Assistant ProfessorMathematics in Medicine ProgramHMRI2021-present.

8. Sara NizzeroPh.D.Postdoctoral Research FellowMathematics in Medicine ProgramHMRI2019-2021.

9. Sara NizzeroPh.D.Visiting Postdoctoral FellowRadiation OncologyMD Anderson Cancer Center2020-2021.

10. Javier Ruiz RamirezPh.D.Postdoctoral Research FellowMathematics in Medicine ProgramHMRI2018-2021.

11. Prashant DograPh.D.Postdoctoral Research FellowMathematics in Medicine ProgramHMRI2018-2021.

12. Joseph ButnerPh.D.Research AssociateMathematics in Medicine ProgramHMRI2018-2021.

13. Zhihui WangNon-Tenure-Track Associate ProfessorMathematics in Medicine ProgramHMRI2018-present.

14. Martina MugnanoPhD candidate at University of Naples Federico II. (Not primary advisor)

15. Geoff V MartinMD. Radiation Oncology ResidentMD Anderson. 2016-2018 (not primary mentor)

16. Yoo-shin KimPh.D.Senior Research ScientistCenter for Proteomics and Systems BiologyThe Brown Institute of Molecular Medicine2016-2017.

17. Angela RugianoPhDDepartment of MathematicsUniv/CalabriaItaly2015-2016 (not primary mentor).

18. Huaming YanPh.D.Department of MathematicsDepartment of MathematicsUniversity of California at Irvine2015-present (not primary advisor).

19. Greg von WinckelPh.D.Postdoctoral studentChemical EngineeringUNMSkinfraredLLCAlbuquerqueNM2013-2015(not primary advisor).

20. Zhihui WangNon-Tenure-Track Assistant ProfessorDepartment of PathologyThe University of New Mexico Health Science Center2011-2015.

21. Jennifer PascalASERT Postdoctoral StudentDepartment of PathologyThe University of New Mexico Health Science Center2011-2013. NIGMS K12GM088021 postdoctoral fellowship.

22. Yao-Li ChuangPostdoctoral StudentDepartment of PathologyThe University of New Mexico Health Science Center2010-2014; The University of Texas Health Science Center2009-2010.

23. Arnaud ChauviereNon-Tenure-Track Assistant ProfessorDepartment of PathologyThe University of New Mexico Health Science Center2010-2012; The University of Texas Health Science Center2009-2010.

24. Fang JinPostdoctoral studentDepartment of PathologyThe University of New Mexico Health Science Center2010-2011; The University of Texas Health Science Center2008-2010.

25. Babis HatzirikouPostdoctoral studentDepartment of PathologyThe University of New Mexico Health Science Center2010-2012; The University of Texas Health Science Center2009-2010.

26. Paul MacklinNon-Tenure-Track Assistant ProfessorSchool of Health Information SciencesThe University of Texas Health Science Center2007-2010.

27. Hermann FrieboesPostdoctoral studentSchool of Health Information SciencesThe University of Texas Health Science Center2007-2010.

28. John SinekPh.D.Postdoctoral studentApplied MathematicsUniversity of California at Irvine2005-2007.

29. Lan PhamPostdoctoral studentApplied MathematicsUniversity of California at Irvine2003-2005.

30. Xiaoming ZhengPostdoctoral studentApplied MathematicsUniversity of California at Irvine2005-2006.

31. Steven WisePostdoctoral studentApplied MathematicsUniversity of California at Irvine2003-2006.

Others (non-graduate/postgraduate)

• Kelan Wu (Undergraduate student)University of HoustonHoustonTXUSA (02/23 – 06/23)Research topic: Machine learning applications to determine nanoparticle properties for tumor targeting and safety (with P Dogra & Z Wang)

• Elisa Misuri (Undergraduate student)Politecnico di TorinoItaly (01/22 – 08/23)Research topic: Multiobjective optimization to guide immunosuppressive therapy in kidney transplant recipients to prevent BK virus infection (with P Dogra)

• Ruchi BirurTexas Academy of Mathematics and Science – summer 2022 (not primary advisor)

• Sri Gouri RajaramB.S. Biomedical EngineeringIndian Institute of TechnologyKharagpurIndia. 2021-2022. (not primary advisor)

• Syed Asad RizviB.S. Computer ScienceUniversity of Houston. 2021-2022. (not primary advisor)

• Meinee ChiuB. PharmacyPanjab UniversityIndia. Summer 2021. (not primary advisor)

• Ananya SinghB. PharmacyPanjab UniversityIndia. Summer 2021. (not primary advisor)

• Jack DelkB.S. Biomedical EngineeringTexas A&M University – summer 2021 (Not primary advisor)

• Jorge TitoPre-Baccalaureate Trainee (High school student) at UTHealth – summer 2017

• Josh BegayUndergraduate researcher (Mechanical EngineeringSouthwestern Indian Polytechnic Institute)Summer 2012 (co-advisor)

• Zachariah HarrisB.S. Chemical EngineeringUniversity of New Mexico2011-2012

• Kristine VelascoB.S. Biomedical EngineeringUniversity of California at Irvine 2006 – BME Engineer of the Year

• Anthony AndersonB.S. Chemical Engineering and Materials ScienceUniversity of Minnesota 2004 – Honors Thesis.

Teaching Responsibilities

• ‘Strategic Consideration for Healthcare Informatics’ CourseMaster’s in Clinical Translation ManagementUniversity of St. ThomasHoustonTXUSA10/30/2023 – Present. (Instructor: P Dogra)

• PhysiologyBiophysics & Systems Biology qBio Bootcamp 202120222023 (& 2024 expected)Houston Methodist Research Institute and Weill Cornell MedicineHoustonTXthe first two weeks of August202120222023. Instructors: Joseph ButnerPrashant Dogra. Supervision: Vittorio CristiniZhihui WangHenry PownellJohn Cooke.

• GS21 1331: Precision BioMedicine and Nanotechnology. Instructors: David Volk and Vittorio Cristini. (Institute of Molecular MedicineThe University of Texas Graduate School of Biomedical Sciences at Houston2017-2018graduate)

• CristiniV. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. 2017 nBME Scholarly Concentration Summer Seminar SeriesUTHealth McGovern Medical SchoolHoustonTXUS. June 132017. (invited lecture)

• California State Summer School for Mathematics and Science (COSMOS) guest lecture 2017UC Irvine.

• Introduction to Computational Biomedicine (BIOM 505-004The University of New MexicoAlbuquerque2012graduate) Developed and taught a multi-disciplinary class in collaboration with the Spatio-Temporal Modeling Center and the New Mexico Cancer Nanoscience and Microsystems Training Center.―In this coursestudents are engaged in novel peer-reviewed research at the interface of medicine and the engineering and physical sciencese.g.knowledge of literature relevant to a specific study and understanding of the corresponding biological backgroundsoundness of the mathematical formulation of equations modeling the biological probleminsight into novel biology obtained from model investigations. The course consists of 33-week long modules: a general one covering tools for computational biomedicine; one focused on modeling tumor spread (with guest instructor cell biologist Prof. Bridget Wilson); and one devoted to modeling intracellular transport (with guest instructor cell biologist Prof. Elaine Bearer). One class meeting/week includes both lecture and assessment of progress to provide feedback/help.

• Foundations of Health Information Sciences II: Mathematical Modeling in Biomedicine (Health Information SciencesThe University of Texas Health Science CenterHouston; Biomedical EngineeringThe University of Texas at Austin2009graduate)

• Numerical Analysis (Health Information SciencesThe University of Texas Health Science CenterHouston; Biomedical EngineeringThe University of Texas at Austin2007-2010graduate)

• Advanced Engineering Mathematics (Biomedical EngineeringThe University of Texas at Austin2007-2009graduate)

• Math modeling and computer simulation for Health Sciences (Health Information SciencesThe University of Texas Health Science CenterHouston; Biomedical EngineeringU.T. Austin2007graduate)

• Bio-Mass Transport (Biomedical EngineeringUniversity of California at Irvine2004-2006undergraduate)

• Introduction to Predictive Oncology (Biomedical EngineeringUniversity of California at Irvine2005-2006graduate)

• Introduction to Math and Computational Biology (COSMOS Program Physical SciencesUniversity of California at Irvine2004-2005high school)

• Applied Engineering Math II—Numerical Analysis (Biomedical EngineeringUniversity of California at Irvine2003-2006graduate)

• Math Modeling and Computer Simulation of Complex Biology Systems (Biomedical EngineeringUniversity of California at Irvine2003-2004graduate)

• Virtual Cancer: A Computer Model of Cancer Progression and Treatment (EngineeringUniversity of California at Irvine2003Freshman Semester)

• Calculus I (School of MathematicsUniversity of Minnesota2002undergraduate)

• Transport Phenomena (Chemical Engineering and Materials ScienceUniversity of Minnesota2000undergraduate)

GRANT SUPPORT

Current Grant Support

• Golfers Against CancerFund #37384: Predicting immunotherapy outcomes from noninvasive blood measures before start of treatment. 9/1/23–8/31/24. 60,000/yr DC. Role: Collaborator (PI: Z Wang)

• BrownSmith & Raymond EnMed Capstone Innovator Award (Texas A&M U & Houston Methodist). Predicting Cancer Immunotherapy Response by combining Mechanistic Modeling and Machine Learning. 9/1/23–8/31/25. 12,000/yr DC. Role: Collaborator (PI: PrakashMentor: Z Wang)

• NIH/NINDS T32 Postdoctoral Fellow Training Grant (PI: P. Horner). Houston Methodist Neurological Institute’s Department of Neurosurgery. 05/01/2022-04/30/2027. Role: Faculty Mentor

• ARTIDIS Ltd./MD Anderson Cancer Center/Houston Methodist Research Institute: Strategic Alliance for Biomechanics Marker Discovery in Clinical Trials. 7/1/2021–6/30/2026. Role: HMRI PI10% time$50,000/yr DC.

• NIH/NCIR01CA253865: Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. 3/4/2021- 2/28/2026. Role: Co-Investigator10% time111,569/yr DC. PI: Z Wang

• NIH/NIBIB1R03EB033576: Physiologically based pharmacokinetic modeling of silica nanoparticles. 7/1/22 – 6/30/24. Role: Collaborator. PI: Yellepeddi; co-I: Dogra

• ARTIDIS Ltd.—Sponsored Research Agreement: Predicting chemotherapy and immunotherapy outcome using measurements of tissue stiffness.8/1/2021- 12/31/2024. Role: PI5% time$165,000/yr DC.

• NIH/NCIP50CA217674: The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma. 9/25/2019 – 8/31/2024. Role: Co-Investigator3% time. $7,807/yr DC. PI: BeretaKaseb.

• The Cockrell Foundation Professorship Award/HMRI: Mathematical modeling to support infectious diseases research. 3/1/21-2/29/24. 102,400/yr DC. (Awardee: Prashant Dogra.)

Pending Grant Support

• NIH IRCN R01 (MPIs: PasqualiniWadihBrinkerCristini). 4/1/24–3/31/29. Rutgers U (NIH). Methodist Funds Requested: $928,626. Title: Antibody-targeted nanoparticles for therapeutic gene editing in aggressive variant prostate cancer. Role: MPI (1.2 calendar)

• NIH RM1 (MPIs: BurleyPasqualini). 4/1/24–3/31/29. Rutgers U (NIH). Methodist Funds Requested: $1,125,000. Title: Integration of In Vivo Phage Display & Machine Learning: A Multidisciplinary Approach for Ligand-Receptor Mapping of the Mammalian Vasculature. Role: Co-I & Methodist PI (1.2 calendar)

• NIH/NIBIB R01 (MPIs: DograNoureddine). 4/1/24–3/31/29. NIH. Total Funds Requested: $2,712,699. Title: Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety. Role: Co-I (0.6 calendar).

• NIH/NIAID 1R21AI178508-01A1 (PI: Dogra). 4/1/24–3/31/26. NIH. Total Funds Requested: $444,125. Title: Mechanistic modeling-based clinical trial simulator to support vaccine development. Role: Co-I (0.6 calendar)

• NIH/NCI (PI: Dogra). 4/1/24–3/31/26. NIH. Total Funds Requested: $161,500. Title: Multiscale modeling to improve efficacy of microRNA therapy in pancreatic ductal adenocarcinoma. Role: Co-I (0.3 calendar)

• CPRIT Individual Investigator Research Awards for. Computational Systems Biology of Cancer (MPIs: WelshCristini). 3/1/24–2/28/27. CPRIT. Total Funds Requested: $300,000. Title: Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy. Role: MPI (1.2 calendar)

• NIH R01 (MPIs: WangOzpolat). 7/1/24–6/30/29. NIH. Total Funds Requested: $2,913,640. Title: A mathematical model for simulating and predicting miRNA-873-based nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH R01 (MPIs: WangChung). 7/1/24–6/30/27. NIH. Total Funds Requested: $2,215,754. Title: Developing a mathematical model-based tool to predict immunotherapy outcomes in melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH R01 (MPIs: WelshCristini). 7/1/24–6/30/29. NIH. Total Funds Requested: $305,477. Title: Development of immune biomarkers related to PET SUV through computational modeling for prediction of treatment response to Immunotherapy. Role: MPI (1.2 calendar)

• NIH 1R01CA285524-01A1 (MPIs: WangOzpolat). 7/1/24–6/30/29. NIH. Total Funds Requested: $2,925,210. Title: Optimizing novel miR-873 nanotherapeutics for targeted cancer treatment using a combination of experimental and mechanistic modeling approaches. Role: Co-I (2.4 calendar)

• NIH U01 (MPIs: WangChung). 7/1/24–6/30/27. NIH. Total Funds Requested: $1,466,223. Title: Development of a clinically applicable tool for physicians to predict checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

Past Grant Support

• NIH/NCIR01CA222007: miR-155 targeted therapeutics for precision medicine in lung cancer. 07/01/2018–06/30/2023. Role: MPI15% time. 64,153/yr DC.

• NIH/NCIR01CA226537: A targeted nanomedicine prototype against enzalutamide-resistant prostate cancer. 04/01/2018–03/31/2023. Role: MPI15% time. 108,654/yr DC.

• NIH/NCIU01CA213759: Targeted Therapeutics for ovarian cancer and its microenvironment treatment and theoretical modeling. 06/01/2017-05/31/2022. Role: Co-Investigator5% time. 20,655/yr DC. PI: Lopez-Berestein

• NIH/NCIU01CA196403: Imaging and Molecular correlates of progression in cystic neoplasms of the pancreas. 09/01/2015-08/31/2021. Role: Co-Investigator5% time. 20,008/yr DC. PI: Maitra

• NIH/NCIU54CA210181: Center for Immunotherapeutic Transport Oncophysics: 07/2017- 07/2021. Role: Collaborator10% time13,012/yr DC.

• National Science Foundation‒Mathematical Sciences (Role: Overall PI5% time; 09/01/2017-08/31/2020). “Collaborative Research: A new multiscale methodology and application to tumor growth modeling,” $250,000. DMS-1930583

• NIH/NIGMS P50GM085273 (PI: Wilson)The New Mexico SpatioTemporal Modeling Center (STMC) 09/01/2014-08/31/20191.2 calendar. Role: Co-Investigator

• UT STAR award - The University of Texas System – Science and Technology Acquisition and Retention (STARS). “Mathematical modeling integrated with experiments and clinical trials to understand tumor heterogeneitydrug delivery and treatment outcome” ($1,000,000). Cristini PI. 07/01/2015-06/30/2018.

• Rochelle and Max Levit endowment for Chair in the Neurosciences ($500,000)– UTHealth 2016-2018

• Pilot project (PIs: KoayCristini 2% effort)Center for Immunotherapy in Transport Oncophysics (CITO)overall PI: Ferrari. “Effects of VEGF and collagen signaling on biodistribution of tumor associated macrophages in pancreatic ductal adenocarcinoma (PDAC)” 2017-2018

• National Science Foundation‒Mathematical Sciences/National Institute of General Medical Sciences (overall PI10% time; 09/15/2013-08/31/2017). “Collaborative Research: Multiscale Modeling of Mammary Gland Development,” $422,472. DMS-1562068

• The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) Graduate Fellowship2014-2017 (Student: Terisse BrocatoUNM)

• University of New Mexico Cancer Center Institutional Support.(1 full-time graduate student) Clinical trial: The Use of Mathematical Modeling to Predict Response to Neoadjuvant Anthracycline / Taxane Based Chemotherapy in Women with HER2 negative Stage II and III Breast Cancer. 12/3/2014-12/3/2016. Co-PI.

• The New Mexico Center for the Spatiotemporal Modeling of Cell Signaling (STMC) Graduate Student Fellowship2014-2016. (Student: Prashant DograBiomedical SciencesUniversity of New Mexico)

• NIH 5U54CA151668-05 (PIs: FerrariGorensteinCristini)Texas Center for Cancer Nanomedicine8/1/15-7/31/162.4 calendar. Cristini Overall PI

• 2014 Pancreatic Cancer Action Network – AACR Cancer Development Award: “Changes in Mass Transport as a Biomarker of Response in Pancreatic Cancer.” $200,000; PI: E Koay (VC Mentor2% time). 07/01/2014-06/30/2016.

• Radiological Society of North America (RSNA) Seed Grant (PI: E Koay)Predicting gemcitabine delivery in human pancreatic cancer with mass transport(VC Co-Investigator2.0% time) 2014-2015.

• King Abdulaziz University Grant 54-130-35-HiCi. “A Multiscale Approach to Developing and Optimizing γδ T Cell-Based Breast Cancer Treatment” $50,000. (Consultant10% time) 6/1/2014-3/31/2015.

• National Cancer InstituteCCNE: Texas Center for Cancer NanomedicineVC (Core co-I4% time). Biosimulation Core (Total Budget of Core: $750,000)2010-2015.

• National Cancer InstituteU54: Physical Science—Oncology Center (PS-OC): Multiscale Complex Systems Transdisciplinary Analysis of Response to TherapyVC (Project PI19% time). Multiscale Cancer Modeling: From Cell Phenotype to Growth and Therapy Response (Total Budget of Project $852,000)2009-2015.

• National Cancer InstituteU54: Physical Science—Oncology Center (PS-OC): Center for Transport OncophysicsVC (Core PI18% time) (Total Budget of Core $1,000,000)2009-2015.

• National Cancer InstituteU54; Integrative Cancer Biology Program (ICBP): Center for Modeling of Cancer DevelopmentVC (Project PI15% time) Computational Biology: Mathematical Modeling and Computer Simulation (Total Budget of Project $750,000)2010-2015.

• Baylor College of Medicine (BCM): Agent Based Modeling of Cell Lineages in Breast CancerVC (Scientific Advisor0%) (Total Budget $253,948)12/1/2010 – 02/28/2015.

• National Cancer InstituteU54: Physical Science—Oncology Center (PS-OC): Center for Transport Oncophysics (PI: Ferrari) - Project 3: Genomic Correlates of Mass Transport DifferentialsVC (Co-Investigator10% time)2009-2015.

• National Cancer InstituteU54: Physical Science—Oncology Center (PS-OC): Center for Transport Oncophysicssupplemental grant: “Clinical implications of mass transport in colorectal liver metastasis,” (VC PI20% time). (Total Budget $80,000). 2013-2014.

• “Mathematical Model of Drug Transport to Determine Chemotherapeutic Outcomes in Patients with Colorectal Liver Metastases,” The New Mexico Cancer Nanoscience and Microsystems Training Center Graduate Fellowships2013-2014 by (Ph.D. student mentored: Romica Kerketta)

• 2013-2014 School of Engineering Award – the Charlotte and William Kraft Graduate Fellowship (Ph.D. student mentored: Terisse Brocato).

• NIH/NIGMS P50GM085273 (PI: Oliver)University of New Mexico Spatio Temporal Modeling Center (STMC)0.5 calendar. Role: Co-Investigator08/01/11–07/31/2014.

• NIH/NIGMS K12GM088021 (PI: Pascal)0 calendarRole: Research mentor09/01/11–08/31/2014.

• National Science Foundation SBIR (Academic PI: VC)($49,000)“Dynamic Infrared Imaging of Skin Cancer”7/1/2013-12/31/2013.

• National Cancer Institute CTO PS-OC Pilot Project (PI: Cristini)0.25 calendarNIH/NCI$100,000. Title: Predictive physical modeling of chemotherapeutic drug transport and tumor response04/01/2012-03/31/2013.

• National Science Foundation—Mathematical SciencesVC PI (6%)“Collaborative Research: Multiscale modeling of solid tumor growth,” (Total Budget $225,000)2008-2012.

• UNM STMC Grand Challenge Award: Modeling the spatiotemporal motor-cargo dynamics in the squid giant axon. VC (PI0% time). $50,000. 03/2011 – 07/2011.

• MD Anderson Cancer Center Award: Quantification of diffusion barriers to chemotherapy in patient tissue. VC (PI1% time). $114,300. 11/2010 – 10/2011.

• United States Department of Defense Innovator AwardM. Ferrari (PIUT Health Science Center)VC (Co-I5%). Towards individualized breast cancer therapy: Leveraging molecular medicine with multi-stage vector technology. (Total Budget $7 Million). 03/01/2009-02/28/2010.

• Cullen Trust for Health CareVC PI (60%)“Virtual cancer: Reducing cancer recurrence and progression – new paradigms in cancer diagnostics and treatment through computational modeling of biological systems” (Total Budget $1.5 million). 2008-2010.

• United States Department of Defense - Telemedicine and Advanced Research Technology Center (TATRC) / Alliance for Nanohealth (ANH). VC PI (10%)“Optimizing Delivery of Paclitaxel in Head and Neck Cancer Treatment Through Nanoparticle Delivery and Interactive Biomathematically Based Nanoparticle Designs,” (Total Budget: $45,000). 2008-2010.

• Komen Foundation. F. Symmans (PIMD Anderson)VC (Collaborator2%). Prospective Evaluation of Molecular Triaging with Pharmacogenomic Tests to Select Neoadjuvant Treatment. ($45,000). 04/01/2008 – 03/31/2009.

• NIH—Bioengineering Research PartnershipsVC Co-I (5%)“Nanovectors for characterization and destruction of breast tumor vasculature,” (Total Budget $400,000). 2007-2010.

• United States Department of Defense - Telemedicine and Advanced Research Technology Center (TATRC). VC Co-PI (5%)“Medical Nanovector Research and Development Center of Alliance for Nanohealth,” (Total Budget: $1.768 Million). 2007-2010.

• United States Department of Defense - U.S. Army Medical Research and Materiel Command (USAMRMC)—The Texas Training and Technology Against Trauma and Terrorism (T5) program NCE. VC Co-PI (38%)(Total Budget $4,792,000). 2007-2008.

• Dekk-Tech. VC PI“Computer simulations of drug delivery to brain tumors,” ($25,000). 2007.

• United Negro College Fund - MERCK Graduate Science Research Dissertation FellowshipVC Mentor“An integrated biological and computational tumor model,” $52,000 (PI: Graduate Student N DeMagalhaes). 2007-2009.

• NIH Graduate FellowshipVC Mentor$60,000 (PI: Graduate Student N DeMagalhaes). 2007-2009.

• NIH—National Cancer InstituteVC Co-PI (10%“R01: Clinical and Microarray Data Predict Lung Cancer Outcomes”. (Total Budget: $1 million). 2006-2009.

• University of California Discovery Grant - IT for life sciences/ORQIS MedicalVC PI“Analysis and Optimization of Blood Circuit Components Using Adaptive CFD,” $188,000. 2005-2007.

• NIH - National Cancer InstituteVC Co-PI“R01: Multidisciplinary studies of tumor vascularity and microenvironment,” $180,000. 2005-2006.

• National Science Foundation—Mathematical SciencesVC PI (10%)“Collaborative Research: Analysis and properties of co-continuous blends-A numerical and experimental investigation,” $132,000. 2003-2006.

• University of California at IrvineCenter for Complex Biological Systems Seed GrantVC PI“Computational and Experimental Modeling of Tumor Spheroid Growth and Photodynamic Therapy: A First Step Towards an In Vivo Model,” $11,000. 2003-2004.

• University of California at IrvineBiomedical Engineering/College of Medicine Seed GrantVC PI“Modeling breast tumor morphology to predict drug response,” $15,000. 2003-2004.

Submitted Proposals (since I joined HMRI on 07/09/2018; selected)

• NIH/R01 (MPIs: WangOzpolat). 7/1/23–6/30/28. NIH. Total Funds Requested: $2,814,645. Title: Development of KRAS-targeted siRNA- or miRNA-mediated nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: OzpolatWang). 7/1/23–6/30/28. NIH. Total Funds Requested: $3,305,000. Title: Dual-targeting of KRAS and PDL1 with novel miRNA nanotherapeutics for targeted cancer treatment. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: OzpolatWang). 7/1/23–6/30/27. NIH. Total Funds Requested: $2,962,660. Title: Novel therapeutic approach for co-targeting of two oncogenic kinases in Triple negative breast cancer. Role: Co-I (1.2 calendar)

• NIH/U01 resubmission (MPIs: WangChung). 7/1/23–6/30/26. NIH. Total Funds Requested: $1,466,223. Title: Development of a clinically applicable tool for physicians to predict checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH/R21 (PI: Dogra). 7/1/23 – 6/30/25. NIH. Total Funds Requested: $444,125. Title: Mechanistic modeling-based clinical trial simulator to support vaccine development. Role: collaborator

• NIH/R01 (PI: Goel). 7/1/23 – 6/30/28. NIH. Total Funds Requested: $198,202. Title: Ultrasmall chemo-radiopharmaceutical nanoconjugates for triple negative breast cancer. Role: collaborator

• NIH R01 (MPI: VillapolLeonard). 4/1/23 – 3/31/28. NIH. Total Funds Requested: $3,114,617. Title: Non-viral CRISPR-lipid nanoparticles-based treatment for traumatic brain injury-induced inflammation in vivo. Role: Collaborator

• NIH R01 (MPIs: StaquiciniDogra). 4/1/23 – 3/31/28. NIH. HM budget: $494,910. Title: Targeted Phage Display Technology for Pulmonary Delivery and Immunotherapy Approaches. Role: Collaborator

• NIH R21 (PI: Puri; co-I: Dogra). 4/1/23 – 3/31/25. NIH. HM budget: $81,660. Title: Development of an iontophoresis-coupled microneedle skin patch of naloxone for rapid and sustained reversal of fentanyl overdose. Role: Collaborator

• NIH/R01 (MPIs: WangChung). 4/1/23–3/31/28. NIH. Total Funds Requested: $3,097,714. Title: Integration of multimodal imaging and biofluid laboratory measurements for mathematical prediction of checkpoint inhibitor immunotherapy outcome in patients with melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH 1R01CA269639-01A1 (MPIs: WangChen). 9/1/22–8/31/27. NIH. Total Funds Requested: $3,463,440. Title: Development of quantitative early indicators for predicting breast cancer response to immunotherapy treatment using mathematical modeling and preclinical models. Role: Co-I (1.2 calendar)

• Concept Award (PI: Filgueira). 9/1/22 – 8/31/24. DoD. Funds Requested: $161,499. Title: Nanoparticle-mediated Zonal Delivery of Therapeutics to the Tumor Microenvironment. Role: Co-Investigator

• DoD/ Investigator-Initiated Research Award. 7/1/22-6/30/26. DoD. Total Funds Requested: $1,285,542. Title: Microneedle dermal patch for amiloride in animals. Role: Co-I (0.24 calendar)

• DOD W81XWH-21-MRP-TRA (PI: Ekmekcioglu). 4/1/22–3/31/25. DOD. Total Funds Requested: $1,050,000. Title: Innate immune markers contribution in the tumor microenvironment architecture predicts response to immunotherapy in acral melanomas. Role: MPI (0.6 calendar)

• NIH/U54 ROBIN (MPIs: KoayAzadJavleCristini). 7/1/22–6/30/27. NIH. Total Funds Requested: $ 8,109,461. Title: MD Anderson/Johns Hopkins Cholangiocarcinoma ROBIN Center. Role: MPI/Data Science Core Co-Leader (1.2 calendar)

• NIH/U01 (MPIs: WangChung). 4/1/22–3/31/25. NIH. Total Funds Requested: $1,453,500. Title: Development of a clinically applicable tool for physicians to predict patient outcome in melanoma brain metastases. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: WangChung). 4/1/22–3/31/27. NIH. Total Funds Requested: $3,671,180. Title: Identification of immunotherapy response indicators in breast cancer treatment through mathematical modeling and preclinical testing. Role: Co-I (1.2 calendar)

• NIH/R01 Resubmission (MPIs: OzpolatWang). 4/1/22–3/31/27. NIH. Total Funds Requested: $2,250,000. Title: Development of targeted therapeutics for pancreatic cancer. Role: Co-I (1.2 calendar)

• Delta Tissue Program (PIs: CristiniPlodinec). 10/1/21–9/30/24. Wellcome Leap Foundation. Total Funds Requested: $2,976,000. Title: Predicting cell states and transitions within the tumor microenvironment in the breast cancer response to chemotherapy and immunotherapy using a combined nanomechanical profilingimagingand mathematical modeling approach. Role: PI (1.2 calendar)

• NIH/K25 (PI: Butner). 9/1/2021-8/30/2026. NIH. Total Funds Requested: $436,275. Title: Designing a predictive clinical tool to improve patient treatment strategies: integration of multiparametric imaging and mathematical modeling to predict patient outcome in melanoma brain metastases

• NIH/R01 (MPIs: ChungHusseinCristini). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: Personalized multimodality treatment of melanoma brain metastases following immunotherapy using mathematical modeling. Role: MPI (1.2 calendar)

• NIH/R01 (MPIs: WangOzpolat). 7/1/2021 – 6/30/2026. NIH. Total Funds Requested: $2,306,675. Title: Understanding and optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-I (1.2 calendar)

• NIH/R01 (MPIs: WangChen). 7/1/2021 – 6/30/2026. NIH. Total Funds Requested: $3,671,180. Title: Development of mathematical markers for early identification of immunotherapy response in ovarian cancer treatment with preclinical testing. Role: Co-I (1.2 calendar)

• NIH/U01 (MPIs: CristiniChenWangThompson). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: Clinically validated physical biomarkers drive treatment outcome prediction in breast cancer and lung metastases. Role: Contact PI (1.2 calendar)

• NIH/P20 (MPIs: ChangEsnaolaGomez). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,120,000. Title: The Houston Methodist Cancer Health Disparity P20 SPORE planning grant. Role: Co-I of Project 2 (1.2 calendar)

• NIH/R01 (MPIs: ChungCristini). 7/1/21–6/30/26. NIH. Total Funds Requested: $4,127,000. Title: Personalization of Treatment for Patients Receiving Immunotherapy for Melanoma Brain Metastases using Imaging and Fluid-Based Mathematical Modeling. Role: MPI (1.2 calendar)

• NIH/U01 (MPIs: CristiniChenWangThompson). 9/1/20–8/31/25. NIH. Total Funds Requested: $4,120,000. Title: Clinically validated physical biomarkers drive treatment outcome prediction in breast cancer and lung metastases. Role: Contact PI (1.2 calendar)

• NIH/R01 (MPIs: WangSood). 9/1/20–8/31/25. NIH. Total Funds Requested: $2,155,000. Title: Developmentexperimental testingand retrospective clinical validation of a mechanistic model of immunotherapy in ovarian cancer treatment. Role: Co-Investigator (1.2 calendar)

• DOD/BCRP (MPIs: ThompsonPlodinec). 9/1/20–8/31/23. DOD. Total Funds Requested: $2,000,000. Title: Proteogenomic and nanomechanical biomarkers in primary breast cancer. Role: Collaborator (1.2 calendar)

• NIH/R01 (MPIs: WangOzpolat). 4/1/21–3/31/26. NIH. Total Funds Requested: $2,306,675. Title: Understanding and optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: WangChen). 4/1/21–3/31/26. NIH. Total Funds Requested: $3,671,180. Title: Development of "mathematical markers" for early identification of immunotherapy response in ovarian cancer treatment with preclinical testing. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: WangOzpolat). 4/1/20–3/31/26. NIH. Total Funds Requested: $2,55,000. Title: Naonparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: OzpolatWang). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,250,000. Title: Novel combinatorial therapies for pancreatic cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: OzpolatCalin). 4/1/20–3/31/25. NIH. Total Funds Requested: $2,770,000. Title: miR-484 targeted therapeutics for breast cancer. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: ChenWangChang). 4/1/20–3/31/25. NIH. Total Funds Requested: $3,550,000. Title: Identification of clinically relevant tumor immune microenvironment biomarkers for predicting immunotherapy outcome in lung and breast cancer patients. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PI: Ozpolat). 4/1/20–3/31/25. NIH. Total Funds Requested: $2,500,000. Title: Development of EF2K targeted Dual effect nanotherapeutics for breast cancer. Role: Co-Investigator (0.5 calendar)

• NIH/R01 (PIs: WangOzpolat). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,250,000. Title: A combined experimental and mathematical modeling approach to optimizing EF2K-targeted nanotherapeutics for pancreatic ductal adenocarcinoma. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (PIs: WangOzpolat). 7/1/20–6/30/25. NIH. Total Funds Requested: $2,55,000. Title: Naonparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer. Role: Co-Investigator (1.8 calendar)

• CPRIT IIRA (MPIs: ChangChen). 3/1/20–2/28/23. NIH. Total Funds Requested: $3,550,000. Title: A translational approach to identification of clinically applicable biomarkers for predicting immunotherapy outcome in lung and breast cancer patients. Role: Co-Investigator (1.2 calendar)

• NIH/U54 RFA-CA-19-013 (MPIs: CristiniChenHong). 9/1/19–8/31/24. NIH. Total Funds Requested: $7,161,919. Title: Houston Center for Cancer ImmunoTherapy Engineering (HC-CITE). Role: Overall PIcontact (3.0 calendar)

• NIH/R01 (PI: Ozpolat). 7/1/19–6/30/24. NIH. Total Funds Requested: $3,500,000. Title: Development of KRAS targeted dual effect nanotherapeutics. Role: Co-Investigator (1.2 calendar)

• NIH/P01 (PI: CalinCroceSlack). 7/1/18–6/30/23. NIH. Total Funds Requested: $5,000,000. Title: MicroRNA targeted therapeutics for precision medicine in human cancers. Role: Bioinformatics & Biostatistics and Mathematics Core Director (1.2 calendar)

• NIH/R01 IRCNPAR-17-240 (MPIs: OzpolatMaitraVolkCristiniWang). 4/1/19–3/31/24. NIH. Total Funds Requested: $3,250,000. Title: Development of miR-based nanotherapeutics for precision medicine in pancreatic cancer. Role: MPI (1.44 calendar)

• NIH/R01 (MPIs: CalinOzpolatWang). 4/1/19–3/31/24. NIH. Total Funds Requested: $3,500,000. Title: Development of KRAS targeted dual effect nanotherapeutics. Role: Co-Investigator (1.2 calendar)

• NIH/R01 (MPIs: Lopez-BeresteinOzpolat). 4/1/19–3/31/24. NIH. Total Funds Requested: $2,750,000. Title: Development of EF2K targeted Dual effect nanotherapeutics for breast cancer. Role: Co-Investigator (1.2 calendar)

• CPRIT/IIRA (PI: OzpolatWang). 3/1/19–2/28/22. NIH. Total Funds Requested: $900,000. Title: Development of Dual effect nanotherapeutics for Breast Cancer. Role: Collaborator (0.5 calendar)

Other Submitted Proposals

• DOD BCRP Breakthrough Award Level 2 Award (PIs: Sen). 6/1/18–5/31/21. DOD. Total Funds Requested: $1,540,000. Title: EF1A2-SCF Complex Regulated Ubiquitination Pathway as Predictor of Prognosis and Drug Response in Breast Cancer. Role: Co-I (10% effort)

• NIH/R01 (PI: Zhou). 10/1/18 – 9/30/23. NIH. Total Funds Requested: $2,250,000. Title: Systematically understanding the immunity leading to castration-resistant prostate cancer progression. Role: Co-I (10% effort)

• DOD PCRP Impact Award (PI: WadihBrinkerCristini). 10/1/18 – 9/30/21. DOD. Total Funds Requested: $2,000,000. Title: Development of a targeted nanoparticle prototype in treating enzalutamide-resistant prostate cancer. Role: Partnering PI (2.4 calendar)

• NIH/R01 (PIs: OzpolatLopez-BeresteinVolkCristiniWang). 7/1/18 – 6/30/23. NIH. Total Funds Requested: $2,402,996. Title: Highly Targeted therapies for pancreatic cancer. Role: MPI (10% effort)

• NIH/U01 MSM (PI: CristiniWangLowengrub). 4/1/18 – 3/31/23. Title: Multiscale Modeling of the Progression of Pancreatic Neoplasms to Invasive Pancreatic Cancer. Role: Overall PI (15% effort)

• CPRIT Computational Biology (PI: CristiniKoay). 3/1/18 – 2/28/21. Title: Modeling Immunotherapy Response in Lung and Colorectal Cancers. Role: PI (10% effort)

• NIH/U01 IRCN (PIs: PasqualiniArapBrinker and Cristini). 9/1/17 – 8/31/22. NIH. Total Funds Requested: $2,500,000. Title: A targeted nanomedicine prototype against enzalutamide-resistant prostate cancer. Role: Co-PI (1.8 calendar)

• NIH/R01 (PIs: OzpolatVolkCristiniWang). 9/1/17 – 8/31/22. NIH. Total Funds Requested: $1,850,000. Title: Highly Targeted Therapies for Pancreatic Cancer. Role: Co-PI (15% effort)

• DOD LCRP Translational Research Partnership (PI: WelshCristini)Pre-application. Title: Quantitative understanding of molecular and cellular characteristics of responders and non-responders in small cell lung cancer treatment. Role: PI

• NIH/R21 (PIs: FuentesElsayesWang). 9/1/17 – 8/31/19. NIH. Total Funds Requested: $$275,000. Title: Mathematical modeling of treatment response of hepatocellular carcinoma. Role: Co-I (5% effort)

• NIH/R01 (PI: Ozpolat). 7/1/17 – 6/30/21. NIH. Total Funds Requested: $1,850,000. Title: Development of Targeted Therapies for Pancreatic Cancer. Role: Co-Investigator (6% effort)

• NIH R01 (PIs: CristiniWangCurley). 7/1/17 – 6/30/22. NIH. Total Funds Requested: $2,929,866. Title: Development of a quantitative method for predicting drug response of hepatocellular carcinoma (HCC) to non-invasive radiofrequency hyperthermia (Ni-RFH) and chemotherapy. Role: PI (2.4 calendar)

• NIH/U01 CTSA (PIs: OzpolatVolk). 6/1/17 – 5/31/22. NIH. Total Funds Requested: $2,250,000. Title: Highly Targeted Therapies for Pancreatic Cancer. Role: Co-I (15% effort)

• DOD BCRP Breakthrough Level 3 (PI: Sen). 5/1/17 – 4/30/21. NIH. Total Funds Requested: $1,250,000. Title: Integrated Molecular and Imaging Biomarker Signatures of Prognosis for High Risk Breast Ductal Carcinoma In Situ (DCIS). Role: Co-I (8% effort)

• Human Frontier Science ProgramInternational (PIs: CasertaCristiniCurley). 4/1/17 – 3/31/22. Total Funds Requested: $1,000,000. Title: A novel microfluidic approach to investigate tumor micro-metabolism and invasion. Role: PI (1.2 calendar)

• NIH/U01 PSOP (PI: Ennio Tasciotti). 4/1/17 – 3/31/22. NIH. Total Funds Requested: $2,500,000. Title: Dietary impact on osteosacroma cellularmetabolic and pharmaceutical transport. Role: Co-Investigator (10% effort)

• NIH/U01 MSM (PIs: CristiniWangLowengrubKoay). 4/1/17 – 3/31/22. NIH. Total Funds Requested: $2,500,000. Title: Multiscale Modeling of the Progression of Pancreatic Neoplasms to Invasive Pancreatic Cancer. Role: PI (15% effort)

• NIH/R21 (PIs: David FuentesKhaled ElsayesZhihui Wang). 4/1/17 – 3/31/19. NIH. Total Funds Requested: $275,000. Title: Mathematical modeling of drug response of hepatocellular carcinoma to targeted therapy. Role: Co-I (5% effort)

• NIH/R21 (PIs: WangKesari). 4/1/17 – 3/31/19. NIH. Total Funds Requested: $275,000. Title: A multiscale analysis to initial selectiontestingand validation of drug targets in glioblastoma. Role: Co-I (10% effort)

• CPRIT Computational Biology (Co-PIs: CristiniKoay). 12/1/16 – 11/30/19. CPRIT. Total Funds Requested: $900,000. Title: Modeling Immunotherapy Response in Lung Cancer. Role: PI (1.8 calendar)

• NIH/U01 Early Detection (PI: Subrata Sen). 9/1/16 – 8/31/21. NIH. Total Funds Requested: $2,000,000. Title: Early Detection Biomarkers of Pre-malignant High-risk Breast Atypical Ductal Hyperplasia (ADH) and Ductal Carcinoma In Situ (DCIS). Role: Co-Investigator (5% effort)

• NIH U01 (PIs: CristiniFreyerShreve). 7/1/16 – 6/30/21. NIH. Total Funds Requested: $2,727,200. Title: An Integrated Model of ChemicalPhysiological and Metabolic Gradients in Solid Tumors. Role: PI (3.0 calendar)

• NIH U54 (PIs: CurleyWilson). 7/1/16 – 6/30/21. NIH. Total Funds Requested: $11,483,811. Title: Center for Translational Electromagnetic Oncology (CTEO). Role: Mathematical Modeling Core PI (3.0 calendar)

• NSF Division of Mathematical Sciences (PIs: CristiniWang). 7/1/16 – 6/30/19. NSF. Total Funds Requested: $270,000. Title: Multiscale modeling of tumor growthinvasion and microenvironmental interactions. Role: PI (1.2 calendar)

• CPRIT Computational Biology (Co-PIs: CristiniKoay). 3/1/16 – 2/28/19. CPRIT. Total Funds Requested: $450,000. Title: Integrated mechanistic mathematical modeling and quantitative imaging analyses for human. Role: PI (1.2 calendar)

• NIH U54 CCNE (Co-PIs: SoodLopezGorenstein). 9/1/15 – 8/31/20. NIH. Total Funds Requested: $ 13,000,000. Title: Texas Center for Cancer Nanomedicine. Role: Co-Investigator (Biomathematics Core; 1.2 calendar)

Proposals Planned (to be submitted)

(Ongoing)

• DOD W81XWH-resubmission (MPIs: EkmekciogluKoayCristini). DOD. Total Funds Requested: $1,050,000. Title: Innate immune markers contribution in the tumor microenvironment architecture predicts response to immunotherapy in acral melanomas. Role: MPI (0.6 calendar)

• R01 (WangOzpolatCristini) (Houston Methodist)PAR-20-284. Research topic: To optimize miR-873-based nanotherapeutics and complete preclinical safety and efficacy studies in clinically relevant TNBC and PDAC models. To be submitted in February 2024

• R01 (ChungWangCristini) (MD Anderson). Research topic: Development of a multiscale mathematical model for optimizing combination therapy based on immunotherapy and radiation therapy in patients with melanoma brain metastases. To be submitted in February 2024

• NIH/R01 resubmission (MPIs: ChungHusseinCristini). NIH. Total Funds Requested: $4,127,000. Title: Personalization of Treatment for Patients Receiving Immunotherapy for Melanoma Brain Metastases using Imaging and Fluid-Based Mathematical Modeling. To be submitted March 2024

• R01 (WangOzpolatCristini) (Houston Methodist)PAR-22-071. Research topic: To develop clinically applicablesafeeffective and highly specific KRAS-targeted RNAi-nanotherapeutics for the molecular targeting of mutated KRAS oncogene and translate them to clinical trials for treatment of pancreatic cancer patients. To be submitted in February 2024

• NIH/R01 (Resubmission) (MPIs: WangSood). Title: Developmentexperimental testingand retrospective clinical validation of a mechanistic model of immunotherapy in ovarian cancer treatment. To be submitted March 2024

• R01 (WangChenCristini) (Houston Methodist). Research topic: Development of quantitative early indicators for predicting breast cancer response to immunotherapy treatment using mathematical modeling and preclinical models. To be submitted in February 2024

• NIH/R01 (MD Anderson) (KoayCristini et al.). Topic: Prediction of the therapeutic efficacy of immunotherapy for pancreatic cancer by accounting for the principles of physics and biology in cancer treatment. To be submitted February 2024

• NIH/R01 (MD Anderson) (WangOzpolatCalin et al.). Topic: A systems biology approach to understand cell to cell communication by TP53 regulation of exosomal non-coding RNAs in human cancers. To be submitted February 2024. (Ongoing)

• NIH/ R21RFA-CA-22-021 (ButnerWangChungCristini). Topic: Hybridizing mechanistic mathematical model with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy. To be submitted October 2023

• NIH/R01PAR-21-166: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (AIP – R01). With MD Anderson Cancer Center (PlodinecKoayHongWelsh et al.). Topic: Development of clinically measureable mathematical markers for prognostic identification of patient response to immunotherapy. To be submitted February 2024

• NIH/U01PAR-22-242: Bioengineering Research Grants (BRG). With HM (Chen et al.)MD Anderson Cancer Center (PlodinecKoayHongWelsh et al.)Baylor College of Medicine (Thompson et al.). Topic: An integrated mathematical modeling and clinical approach to cancer treatment prediction. To be submitted June 2024

• NSF 22-1 (MPIs: CristiniLowengrub). NSF. Total Funds Requested: TBD. Title: Mathematical modeling of biophysical transport of immune infiltrates in lung cancer. Role: Co-Leader. To be submitted September 2024

• NIH/U54 ROBIN (MPIs: KoayAzadJavleCristini). NIH. Total Funds Requested: $8,109,461. Title: MD Anderson/Johns Hopkins Cholangiocarcinoma ROBIN Center. Role: MPI/Data Science Core Co-Leader (1.2 calendar). To be submitted October 2024

PUBLICATIONS

Abstracts (selected)

1. P. DograJ. CaveJ.D. ButnerV. CristiniZ. Wang. Multiscale Modeling-Identified Synergistic Combinations of Anti-microRNA-155 and Standard-of-Care Drugs for Improved Outcomes in Non-small Cell Lung Cancerin AAPS PharmSci 360 Conference. 2023: OrlandoFL.

2. M. FarhatJ.D. ButnerZ. WangM. ShankerW. TalpurS. ThrowerL. EricksonJ. BronkH. LangshawB.L. TranD. YadavA. ElliottC. WangH.A. TawbiV. CristiniC. Chung. Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis. Journal of Clinical Oncology2023. 41(16_suppl): p. e14013-e14013.

3. Peláez MJRamírez JRShen YBirur RMSchiavone CCristini VPuri AWang ZDogra P*. “Mechanistic modeling for optimal design of dissolvable microneedle-based patches for transdermal drug delivery” Proceedings of the 2021 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2023 Jul; SydneyAustralia.

4. Cave JShinglot VButner JDCristini VBulent OCalin GADogra P*Wang Z*. “Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer” Proceedings of the 2021 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2023 Jul; SydneyAustralia.

5. Dogra PShinglot VCave JCristini VWang Z. Muliscale Mechanisic Modeling of Nanoparticle-Delivered Anti-microRNA-155 Therapy and Its Combination With Standard-of-Care Drugs in Lung Cancer. 17th U. S. National Congress on Computational MechanicsAlbuquerqueNMUSA. July 23-272023.

6. M. FarhatJ. D. ButnerM. ShankerW. TalpurS. ThrowerL. EricksonD. YadavB. TranJ. BronkH. LangshawA. ElliottZ. WangV. Cristiniand C. Chung. Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis. ASCO Annual Meeting 2023June 2-62023.

7. Akeemat TPuri APeláez MJDogra PRapidly Development of an Iontophoresis-Coupled Microneedle Skin Patch of Naloxone for Emergency Treatment of Opioid Overdose. 2023 Appalachian Student Research ForumJohnson CityTNUSA. April 252023

8. Capuani SHernandez NPaez-Mayorga JDogra PWang ZCristini VChua CYXNichols JEGrattoni A. Local Delivery of Drugs in a 3D Bioengineered Subcutaneous Niche: Biodistribution and Pharmacokinetics. 8th Nano Today Conference. April 22-252023. San DiegoCAUSA

9. Nizzero SZaugg GZhang LXu YPeláez MJMariam Gachechiladze Gchechiladze MDogra PMenegaz BAJordan LBPurdie CAQuinlan PRNagi CSepulveda KAOertle PAppenzeller AChen SHLoparic MWang ZCristini VPlodinec MThompson AM. Heterogeneity of Mechano-Physical Biomarkers Drive Outcome in Breast Cancer: A Quantitative Spatial Analysis Approach. Gordon Research Conference Physical Sciences of Cancer: Physical Oncology Across Biological Scales: SignalsSystemsForces and FluxesGalvestonTXUSA. Feb 5-10 2023. Invited talk.

10. Nizzero SGchechiladze MZaugg GZhang LXu YPeláez MJDogra PMenegaz BAJordan LBPurdie CAQuinlan PRNagi CSepulveda KAOertle PAppenzeller AChen SHLoparic MWang ZCristini VPlodinec MThompson AM. Highly Multiplexed Spatial Analysis of Breast Cancer Tissues Reveals Functional Mechanical Drivers for Long Term Patient Outcome. Gordon Research Seminar Physical Sciences of Cancer: Quantitative Hallmarks of the Tumor MicroenvironmentGalvestonTXUSA. Feb 5-10 2023. Invited talk.

11. Nizzero SG SrivastavaP OertleM WasleyM KimAppenzeller TBarsoumian HLoparic MWang ZA CortezN PueblaP DograCristini VM Plodinec MWelsh. Nanomechanical Signature of Low Dose Radiation-induced Tumor Stroma Remodulation Mediates Tumor Response in Lung Adenocarcinoma. Gordon Research Seminar Physical Sciences of Cancer: Quantitative Hallmarks of the Tumor MicroenvironmentGalvestonTXUSA. Feb 5-10 2023. Invited talk.

12. Capuani SHernandez NPaez-Mayorga JDogra PWang ZCristini VChua CYXNichols JEGrattoni A. Biodistribution of locally delivered drugs in a 3d bioengineered subcutaneous niche. 7th Bioengineering & Translational Medicine ConferenceBostonMAUSA. December 14-162022.

13. Nizzero SZhang LXu YPeláez MJDogra PMenegaz BAJordan LBPurdie CAQuinlan PRNagi CSepulveda KAOertle PAppenzeller AChen SHLoparic MWang ZCristini VPlodinec MThompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. American Association of Cancer ResearchNew OrleansLAUSA. April 8-13 2022. Cancer Research 82 (12S)19632022.

14. Dogra PSchiavone CCaserta SWang ZCristini V. Mathematical modeling identifies optimal dosing schedules for COVID-19 vaccines to minimize breakthrough infections. American Association of Pharmaceutical Scientists PharmSci 360 ConferenceBostonMAUSA. October 16-192022.

15. Farhat M.JD ButnerS ThrowerL EricksonZ WangV CristiniD YadavB TranJ BronkH LangshawA ElliottC ChungGrowth Kinetic Mathematical Modeling to Predict Individual Melanoma Brain Metastasis Response to Immunotherapyin Radiological Society of North America 108th Scientific Assembly and Annual Meeting. 2022: ChicagoIL.

16. Dogra PRuiz Ramírez JButner JDPeláez MJCristini VWangZ2021. A Multiscale Model to Identify Limiting Factors in Nanoparticle-Based miRNA Delivery for Tumor Inhibition. Proceedings of the 2021 43nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2021 Oct-Nov; GuadalajaraMexico.

17. Dogra P.Peláez J. M.RamirezJ.R.SinhaK.ButnerJ.D.CristiniV.Wang Z. “Investigating the role of innate immunity in the control of SARS-CoV-2 infection using a mathematical model” American Association of Pharmaceutical Scientists PharmSci 360 Conference. 2021.

18. DograP.RamírezJ.R.PeláezM.J.ButnerJ.D.CristiniV.WangZ. Translational mechanistic modeling for treatment optimization of nanoparticle-delivered miRNA-22 therapy in triple negative breast cancer. 9th Annual Houston Methodist Cancer Symposium. Virtual. 2021.

19. KCE TallawiD KitkungvanJ XuV CristiniEY YangMA Quinones... Potential explanation for disproportionate left ventricular enlargement in Barlow's disease: insights from cardiovascular magnetic resonance. Journal of the American College of Cardiology 75 (11_Supplement_1)2128-21282020

20. DograP.Peláez J. M.RamirezJ.R.ButnerJ.D.CristiniV.Wang Z. “Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine”. Special poster presentation session at the American Association of Pharmaceutical Scientists PharmSci 360 Conference. 2020.

21. D.A. AnayaJ.G. WilkesP. DograZ. WangM. HaiderJ. EhabD.K. JeongM. GhayourimG.Y. LauwersK. ThomasR. KimJ.D. ButnerS. NizzeroJ.R. RamirezJ.B. FlemingV. CristiniTumor-Site Chemotherapy Concentration Predicts Response To Treatment In Patients With Colorectal Liver Metastasis: A New Paradigm For Individualized Cancer Care. HPB202022(10).

22. P DograMJ PeláezJR RamírezJD ButnerV CristiniZ Wang“Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine.” PharmSci3602020.

23. Dogra PChuang Y-LButner JDCristini VWang Z. 2020. Investigating the Effect of Aging on the Pharmacokinetics and Tumor Delivery of Nanomaterials using Mathematical Modeling. 42nd Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. MontrealCanada. July 20-242020.

24. Dogra PChuang Y-LButner JDRamirez JRCristini VWang Z. 2019. A multiscale mathematical model to study nanomedicine delivery in solid tumors. American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Conference. San AntonioTXUSA. November 3-62019.

25. Dogra PChuang Y-LButner JDCristini VWang Z. 2019. Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors. 41st Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. BerlinGermany. July 23-272019.

26. C WangD ElganainyM ZaidJ ButnerV CristiniE Koay. “Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer”. International Journal of Radiation Oncology• Biology• Physics103:5E48–E49April 2019.

27. Butner JDCristini VWang Z. Multiscale modeling of ductal carcinoma in situ. The 63rd Annual Meeting of the Biophysical Society. BaltimoreMD. March 2-62019. Biophysical J 116(3)322a2019.

28. Butner JDCristini VWang Z. 2018. Understanding Ductal Carcinoma In Situ Invasion using a Multiscale Agent-Based Model. The 40th Annual International IEEE EMBS Conference. HonoluluHIUSA.

29. S CurleyV CristiniA novel mechanistic mathematical model of the heat equation and energy balance for absorption of non-invasive radiofrequency (RF) energy in biologic tissues. Society for Thermal Medicine annual meeting 2018.

30. Butner JDCristini VWang Z. 2017. Development of a Three DimensionalMultiscale Agent-Based Model of Ductal Carcinoma In Situ. 39th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. Jeju IslandKorea. Pp. 86-89.

31. Y LeeV CristiniGR VaradhacharyM KatzH WangP BhosaleEP TammJB FlemingEJ Koay2016/10/1Quantitative Computed Tomography Analysis Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. International Journal of Radiation Oncology• Biology• Physics962E199Elsevier

32. ButnerJ.CristiniV.WangZ. Development of a Three DimensionalLattice-free Multiscale Model of the Mammary Terminal End Bud. 38th Annual International IEEE EMBS ConferenceOrlandoFLUS. August 16-202016

33. ButnerJ.CristiniV.WangZ. A Modeling Approach to Study the Normal Mammary Gland Growth Process. 37th Annual International IEEE EMBS Conference. MilanItaly. August 25-292015.

34. SimbawaE.CristiniV. 2015 The 4th International Conference on Pure and Applied Mathematics (ICPAM 2015). RomaItalyJuly 16-172015.

35. KoayE.J.CristiniV.FlemingJ.B.FerrariM.CraneC.H. Advanced imaging analysis and mechanistic mathematical oncology in human pancreatic cancer. 36th Annual International IEEE EMBS Conference ChicagoILUS. August 26-302014.

36. WangZ.KerkettaR.ChuangY.L.CristiniV. Development of a Diffusion-Based Mathematical Model for Predicting Chemotherapy Effects. 36th Annual International IEEE EMBS Conference. ChicagoILUS. August 26-302014.

37. DograP.TownsonJ.ChuangY.L.WangZ.BrinkerC.J.CristiniV. “Understanding and Optimizing Intravascular Nano-Bio Interactions with Mathematical Modeling.” The Eighth q-bio Conference. Santa FeNMUS. August 13-162014.

38. KerkettaR.ButnerJ.BrocatoT.DograP.DayA.JohnJ.ChuangY.L.WangZ.CurleyS.CristiniV. Predicting chemotherapeutic outcomes in patients with colorectal cancer liver metastases. The Eighth q-bio Conference. Santa FeNMUS. August 13-162014.

39. BearerE.L.WangZ.CristiniV. Mathematical modeling and correlation of Histopathology with perfusion-contrast CT for prediction of vascular permeability and chemotherapeutic diffusion parameters. Minisymposium - Cancer Inflammation Immunity and Angiogenesis. American Society for Investigative Pathology Meeting. San DiegoCAUS. Apr 26-302014.The FASEB J 28397.72014.

40. LoewenbergM.PascalJ.ChauviereA.CristiniV. Modeling Motor-Assisted Intracellular Cargo TransportAIChE Annual Meeting. San FranciscoCAUS. November 62013.

41. KerkettaR.WangZ.CristiniV. Mathematical Modeling of Diffusion Barriers in Colorectal Cancer Metastases to the Liver. Nanoparticle Synthesis and Applications to Cancer Imaging and Treatment Symposium (CNTC)Science & Math Learning CenterMain CampusUNM. AlbuquerqueNMUS. August 162013.

42. KerkettaR.WangZ.CristiniV.Mathematical Modeling of Diffusion Barriers in Colorectal Cancer Metastases to the Liver. The Seventh q-bio ConferenceSt. John’s CollegeSanta FeNMUS. August 82013.

43. ChuangY.L.LewisM.T.WangZ.CristiniV.ChauviereA. Self-organization and pattern formation in mammary gland development. The Seventh Annual q-bio Conference on Cellular Information Processing. Santa FeNMUS. August 7-102013.

44. Chuang,Y.L.WangZ.CristiniV.LewisM.T.ChauviereA. Modeling mammary ductal morphogenesis: self-organization and pattern formation in mammary gland development. The Society for Mathematical Biology Annual Meeting and Conference. PhoenixAZUS. June 10-132013.

45. ChuangY.L.CristiniV.ChenY.L.LiX.FrieboesH.B.LowengrubJ.S. Modeling growth and dissemination of lymphoma in a co-evolving lymph node: a diffuse-domain approach. Bulletin of the American Physical Society Vol 582013.

46. FrieboesH.B.WuM.LowengrubJ.DecuzziP.CristiniV. Analysis of nanoparticle uptake by tumor vasculature using computational modeling. Poster at ASME 2nd Global Congress on Nanoengineering for Medicine & Biology. BostonMAUS. February 4-62013.

47. KoayE.CristiniV.et al. Novel CT-derived biophysical markers describe gemcitabine delivery and chemoradiation response in human pancreatic adenocarcinoma. American Radium Society Annual Meeting. ScottsdaleAZUS. April 27 - May 12013.

48. WangZ.PascalJ.ChuangY.L.DasH.GurcanM.CristiniV. Impact of Diffusion Barriers to IFN-γ on Breast Cancer Immunotherapy. Poster presentation. Physical Sciences in Oncology (PSOC) 4th Annual MeetingScottsdaleAZUS. April 17-192013.

49. GehlotP.PascalJ.CristiniV.CurleyS. Biomathematical Modeling of Diffusion Barriers in Gottingen Mini Pigs. Poster Presentation. Physical Sciences in Oncology (PSOC) 4th Annual MeetingScottsdaleAZUS. April 17-192013.

50. PascalJ.WangZ.CurleyS.BearerE. L.CristiniV. Diffusion Properties Limit Effectiveness of Chemotherapy in Metastatic Colorectal Cancer. Poster presentation. Physical Sciences in Oncology (PSOC) 4th Annual MeetingScottsdaleAZUS. April 17-192013.

51. PascalJ.AshleyC.WangZ.BrinkerC.J.CristiniV. Predictive Biophysical Modeling of Dose Response of Tumor Cells Treated with Free Drug and Protocells. Selected for Oral Presentation at Young Investigator’s Meeting. Physical Sciences in Oncology (PSOC) 4th Annual MeetingScottsdaleAZUS. April 17-192013.

52. ChuangY.L.CristiniV.ChenY.LiX.FrieboesH.B.LowengrubJ.S. Modeling tumor growth in an evolving tissue structure: a diffuse domain approach. 57th Annual Meeting of Biophysical Society. PhiladelphiaPAUS. February 2-62013. Biophysical J 104(2)496a-497a2013.

53. Spatio-Temporal Modeling Center workshopUniversity of New MexicoUnderstanding Cell Behavior through Single Cell and Single Molecule Biology. Poster Presentation. University of New MexicoAlbuquerqueNMUS. January 10-122013.

54. FrieboesH.B.WuM.LowengrubJ.DecuzziP.CristiniV. Analysis of nanoparticle uptake by tumor vasculature using computational modeling. Poster Presentation. Physical Sciences in Oncology Annual ConferencePhoenixAZUS. 2013.

55. CristiniV.KoayE.BearerE.CurleyS.FerrariM.GambhirS.S.FrieboesH.B.SmithB.PascalJ.WangZ. Mathematical Models of Tumor Microenvironment Transport Accurately Predict Limitations to Chemo/Radiation Delivery and Outcome. Poster Presentation. Physical Sciences in Oncology Annual ConferencePhoenixAZUS. 2013.

56. DograPWangZ.CristiniV. ‘Cancer Research at the Interface of Physical Sciences and Biology.’ Biomedical Sciences Graduate Program SymposiumUNM. AlbuquerqueNMUS. 2013.

57. PascalJ.LoewenbergM.GonzalesA.AdairE.CristiniV.BearerE.L. Measurements and modeling of axonal transport: Amyloid precursor protein wins over negative charge in the race to the synapse. The American Society for Cell Biology Annual Meeting. San FranciscoCAUS. Dec 15-192012.

58. FrieboesH.B.WuM.LowengrubJ.S.DecuzziP.CristiniV. Biomathematical Modeling of Nanoparticle Transport in Tumor Tissue. NCI Alliance for Nanotechnology in Cancer Annual Meeting. HoustonTXUS. November 13-172012.

59. ChuangY.L.CristiniV.ChenY.LiX.FrieboesH.Lowengrub. J. Modeling Lymphoma Growth in an Evolving Lymph Node Using a Diffuse Domain Approach. 65th Annual Meeting of the APS Division of Fluid Dynamics. San DiegoCAUS. November 18-202012.

60. PascalJ.AshleyC.WangZ.BrinkerC.J.CristiniV. Overcoming Transport Barriers to Deliver Drugs to Tumors. AIChE National Meeting. PittsburghPAUS. October 28-November 22012.

61. PascalJLoewenbergM.ChauviereA.SeamsterP.BearerE.CristiniV. Mathematical Modeling of Intracellular Transport in the Squid Giant Axon. AIChE National Meeting. PittsburghPAUS. October 28-November 22012.

62. BearerE.L.PascalJ.SeamsterP.HarrisZ.LoewenbergM.DeGiorgisJ.CristiniV. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. STMC site visitAlbuquerqueNM. August 2012.

63. ChuangY.L.CristiniV.ChenY.LiX.FrieboesH.LowengrubJ. Adapting a Tumor Growth Model to an Evolving Domain Using a Diffuse-Domain Approach. The Society for Mathematical Biology Annual Meeting and Conference. KnoxvilleTNUS. July 25-282012.

64. PascalJ.LoewenbergM.ChauviereA.SeamsterP.BearerE.CristiniV. Mathematical Modeling of Intracellular Transport in the Squid Giant Axon. the Society for Mathematical Biology Annual Meeting and Conference. KnoxvilleTNUS. July 25-282012.

65. “Cell Migration Features in Brain Tumor Invasion: Mathematical Modeling and Analysis.” 9th AIMS International Conference on Dynamical SystemsDifferential Equations and Applications. Submitted to the special session: “Mathematical Models of Cancer and Cancer Therapy.” OrlandoFLUS. July 2012 (A. Chauviere).

66. "Dynamical SystemsDifferential Equations and Applications," 9th AIMS International Conference. Invited to mini-symposium: "Mathematical Models of Cancer and Cancer Therapy." OrlandoFLUS. July 2012 (A. Chauviere).

67. "Data-driven Modeling in Mathematical Oncology," Annual meeting of Society for Mathematical BiologyNIMBioSInvited in mini-symposiumKnoxvilleTNUS. July 2012 (A. Chauviere).

68. BearerE.L.PascalJ.SeamsterP.HarrisZ.LoewenbergM.DeGiorgisJ.CristiniV. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. Department of Pathology Research DayEmbassy SuitesAlbuquerqueNMUS. May 2012.

69. van de VenWuM.LowengrubJ.CristiniV.FerrariM.FrieboesH.B. Optimization of Nanotherapeutics Delivery via an Integrated Intravital Microscopy/Mathematical Modeling Approach. Physical Sciences in Oncology Annual Conference. TampaFLUS. April 16-18 2012.

70. FrieboesH.B.WuM.LowengrubJ.DecuzziP.CristiniV. Modeling of Biobarriers to Nanoparticle Transport in Tumors. Physical Sciences in Oncology Annual ConferenceTampaFLUS. April 16-182012.

71. PascalJ.LoewenbergM.ChauviereA.SeamsterP.BearerE.CristiniV. Mathematical Modeling of Intraceullar Transport in the Squid Giant Axon. Poster presentation. IRACDA Annual Meeting. PhiladelphiaPAJune 2012.

72. BearerE.L.CristiniV. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. The New Mexico SpatioTemporal Modeling Center. Invited Presentation. March 2012.

73. ChauviereA.HatzikirouH.KevrekidisI.G.LowengrubJ.S.CristiniV. Multiscale Modeling of Interacting Multicellular Systems: Preliminary Models of Solid Tumor Growth. Workshop: "Mathematics of ICBP”TampaFLUS. March 2012.

74. ChuangY.L.EdgertonM.E.MacklinP.YangW.BearerE.L.CristiniV. Predicting Tumor Sizes of Ductal Carcinoma in situ from Immunohistochemical Images Using a Novel Approach of Mathematical Pathology: Preliminary ResultsPotentials and Challenges Ahead. American Physical Society Annual Meeting. BostonMAUS. February 27- March 22012.

75. ChuangY.L.CristiniV.ChenY.LiX.FrieboesH.B.LowengrubJ. A Cahn-Hilliard Model of Vascularized Tumor Growth in a Complex Evolving Confinement Using a Diffuse Domain Approach. American Physical Society Annual Meeting. BostonMAUS. February 27-March 22012.

76. J PascalM LoewenbergA GonzalesE AdairV CristiniEL Bearer. Measurements and modeling of axonal transport: Amyloid precursor protein wins over negative charge in the race to the synapse. Molecular biology of the cell 232012

77. Cristini. V. A NovelPatient-Specific Mathematical Pathology Approach for Prediction of Tumor Growth. Annual Interdisciplinary Symposium of the NCI-ICBP Center for Modeling Cancer Development. HoustonTXUS. February 2012.

78. ChauviereA. CristiniV. From Normal Mammary Gland Development to Breast Tumor Growth: Development of Well-Suited Multiscale Modeling Approach. Annual

Interdisciplinary Symposium of the NCI-ICBP Center for Modeling Cancer Development. HoustonTXUS. February 2012.

79. FrieboesH.B.SmithB.ChuangY.L.ItoK.RoettgersA.GambhirS.S.CristiniV. Integrated Computational/Experimental Modeling of Lymphoma Growth. Physical Sciences in Oncology Annual Conference. TampaFL2012.

80. WangZ.ChauviereA.LewisM.CristiniV. Multiscale Modeling of Mammary Gland Development. The Methodist Hospital Research Institute. HoustonTXUS. 2012.

81. CristiniV. Multiscale in-silico modeling of drug/nanoparticle transport barriers and tumor response. Sandia/UNM Cancer Center Symposium on Nanoparticle Human Interactions. June 2-32011

82. ChuangY.LowengrubJ.Chen,Y.LiX.FrieboesH.Cristini,V. Modeling tumor growth in a complex evolving confinement using a diffuse domain approach. Conference Abstract: 64th Annual Meeting of the American Physical Society’s Division of Fluid Dynamics. BaltimoreMaryland. 2011.

83. EL BearerV Cristini. Physical laws predict that tumor eradication by systemic therapy is limited. The FASEB Journal 25243.12-243.122011

84. BearerE.SeamsterP.Z. HarrisZ.LoewenbergM.DeGiorgisJ.,CristiniV. Mathematical Modeling of Competitive Cargo Motor Receptors in the Squid Giant Axon. Conference Abstract: American Society for Cell Biology Annual Meeting. DenverColorado. 2011.

85. BearerE.CristiniV. Predictive modeling of chemotherapy. Annual Meeting of the American Society for Investigative Pathology. WashingtonD.C. 2011.

86. PE SeamsterEL BearerZ HarrisM LoewenbergJ DeGiorgisV Cristini. Analysis of competition between cargo motor receptors during active transport in the squid giant axon: Evidence for a hierarchy of motor-affinities. Molecular biology of the cell 222011

87. ChuangY.EdgertonM.MacklinP.YangW.BearerE.CristiniV. A NovelPatient-Specific Mathematical Pathology Approach for Accurate Prediction of Tumor Growth. Conference Abstract: 5th Annual q-bio Conference on Cellular Information Processing. Santa FeNew Mexico. 2011. (Presenter: CristiniV.)

88. ChauviereA.HatzikirouH.CristiniV. The Go-or-Grow hypothesis in glioma growth: mathematical modeling and analysis. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). KrakowPoland. 2011.

89. ItoK.SmithB.FrieboesH.CristiniV.GambhirS. Determination of molecular and cellular characteristics in drug-resistant and –sensitive lymphoma using multiple co-localized marker immunohistostaining for accurate multiscale model calibration. Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La JollaCalifornia. 2011.

90. MacklinP.EdgertonM.EvansA.PurdieC.JordanL.ThompsonA.CristiniV. Patient-calibrated modeling of ductal carcinoma in situ (DCIS): From microscopic measurements to macroscopic predictions of clinical progression. Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La JollaCalifornia. 2011

91. FrieboesH.CristiniV. 3D Mathematical Modeling and Simulation of Lymphoma. Poster Presentation: Second Annual National Cancer Institute Physical Sciences-Oncology Centers (NCI PS-OCs) Network Investigators' Meeting. La JollaCalifornia.2011

92. ChauviereA.CristiniV. Multiscale modeling of the role of stem cells in mammary gland development and carcinogenesis. The Methodist Hospital Research Institute Integrative Cancer Biology Program Seminar Series. HoustonTexas. 2011.

93. MacklinP.EdgertonM.ThompsonA.CristiniV. An illustration of patient-specific cancer modeling: from microscopic data to macroscopicquantitative predictions. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). KrakowPoland. 2011.

94. MacklinP.EdgertonM.ThompsonA.CristiniV. Mechanistic cell-scale modelling of ductal carcinoma in situ (DCIS): impact of cell biomechanics. 8th European Conference on Mathematical and Theoretical Biology / Annual Meeting of the Society for Mathematical Biology (ECMTB/SMB). KrakowPoland. 2011

95. CristiniV. Multiscale Modeling of Cancer Stem Cells. The Center for Modeling Cancer Development Annual Interdisciplinary Symposium. HoustonTexas. 2011.

96. EdgertonM.ChuangY.MacklinP.KimJ.TomaiuoloG.BroomA.SangaS.CristiniV. Simulations of Growth of DCIS Parameterized from IHC. Lab. Invest. 89:37A. 2011.

97. WongA.MacklinP.ChuangY.CristiniV.SandersM.SchuylerP.DupontW.PageS.EdgertonM. Development of a Population Based Model for Progression of DCIS to Invasion. Lab. Invest. 90:78A. 2010.

98. LeS.SangaS.BroomB.AldapeK.CristiniV.EdgertonM. Analysis of Microarray Data from High Grade Gliomas across Multiple Institutions. Lab. Invest. 90:425A. 2010.

99. WongA.MacklinP.ChuangY.CristiniV.SandersM.SchuylerP.DupontW.PageD.EdgertonM.. “Development of a Population Based Model for Progression of DCIS to Invasion.” Modern Pathol. 23(1):78A. 2010

100. LeS.SangaS.BroomB.AldapeK.CristiniV.and M. EdgertonM. Analysis of Microarray Data from High Grade Gliomas across Multiple Institutions. Modern Pathol. 23(1):425A. 2010.

101. FrieboesH.CristiniV. Integrated Computational/Experimental Modeling of Cancer. Poster Presentation: Second Annual Univ. of Southern California PS-OC Symposium. Los AngelesCalifornia. 2010.

102. KumarA.ChuangY.MacklinP.SangaS.KimJ.TamaiuoloG.CristiniV.EdgertonM.A model to predict the proliferation index of ductal carcinoma in situ. Proceedings of the 100th AACR Annual Meeting. 50:592. 2010. Cancer Res 69 (9S)24442009.

103. EdgertonM.ChuangY.MacklinP.SangaS.KimJ.TamaiuoloG.YangW.BroomA.DoK.,CristiniV. Using mathematical models to understand the time dependence of the growth of ductal carcinoma in situ. Cancer Research. 62(2):156S. 2009.

104. Thomas C ChenSandeep SangaTina Y ChouVittorio CristiniMary E Edgerton. Neural network with K-means clustering via PCA for gene expression

profile analysis. 2009/3/31 2009 WRI World Congress on Computer Science and Information Engineering 3 670-673 IEEE

105. M ChaplainP MacklinSteven Robert McDougallA AndersonV CristiniJ Lowengrub. Multiscale modelling of vascular tumour growth. 2009/7 International Conference on Mathematical Biology and Annual Meeting of the Society for Mathematical Biology

106. EdgertonM.SangaS.Downs-KelleyE.CristiniV. Does Androgen Receptor Have a Role in a Subgroup of ER Negative Breast Cancer? Lab. Invest. 89:370A. 2009.

107. EdgertonM.SangaS.Downs-KelleyE.CristiniV. Cristini. Does Androgen Receptor Have a Role in a Subgroup of ER Negative Breast Cancer? Modern Pathol. 89:370A. 2009.

108. CristiniV.BearerE. Computational modeling identifies morphologic predictors of tumor invasion. The FASEB J. 22(321.7) 2008

109. CristiniV.BearerE. Computational modeling identifies morphologic predictors of tumor invasion. Neuro-oncology. 9(4):512. 2007

110. LiX.CristiniV.NieQ.LowengrubJ. Nonlinear three-dimensional simulation of solid tumor growth. Discr. and Contin. Dynam. Syst. Series B. 7(3):581-604. 2007.

111. TrappV.HanE.CristiniV.FruehaufJ. Thrombospondin-1 modulation of response to antiangiogenic agents determined in vitro using a melanoma-vascular endothelial cell spheroidal co-culture model. Proceedings of the 98th AACR Annual Meeting. 48:1100. 2007. Cancer Res 67 (9S)46482007.

112. CristiniV.BearerE. Computational modeling identifies morphologic predictors of tumor invasion. Proceedings of the 98th AACR Annual Meeting. 48:936. 2007. Cancer Res 67 (9S)39522007.

113. B BadieEL BearerE BullittV CristiniZH ChoVR Edgerton...Board of Directors of IBMISPS and IBMISPS-Foundation. NeuroImage 37S22007

114. V CristiniH FrieboesJ FruehaufPredictive computer simulations of tumor drug response demonstrate that 3-D hypoxic gradients significantly increase drug resistance. Journal of Clinical Oncology 24 (18_suppl)2071-20712006

115. V TrappE HanV CristiniJP FruehaufThe use of vascularized spheroids to evaluate the in vitro activity of antiangiogenic drugs. Cancer Research 66 (8_Supplement)1202-12022006

116. S LiuJL GaudiotV CristiniPrototyping virtual cancer therapist (VCT): a software engineering approach. 2006 International Conference of the IEEE Engineering in Medicine2006

117. CristiniV. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. Nanomedicine: NanotechnologyBiologyand Medicine 4 (2)2762006

118. V CristiniTwo-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Journal of Clinical Oncology 23 (16_suppl)2118-21182005

119. HB FrieboesES HanV CristiniJP FruehaufModeling breast cancer tumor morphology to predict drug response. Cancer Res 65 (9 Supplement)1403-14032005

120. S LiX LiJ LowengrubP LeoV CristiniNonlinear crystal growth and control of the Mullins-Sekerka instability. 2004 MRS Fall Meeting88-932004

121. X ZhengV CristiniJ LowengrubA AndersonAdaptive numerical simulation of drop/interface and drop/drop interactions. APS Division of Fluid Dynamics Meeting Abstracts 57NB. 0042004

122. YN YoungF HamN RiemerM HerrmannV CristiniDrop Size Distribution in Turbulent Mixing of Two-Phase Flows. APS Division of Fluid Dynamics Meeting Abstracts 57FJ. 0092004

123. V CristiniP LeoS LiX LiJ LowengrubNonlinear Crystal Growth and Control of the Mullins-Sekerka Instability. Materials research society symposium proceedings 859882004

124. L PhamV CristiniJS LowengrubComputer simulations of blood flow. APS Division of Fluid Dynamics Meeting Abstracts 56AR. 0072003

125. S WiseV CristiniJ LowengrubX ZhengA fluid model of cancer progression and treatment. APS Division of Fluid Dynamics Meeting Abstracts 56KE. 0042003

126. J LowengrubV CristiniThe effect of flow on the morphology of growing crystals. APS Division of Fluid Dynamics Meeting Abstracts 56JQ. 0102003

127. J LowengrubV CristiniJS KimX LiJ GallowayC MacoskoNumerical simulation of co-continuous fluids. APS Division of Fluid Dynamics Meeting Abstracts 56JG. 0052003

128. J LowengrubV CristiniJS KimX ZhengZ Mohammed-Kassim...Studies of Drop/Drop and Drop/Interface Impact. APS Division of Fluid Dynamics Meeting Abstracts 56AF. 0102003

129. X ZhengV CristiniJ LowengrubT AndersonAn algorithm for adaptive remeshing of 2D and 3D domains: Application to the level-set method. APS Division of Fluid Dynamics Meeting Abstracts 56KH. 0092003

130. V CristiniJ LowengrubH ZhouC MacoskoNumerical simulation of drop breakup and coalescence with soluble. APS Division of Fluid Dynamics Meeting Abstracts 56AQ. 0082003

131. A AndersonJ LowengrubC MacoskoV CristiniAn adaptive unstructured tetrahedral mesh. APS Division of Fluid Dynamics Meeting Abstracts 55JA. 0032002

132. X ZhengJ LowengrubE LongmireV CristiniAdaptive simulations of drop/interface impact and rupture. APS Division of Fluid Dynamics Meeting Abstracts 55FC. 0072002

133. V CristiniH ZhouJ LowengrubC MacoskoThe effect of surfactants on drop deformationcollisions and breakup. APS Division of Fluid Dynamics Meeting Abstracts 54FM. 0042001

134. J LowengrubV CristiniJS KimC MacoskoNumerical simulation of co-continous emulsions. APS Division of Fluid Dynamics Meeting Abstracts 54KA. 0122001

135. V CristiniJ LowengrubQ NieSelf-similar tumor growth with angiogenesis. APS Meeting Abstracts 46C2. 0052001

136. V CristiniR HooperJ LowengrubS ShakyaThree-dimensional multiphase flows. APS Division of Fluid Dynamics Meeting Abstracts 53ML. 0092000

137. Y RenardyV CristiniNumerical simulations of a drop under simple shear. APS Division of Fluid Dynamics Meeting Abstracts 53MM. 0042000

138. X ZhengV CristiniJ LowengrubAdaptive mesh simulations of very viscous multi-component flows. APS Division of Fluid Dynamics Meeting Abstracts 53GP. 0022000

139. J BlawzdziewiczV CristiniM LoewenbergNear-critical behavior and critical conditions for drop breakup in linear flows with rotation. APS Division of Fluid Dynamics Meeting AbstractsFK. 021999

140. J BlawzdziewiczV CristiniM LoewenbergSurfactant-covered constant-shape interfaces. APS Division of Fluid Dynamics Meeting AbstractsLJ. 041998

141. J BlawzdziewiczV CristiniM LoewenbergCritical conditions for drop breakup in linear flows. APS Division of Fluid Dynamics Meeting AbstractsJA. 071998

142. J BlawzdziewiczV CristiniM LoewenbergLR Collins Direct numerical simulation of three-dimensional drop breakup in isotropic turbulence. Microgravity Fluid Physics & Transport Phenomena Conference4 thCleveland …1998 5

143. J BlawzdziewiczV CristiniM LoewenbergAnalysis of drop breakup in creeping flows. APS Division of Fluid Dynamics Meeting AbstractsAf. 071997

Refereed Original Articles in Journals

1. Messina LFerraro RPeláez MJWangZCristiniVDograPCasertaS. Hybrid Cellular Automata Modeling Reveals the Effects of Glucose Gradients on Tumour Spheroid Growth. Cancers. 2023155660. doi: 10.3390/cancers15235660. PMC10705082

2. Migliaccio GFerraro RWang ZCristini VDogra PCaserta S. Cellular Automata Modelling Reveals Dynamics of Wound Healing Assay. Cancers. 2023 Nov 3;15(21). doi: 10.3390/cancers15215284. PMC10647277

3. Staquicini DICardó-Vila MRotolo JAStaquicini FITang FHFSmith TLGanju ASchiavone CDogra PWang ZCristini VGiordano RJOzawa MGDriessen WHPProneth BSouza GRBrinker LMNoureddine ASnider AJCanals DGelovani JGPetrache ITuder RMObeid LMHannun YAKolesnick RNBrinker CJPasqualini RArap W. Ceramide as an endothelial cell surface receptor and a lung-specific lipid vascular target for circulating ligands. Proc Natl Acad Sci U S A. 2023 120(34):e2220269120. doi: 10.1073/pnas.2220269120. PMID: 37579172

4. Dogra PSchiavone CWang ZRuiz-Ramírez JCaserta SStaquicini DIMarkosian CWang JSostman HDPasqualini RArap WCristini V. A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection. JCI Insight. 2023 8(13):e169860. doi: 10.1172/jci.insight.169860. PMC10371350

5. Sarkar SMishra APeriasamy SDyett BDogra PBall ASYeo LYWhite JFWang ZCristini VJagannath CKhan ASoni SKDrummond CJConn CE. Prospective Subunit Nanovaccine against Mycobacterium tuberculosis Infection-Cubosome Lipid Nanocarriers of Cord FactorTrehalose 6,6' Dimycolate. ACS Appl Mater Interfaces. 2023 15(23):27670-27686. doi: 10.1021/acsami.3c04063. Epub 2023 Jun 1. PMID: 37262346

6. Butner JDDogra PChung CPasqualini RArap WLowengrub JCristini VWang Z. Mathematical Modeling of Cancer Immunotherapy for Personalized Clinical Translation. Nature Computational Science 2785–796 (2022 Dec). https://doi.org/10.1038/s43588-022-00377-z

7. J.D. ButnerM. FarhatV. CristiniC. Chungand Z. WangProtocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. STAR Protocols2022 Dec. 3(4): p. 101886.

8. Terracciano RCarcamo-Bahena YRoyal ALRMessina LDelk JButler EBDemarchi DGrattoni AWang ZCristini VDogra PFilgueira CS. Zonal Intratumoral Delivery of Nanoparticles Guided by Surface Functionalization. Langmuir. 2022 Nov 1;. doi:10.1021/acs.langmuir.2c02319. PubMed PMID: 36318182.

9. Syed MCagely MDogra PButner JDCristini VKoay EJ. Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models. WIREs Nanomedicine and Nanobiotechnology 2022 Sep 23;:e1855. doi: 10.1002/wnan.1855. [Epub ahead of print] Review. PubMed PMID: 36148978.

10. Capuani SHernandez NPaez-Mayorga JDogra PWang ZCristini VChua CYXNichols JEGrattoni A. Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment. Materials Today Bio. 2022 Dec;16:100390. doi: 10.1016/j.mtbio.2022.100390. eCollection 2022 Dec. PubMed PMID: 36033374; PubMed Central PMCID: PMC9403502.

11. Puri A.Tijani ADogra PPeláez MJWang ZCristini VMechanistic modeling-guided optimization of microneedle-based skin patch for rapid transdermal delivery of naloxone for opioid overdose treatment. Drug Deliv Transl Res. 2022 Jul 25;. doi: 10.1007/s13346-022-01202-w. [Epub ahead of print] PubMed PMID: 35879533.

12. Butner JDDogra PChung CRuiz-Ramírez JNizzero SPlodinec MLi XPan PYChen SHCristini VOzpolat BCalin GAWang Z. Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death Dis. 2022 May 21;13(5):485. doi: 10.1038/s41419-022-04939-x. PubMed PMID: 35597788; PubMed Central PMCID: PMC9124196.

13. WangC.X.D. ElganainyM.M. ZaidJ.D. ButnerA. AgrawalS. NizzeroB.D. MinskyE.B. HollidayC.M. TaniguchiG.L. SmithA.C. KoongJ.M. HermanP. DasA. MaitraH. WangR.A. WolffM.H. KatzC.H. CraneV. Cristiniand E.J. KoayMass transport model of radiation response: calibration and application to chemoradiation for pancreatic cancer. Int J Radiat Oncol Biol Phys2022. PMID 35643254.

14. Markosian CStaquicini DIDogra PDodero-Rojas ELubin JHTang FHFSmith TLContessoto VGLibutti SKWang ZCristini VKhare SDWhitford PCBurley SKOnuchic JNPasqualini RArap W. Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection. Mol Biol Evol. 2022 May 3;39(5). doi: 10.1093/molbev/msac091. PubMed PMID: 35511693.

15. AO KasebE HasanovHST CaoL XiaoJN Vauthey… Cristini VJ AllisonP SharmaPerioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomisedopen-labelphase 2 trial. The Lancet Gastroenterology & Hepatology7(3)208-2182022

16. Ferraro RAscione FDogra PCristini VGuido SCaserta S. (2022)Diffusion-induced anisotropic cancer invasion: a novel experimental method based on tumour spheroids. AIChE J. e17658. doi: 10.1002/aic.17678

17. Dogra PRamírez JRButner JDPeláez MJChung CHooda-Nehra APasqualini RArap WCristini VCalin GAOzpolat BWang Z. Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharm Res. 2022 Mar 16;. doi: 10.1007/s11095-022-03176-3. [Epub ahead of print] PubMed PMID: 35294699.

18. Butner JDMartin GVWang ZCorradetti BFerrari MEsnaola NChung CHong DSWelsh JWHasegawa NMittendorf EACurley SAChen SHPan PYLibutti SKGanesan SSidman RLPasqualini RArap WKoay EJCristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. ELife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130. PMID: 34749885. PMC8629426

19. Gok Yavuz BHasanov ELee SSMohamed YICurran MAKoay EJCristini VKaseb AO. J Hepatocell Carcinoma. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021 Sep 24;8:1195-1207. doi: 10.2147/JHC.S322289. PMC8478438

20. FI StaquiciniRL ZemansBK DrayM Cardo-VilaJ Ruiz-RamirezP DograZ WangV CristiniDI StaquiciniRL SidmanR PasqualiniW Arap. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. ELife. 2021;10:e65145. doi: 10.7554/eLife.65145. PMID: 34060472. PMC8169110

21. P DograEJ KoayZ WangFS VahidyM FerrariR PasqualiniW ArapML BoomHD SostmanV Cristini. Is the worst of the COVID-19 global pandemic yet to come? Application of financial mathematics as candidate predictive tool. Translational Psychiatry. 2021;11(1):299. doi: 10.1038/s41398-021-01429-0. PMID: 34016952. PMC8134815

22. P AmeroGLR LokeshR Cardenas-ZunigaRR ChaudhariYM AttiaE Montalvo-GonzalezZ WangV CristiniV de FranciscisS ZhangDE VolkR MitraCristian Rodriguez-AguayoAK SoodG Lopez-Berestein. Translation of RNA aptamer into modified DNA aptamers provide for prolonged stability and enhanced antitumor activity. Journal of the American Chemical Society. 2021;143(20):7655-7670. doi: 10.1021/jacs.9b10460. PMID: 33988982

23. Corradetti BDogra PPisano SWang ZFerrari MChen S-HSidman RLPasqualini RArap WCristini V. Comparing and Contrasting Amphibian Tissue Regeneration to Mammalian Cancer: An Evolutionary Perspective. BioEssays. 2021. e2000339. doi: 10.1002/bies.202000339. PMID: 33751590

24. D AnayaP DograZ WangM HaiderJ EhabD JeongM GhayouriR KimJB FlemingV Cristini. Chemotherapy Concentration at the Tumor Site Predicts Response to Chemotherapy in Patients with Liver Metastasis: Application of a Mechanistic Mathematical Model. Cancers. 2021; 13(3):444. doi: 10.3390/cancers13030444. PMC7866038

25. Carlos El-TallawiKitkungvan DXu JCristini VYang EYQuinones MALawrie GMZoghbi WAand Shah DJ. Resolving the Disproportionate Left Ventricular Enlargement in Mitral Valve Prolapse Due to Barlow Disease: Insights from Cardiovascular Magnetic Resonance. JACC: Cardiovascular Imaging. 2021 Mar;14(3):573-584. doi: 10.1016/j.jcmg.2020.08.029. PMID: 33129724

26. Dogra PRuiz-Ramírez JSinha KButner JDPeláez MJRawat MYellepeddi VKPasqualini RArap WSostman HDCristini VWang Z. Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model. ACS Pharmacology & Translational Science. 2021; 4: 248-265. DOI: 10.1021/acsptsci.0c00183. PMCID: PMC7805603

27. A GorurR BayraktarC IvanP KanlikilicerN KahramanE BayraktarHA Mokhlis,N KabilC RodriguezL TamerB AslanZ WangV CristiniG CalinG Lopez-BeresteinB Ozpolat. ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Molecular Therapy Nucleic Acids. 2021 Jan 20;23:930-943. doi: 10.1016/j.omtn.2021.01.016. PMC7868999

28. M ZaidD ElganainyP DograA DaiL WidmannP FernandesZ WangMJ PelaezJR RamirezAD SinghiAK DasyamRE BrandWG ParkS RahmanuddinMH RosenthalBM WolpinN KhalafA GoelDD Von HoffEP TammA MaitraV CristiniEJ Koay. Imaging-based subtypes of pancreatic ductal adenocarcinoma exhibit differential growth and metabolic patterns in the pre-diagnostic period: implications for early detection. Frontiers in Oncology. 2020; 10:596931. DOI: 10.3389/fonc.2020.596931. PMC7738633

29. G BrachiJ Ruiz-RamirezP DograZ WangV CristiniR RostomilyG CiardelliM FerrariA MikheevE BlancoC Mattu. Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma. Nanoscale. 2020; 12(46):23838-23850. DOI: 10.1039/d0nr05053a. PMID: 33237080

30. DI StaquiciniEM BarbuRL ZemansBK DrayFI StaquiciniP DograM Cardó-VilaCK MirantiWB BazeLL VillaJ KalilG SharmaER ProssnitzZ WangV CristiniRL SidmanAR BermanRA Panettieri JrRM TuderR PasqualiniW Arap. Targeted Phage Display-based Pulmonary Vaccination in Mice and Non-human Primates. Cell Med. 2021; 2(3):321-342. 10.1016/j.medj.2020.10.005

31. JD ButnerZ WangD ElganainyKA FeghaliM PlodinecGA CalinP DograS NizzeroJ Ruiz RamirezGV MartinHA TawbiC ChungEJ KoayJW WelshDS HongV CristiniA mechanistic immunotherapy model provides patient-specific quantification of immune response and associated long-term tumor burden. Nature Biomedical Engineering. 2021; 5(4):297-308. 10.1038/s41551-020-00662-0.

32. E SimbawaS AlharbiJ AljohaniH AbosamraS AboushoushahCristini VMathematical model of immunotherapy response to antibodies as a treatment for cancer. Commun. Math. Biol. Neurosci. 2020Article ID 232020

33. S GoelG ZhangP DograS NizzeroJ GuV CristiniZ WangZ LiX LiuH ShenM Ferrari. Sequential deconstruction of composite drug transport in metastatic breast cancer. Science Advances. 2020; 6(26):eaba4498. doi: 10.1126/sciadv.aba4498. PMC7314527

34. Butner JDFuentes DOzpolat BGeorge CAZhou XJohn JCristini VWang Z. A Multiscale Agent-Based Model of Ductal Carcinoma in Situ. IEEE Trans Biomed Eng. 2020 May;67(5):1450-1461. PMID: 31603768

35. JD ButnerD ElganainyCX WangZ WangS-H ChenNF EsnaolaR PasqualiniW ArapDS HongJ WelshEJ KoayV CristiniMathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Science Advances. 2020; 6(18):eaay6298. PMC7190324

36. Dogra PButner JRuiz-Ramirez JPelaez MJCJ BrinkerCristini VWang Z. A Mathematical Model to Predict Nanomedicine Pharmacokinetics and Tumor Delivery. Computational and Structural Biotechnology Journal. 2020;18:518-531. PMC7078505

37. Dogra PRuiz-Ramirez JButner JNizzero SElganainy DPelaez MJNoureddine ALe A-DKoay ELeong H-SCJ BrinkerCristini VWang Z. Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. WIREs Nanomedicine and Nanobiotechnology. 2020. Apr 21;e1628. PMID: 32314552

38. Pichler MRodriguez-Aguayo CNam SYAnfossi SKnutsen EFuentes-Mattei ELee SKLing HIvkovic TCHuang GHuang LOkugawa YBayraktar EBhattacharya RPaola AVychytilova-Faltekova PKlec CEscobar DBZhang XKapitanovic SBozo LGafà RWang ZCristini VIvan CBar-Eli MLanza GSlaby OGoel ARigoutsos ILopez-Berestein GCalin GA. FLANCa novel primate-specific long non-coding RNAis involved in colorectal carcinogenesis and holds potential as a novel therapeutic target. Gut. 2020. pii: gutjnl-2019-318903. doi: 10.1136/gutjnl-2019-318903. PMID: 31988194

39. Dogra PRamírez JRPelaez MJWang ZCristini VParasher GRawat M. Mathematical Modeling of Pancreatic Cancer: Applications in DiagnosisPrognosisand Treatment. Current topics in medicinal chemistry. 2020;20(5):367-376.. doi: 10.2174/1568026620666200101095641. PMID: 31893993

40. OD LaraS KrishnanZ WangS CorvignoY LyonsR DoodW HuL QiJ LiuRL ColemanSN WestinN FlemingV CristiniA RaoJ BurksAK Sood. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports. 2019; 9(1):17589. doi: 10.1038/s41598-019-53872-1. PMC6879510

41. S GoelC FerreiraP DograB YuC KutyreffC SiamofJ EngleT BarnhartV CristiniZ WangW Cai. Size-optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-based Differential Targeting in Triple Negative Breast Cancer/Tumor Targeting. Small. 2019;e1903747. 10.1002/smll.201903747. PMC6854296

42. Brocato TAGlaberman-Brown UWang ZSelwyn RGWilson CMWyckoff EFLomo LSaline JHooda-NehraAPasqualini RArap WBrinker CJCristini V. Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies. JCI Insight. 2019;4(8):e126518. PMC6538356

43. Dogra PButner JDChuang YLCaserta SGoel SBrinker CJCristini VWang Z. Mathematical modeling in cancer nanomedicine: a review. Biomed Microdevices. 2019 21(2):40 [PMC6449316] (Invited)

44. Dogra PAdolphi NLWang ZLin YSButler KSDurfee PNCroissant JGNoureddine ACoker ENBearer ELCristini V**Brinker CJ**. Establishing the effects of mesoporous silica nanoparticle size and surface chemistry on in vivo disposition using imaging-based pharmacokinetics. Nature Communications. 2018 Oct 31;9(1):4551. doi: 10.1038/s41467-018-06730-z.PubMed PMID: 30382084; PubMed Central PMCID: PMC6208419. (**Co-senior Authors).

45. TA BrocatoEN CokerPN DurfeeY-S LinJ TownsonEF WyckoffV CristiniCJ BrinkerZ Wang. Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling. Scientific Reports 2018. 8(1):7538. PMC5967303

46. Koay EJLee YCristini VLowengrub JSKang YLucas FASHobbs BPYe RElganainy DAlmahariq MAmer AMChatterjee DYan HPark PCRios Perez MVLi DGarg NReiss KAYu SChauhan AZaid MNikzad NWolff RAJavle MVaradhachary GRShroff RTDas PLee JEFerrari MMaitra ATaniguchi CMKim MPCrane CHKatz MHWang HBhosale PTamm EPFleming JB: A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-58942018

47. ButnerJ.D.ChuangY-L.SimbawaE.AL-FhaidA.S.MahmoudS.R.CristiniV.WangZ. (2016). A hybrid agent-based model of the developing mammary terminal end bud. Journal of Theoretical Biology. 407:259-270. [PMC5010453].

48. WangZ.KerkettaR.ChuangY.L.DograP.ButnerJ.D.BrocatoT.A.DayA.XuR.ShenH.SimbawaE.Al-FhaidA.S.MahmoudS.R.CurleyS.A.FerrariM.KoayE.J.CristiniV. (2016). Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. PLoS Comput Biol. 10;12(6):e1004969. [PMC4902302]

49. PaineI.ChauviereA.LanduaJ.SreekumarA.CristiniV.RosenJ.LewisM.T. (2016). A Geometrically-Constrained Mathematical Model of Mammary Gland Ductal Elongation Reveals Novel Cellular Dynamics within the Terminal End Bud. PLoS Comput Biol. 26;12(4):e1004839. [PMC4845990]

50. HosoyaH.DobroffA.S.Driessen W.H.Cristini V.Brinker L.M.StaquiciniF.I.Cardó-VilaM.D'AngeloS.FerraraF.PronethB.LinY.S.DunphyD.R.DograP.MelanconM.P.StaffordR.J.MiyazonoK.GelovaniJ.G.KataokaK.BrinkerC.J.SidmanR.L.ArapW.PasqualiniR.(2016). Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A. 2016. 16;113(7):1877-82. [PMC4763738]

51. FrieboesH.B.SmithB.R.WangZ.KotsumaM.ItoK.DayA.CahillB.FlindersC.MumenthalerS.M.MallickP.SimbawaE.Al-FhaidA.S.MahmoudS.R.GambhirS.S.CristiniV. (2015). Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PloS one. 10:e0129433. [PMC4464754]

52. WangZ.,ButnerJ.KerkettaR.CristiniV.DeisboeckT.S. (2015). Simulating cancer growth with multiscale agent-based modeling. Seminars in Cancer Biology 30:70-78. [PMC4216775] (Invited)

53. KiruiD.K.KoayE.J.GuoX.CristiniV.ShenH.FerrariM. (2014). Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport. Nanomedicine: NanotechnologyBiology and Medicine 2014 10(7):1487-96. [PMC4025989]

54. KoayE.TrutyM.Cristini**V.et al. (2014). Transport properties of pancreatic cancer describe gemcitabine delivery and response. J. Clinical Investigation 124(4):1525-1536. [PMC3973100] (** co-first author)

55. WuM.FrieboesH.B.S.R.ChaplainM.A.J.CristiniV.LowengrubJ.S. (2014).The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems. J Theor Biol. 355:194-207.

56. KoayE.J.BaioF.E.OndariA.TrutyM.J.CristiniV.ThomasR.M.ChenR.ChatterjeeD.KangY.ZhangJ.CourtL.BhosaleP.R.TammE.P.QayyumA.CraneC.H.JavleM.KatzM.H.GottumukkalaV.N.RoznerM.A.ShenH.LeeJ.E.WangH.ChenY.PlunkettW.AbbruzzeseJ.L.WolffR.A.MaitraA.FerrariM.VaradhacharyG.R.JB Fleming. (2014). Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Physical biology. 11:065002. [PMC4266401]

57. BrocatoT.DograP.KoayE.J.DayA.ChuangY-L.WangZ.CristiniV. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports 2014 6(2): 110-120. [PMC4039558] (Invited)

58. TangL.Van de VenA.L.GuoD.CristiniV.LiK.C.ZhouX. (2014) Computational Modeling of 3D Tumor Growth and Angiogenesis for Chemotherapy Evaluation. PLoS One. 9(1):e83962 [PMC3880288]

59. WangZ.ButnerJ.D.CristiniV.DeisboeckT.S. (2014). Integrated PK-PD and agent-based modeling in oncology. J Pharmacokinetics and Pharmacodynamics. 42:179-189. [PMID: 25588379]

60. WangZ.DeisboeckT.S.CristiniV. (2014). Development of a sampling-based global sensitivity analysis workflow for multiscale computational cancer models. IET Systems Biology 8(5):191-7. [PMC4180114]

61. DasH.Wang Z.NiaziK.AggarwalR.LuJ.KanjiS.DasM.JosephM.GurcanM.CristiniV. (2013) Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer. PloS One. 8:e61398. [PMC3631240]

62. PascalJ.BearerE.L.WangZ.KoayE.J.CurleyS.A.CristiniV. (2013). Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc. Natl. Acad. Sci. USA. 110: 14266-14271. [PMC3761643]

63. PascalJ. AshleyC.E.,WangZ.BrocatoT.A.ButnerJ.CarnesE.C.KoayE.J.BrinkerC.J.CristiniV. (2013). Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nanocarrier-mediated response. ACS Nano. 7(12): 11174-11182. [PMC3891887]

64. WuM.FrieboesH.B.McDougallS.R.ChaplainM.A.J.CristiniV.LowengrubJ.S. (2013).The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol. 320:131-151. [PMC3576147]

65. FrieboesH.B.WuM.LowengrubJ.DecuzziP.CristiniV. (2013). A computational model for predicting nanoparticle accumulation in tumor vasculature. PloS One. 8:e56876. [PMC3585411]

66. FrieboesH.B.SmithB.R.ChuangY.L.Ito. K.RoettgersA.MGambhirS.S.CristiniV. (2013). An integrated computational/experimental model of lymphoma growth. PLoS Computational Biology. 9:e1003008. [PMC3610621]

67. HatzikirouH.ChauviereA.BauerA.LeierA.LewisM.MacklinP.Marquez-LagoTBearerE.CristiniV. (2012) Integrative Physical Oncology. WIREs Syst. Biol. Med. 4(1): 1-14. [PMC3622087]

68. MacklinP.EdgertonM.E.ThompsonA.M.CristiniV. (2012) Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): From microscopic measurements to macroscopic predictions of clinical progression. J. Theor. Biol. 301:122-40. [PMC3322268]

69. SeamsterP.E.LoewenbergM.PascalJ.ChauviereA.GonzalesA.CristiniV.BearerE. (2012). Quantitative measurements and modeling of cargo-motor interactions during fast transport in the living axon. Phys Biol. 9:055005. [PMC3625656]

70. PhamK.ChauviereA.HatzikirouH.LiX.ByrneH.M.CristiniV.LowengrubJ. (2012). Density-dependent quiescence in glioma invasion: instability in a simple reaction-diffusion model for the migration/proliferation dichotomy. Journal of Biological Dynamics. 6 Suppl 1:54-71. [PMC3623708]

71. ChauviereA.HatzikirouH.KevrekidisI.G.LowengrubJ.S.CristiniV. (2012). Dynamic density functional theory of solid tumor growth: Preliminary Models. AIP Advances 2011210special topic on Physics of Cancer [PMC3321520]

72. Van de VenA.WuM. LowengrubJ.S.McDougallS.R.ChaplainM.A.J.CristiniV.FerrariM.FrieboesH.B. (2012). Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Advances2:011208special topic on Physics of Cancer. [PMC3321519]

73. DeisboeckT.WangZ.MacklinP.,CristiniV. (2011). Multiscale Cancer Modeling. Annual Review of Biomedical Engineering.13(1):127-155. [PMC3883359]

74. PhamK.FrieboesH.CristiniV.LowengrubJ. (2011). Predictions of tumour morphological stability and evaluation against experimental observations. J R Soc Interface. 8(54): 16-29. [PMC3024820]

75. EdgertonM.ChuangY.-L.MacklinP.YangW. BearerE. L.CristiniV. (2011). A NovelPatient-Specific Mathematical Pathology Approach For Assessment Of Surgical Volume: Application To Ductal Carcinoma In Situ Of The Breast. Anal. Cell. Pathol. 34(5):247-63. [PMC3613121]

76. LowengrubJ.FrieboesH.JinF.ChuangY.-L.LiX.MacklinP.WiseS.CristiniV. (2010). Nonlinear modeling of cancer: Bridging the gap between cells and tumors. Nonlinearity. 23:R1-R91.

77. FrieboesH.B.JinF.ChuangY.L.WiseS.M.LowengrubJ.S.CristiniV. (2010). Three-Dimensional Multispecies Nonlinear Tumor Growth II: Tumor Invasion and Angiogenesis. J. Theor. Biol. 264(4):1254-78.

78. De MagalhaesN.LiawL.BernsM.CristiniV.ChenZ.StupackD.LowengrubD. (2010). Applications of a new In vivo tumor spheroid based shell-less chorioallantoic membrane 3-D model in bioengineering research. J Biomed Sci Eng. 3(1): 20-26.

79. ChauviereA.HatzikirouH.LowengrubJ.FrieboesH.ThompsonA.CristiniV. (2010). Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer?. Curr Breast Cancer Rep. 2(3): 121-129.

80. FrieboesH.ChaplainM.A.J.ThompsonA.BearerE. L.LowengrubJ.CristiniV. (2011). Physical oncology: a bench-to-bedside quantitative and predictive approach. Cancer Research. 71(2): 298-302.

81. SM WiseJS LowengrubV Cristini. An adaptive multigrid algorithm for simulating solid tumor growth using mixture models. Mathematical and Computer Modelling 53 (1-2)1-202011

82. BearerE.L.LowengrubJ.S.ChuangY.-L.HermannB.FrieboesH.B.JinF.WiseS.M.FerrariM.AgusD.CristiniV. (2009) Multiparameter Computational Modeling of Tumor Invasion.^[4][5] Cancer Research. 69: 4493-4501.

83. FrieboesH. B.EdgertonM.E.FruehaufJ. P.RoseF.R.A.J.WorrallL. K. R.GatenbyA.FerrariM.CristiniV. Prediction of drug response in breast cancer using integrative experimental/computational modeling.^[6] Cancer Research. 69: 4484-4492. 2009

84. SinekJ.SangaS.ZhengX.FerrariM.CristiniV. (2009). Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. Journal of Mathematical Biology. 58(4-5):485-510. (Invited)

85. MacklinP.McDougallS.AndersonA.R.A.ChaplainM.A.J.CristiniV.LowengrubJ. (2009). Multiscale modeling and nonlinear simulation of vascular tumour growthJournal of Mathematical Biology. 58(4-5):765-98.

86. CristiniV.LiX.LowengrubJ.S.WiseS.M. (2009) Nonlinear simulations of solid tumor growth using a mixture model: invasion and branching. Journal of Mathematical Biology. 58(4-5):723-63.

87. SangaS.BroomB.M.CristiniV.EdgertonM.E. (2009). Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Medical Genomics. 2:59.

88. WiseS.M.LowengrubJ.FrieboesH.B.CristiniV. (2008). Three-dimensional multispecies nonlinear tumor growth—I Model and numerical method. J Theor Biology. 253(3):524-43.

89. YoungY.-N.BlawzdziewiczJ.CristiniV.GoodmanR. (2008). Hysteretic and chaotic dynamics of viscous drops in creeping flows with rotation. Journal of Fluid Mechanics. 607:209-34.

90. LemaireJ.J.CosteJ.OuchchaneL.CaireF.NutiC.DerostP.CristiniV.GabrillarguesJ.HemmS.DurifF.ChazalJ.(2007). Brain Mapping in Stereotactic Surgery: A Brief Overview From the Probabilistic Targeting To the Patient-Based Anatomic Mapping. NeuroImage; 37S 1. S109-S115 (review).

91. FrieboesH.LowengrubJ.WiseS.ZhengX.BearerE.CristiniV. (2007). Computer simulation of glioma growth and morphology. NeuroImage; 37S 1. S59-S70.

92. SangaS.Frieboes,H.ZhengX.GatenbyR.BearerE.CristiniV. (2007) Predictive oncology: a review of multidisciplinarymultiscale in-silico models connecting phenotypemorphology and growth. NeuroImage; 37S 1. S120-S134 (invited review).

93. LiXCristiniV.NieQ.LowengrubJ. (2007). Nonlinear three-dimensional simulation of solid tumor growth. Discrete and Continuous Dynamical Systems B. 7(3):581-604. (invited)

94. FrieboesH.ZhengX.SunC.-H.TrombergB.GatenbyR.CristiniV. (2006). An integrated computational/experimental model of tumor invasion^[7]. Cancer Research. 66(3):1597-604.

95. MadsenS. J.SunC.-H.TrombergB. J.CristiniV.DeMagalhaesN.HirschbergH. (2006). Multicell tumor spheroids in photodynamic therapy. Lasers in Surgery and Medicine. 38(5):555-64 (review).

96. SangaS.SinekJ.FrieboesH.FerrariM.FruehaufJ.CristiniV. (2006). Mathematical modeling of cancer progression and response to chemotherapy: towards the development of a multiscale computer simulator. Expert Review of Anticancer Therapy. 6(10):1361-76.

97. TanY.-C.CristiniV.LeeA. P. (2006). Monodispersed microfluidic droplet generation by shear focusing microfluidic device. Sensors & Actuators B: Chemical 2006;114(1):350-6.

98. CristiniV.RenardyY. (2006). Scalings for droplet sizes in shear-driven breakup: non-microfluidic ways to monodisperse emulsions. Fluid Dynamics and Materials Processing. 2(2):77-94 (invited review).

99. DunnJ. C. Y. ChanW. Y.CristiniV.KimJ. S.LowengrubJ.,SinghS.WuB. M. (2006). Analysis of cell growth in three-dimensional scaffolds. Tissue Engineering. 12(4):705-16.

100. SibilloV.PasquarielloG.SimeoneM.V. CristiniV.GuidoS. (2006). Drop deformation in microconfined shear flow. Physical Review Letters. 97:054502.

101. YangX.JamesA.J.LowengrubJ.ZhengX.CristiniV. (2006). An adaptive coupled level-set/volume-of-fluid interface capturing method for unstructured triangular grids. J. of Computational Physics 2006;217(2): 364-394.

102. CristiniV.FrieboesH.GatenbyR.CasertaS.FerrariM.SinekJ. (2005). Morphological instability and cancer invasion. Clinical Cancer Research. 11(19):6772-9.

103. S LiJS LowengrubPH LeoV Cristini. Nonlinear stability analysis of self-similar crystal growth: control of the Mullins–Sekerka instability. Journal of Crystal Growth 277 (1-4)578-5922005

104. ZhengX.WiseS.CristiniV. (2005). Nonlinear simulation of tumor necrosisneo-vascularization and tissue invasion via an adaptive finite-element/level-set method^[8]. Bulletin of Math Biology. 67(2):211-59.

105. CristiniV.KassabG.S. (2005). Computer modeling of red blood cell rheology in the microcirculation: A brief overview. Annals of Biomedical Engineering. 33(12):1724-7 (invited review).

106. A AndersonX ZhengV Cristini. Adaptive unstructured volume remeshing–I: The method. Journal of Computational Physics 208 (2)616-6252005

107. X ZhengJ LowengrubA AndersonV Cristini. Adaptive unstructured volume remeshing–II: Application to two-and three-dimensional level-set simulations of multiphase flow. Journal of Computational Physics 208 (2)626-6502005

108. XieF.SheuP.LanderA.CristiniV. (2005). Semantic Analysis and Synthesis of Complex Biological Systems. International J. of Software Engineering and Knowledge Engineering. 15(3):547-69.

109. SinekJ.FrieboesH.ZhengX.CristiniV. (2004). Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Biomed Microdev. 6(4):297-309 (invited).

110. TanY.-C.FisherJ.S.LeeA.I.CristiniV.LeeA.P. (2004). Design of Microfluidic Channel Geometries for the Control of Droplet VolumeChemical Concentrationand Sorting. Lab on a Chip. 4(4):292-8.

111. CristiniV.TanY.-C. (2004). Theory and numerical simulation of droplet dynamics in complex flows-A review. Lab on a Chip. 4(4):257-64 (invited review).

112. CristiniV.LowengrubJ. (2004). Three-dimensional crystal growth-II: Nonlinear simulation and control of the Mullins-Sekerka instability. Journal of Crystal Growth. 266(4):552-67.

113. LiS.LeoP.LowengrubJ.CristiniV. (2004). Nonlinear theory of self-similar crystal growth and melting. Journal of Crystal Growth. 267(3-4):703-13.

114. CristiniV.LowengrubJ.NieQ. (2003). Nonlinear simulation of tumor growth. Journal of Mathematical Biology. 46(3):191-224.

115. KhismatullinD.RenardyY.CristiniV. (2003). Inertia-induced breakup of highly viscous drops subjected to simple shear. Physics of Fluids. 15(5):1351-4.

116. PatelP.ShaqfehE.ButlerJ.E.CristiniV.BlawzdziewiczJ.LoewenbergM. (2003). Drop breakup in the flow through fixed fiber beds: An experimental and computational investigation. Physics of Fluids. 15(5):1146-57.

117. V. CristiniV.Guido,S.AlfaniA.BlawzdziewiczJ.LoewenbergM. (2003). Drop breakup and fragment size distribution in shear flow. Journal of Rheology. 47(5):1283-98.

118. BlawzdziewiczJ.CristiniV.Loewenberg,M. (2003). Multiple stationary states for deformable drops in linear Stokes flows. Physics of Fluids. 15(5):L37-40.

119. CristiniV.BlawzdziewiczJ.LoewenbergM.CollinsL. (2003). Breakup in stochastic Stokes flows: sub-Kolmogorov drops in isotropic turbulence. J. of Fluid Mechanics. 492:231-50.

120. LiX.LowengrubJ.NieQ.CristiniV.LeoP. (2003). Microstructure evolution in three-dimensional inhomogeneous elastic media. Metallurgical and Materials Transactions A. 34A(7):1421-31.

121. RenardyY.Y.RenardyM.CristiniV. (2002). A new volume-of-fluid formulation for surfactants and simulations of drop deformation under shear at a low viscosity ratio. European J. of Mechanics B/Fluids. 21(1):49-59.

122. RenardyY.CristiniV.LiJ. (2002). Drop fragment distributions under shear with inertia. International J. of Multiphase Flow. 28(7):1125-47.

123. CristiniV.HooperR.MacoskoC.W.SimeoneM.GuidoS. (2002). A numerical and experimental investigation of lamellar blend morphologies. Industrial & Engineering Chemistry Research. 41(25):6305-11.

124. CristiniV. (2002). Flow-independent drop deformation with zero surface tension. Physics of Fluids. 14(8):2929-32.

125. BlawzdziewiczJ.CristiniV.LoewenbergM. (2002). Critical behavior of drops in linear flows: I. Phenomenological theory for drop dynamics near critical stationary states. Physics of Fluids. 14(8):2709-18.

126. CristiniV.MacoskoC.W.JansseuneT. (2002). A note on transient stress calculation via numerical simulations. Journal of Non-Newtonian Fluid Mechanics. 105(2-3):177-87.

127. CristiniV.LowengrubJ. (2002). Three-dimensional crystal growth-I: linear analysis and self-similar evolution. Journal of Crystal Growth 2002; 240(1-2):267-76.

128. RenardyY.Y.CristiniV. (2001). Effect of inertia on drop breakup under shear. Physics of Fluids. 13(1):7-13.

129. RenardyY.Y.CristiniV. (2001). Scalings for fragments produced from drop breakup in shear flow with inertia. Physics of Fluids. 13(8):2161-4.

130. CristiniV.BlawzdziewiczJ.LoewenbergM. (2001). An adaptive mesh algorithm for evolving surfaces: simulations of drop breakup and coalescence. Journal of Computational Physics. 168(2):445-63.

131. BlawzdziewiczJ.V. CristiniV.LoewenbergM. (1999). Near-contact motion of surfactant-covered spherical drops: Ionic surfactants. Journal of Colloid and Interface Science. 211(2):355-66.

132. BlawzdziewiczJ.V. CristiniV.LoewenbergM. (1999). Stokes flow in the presence of a planar interface covered with incompressible surfactant. Physics of Fluids. 11(2):251-8.

133. CristiniV.BlawzdziewiczJ.LoewenbergM. (1998). Near-contact motion of surfactant-covered spherical drops. J. of Fluid Mechanics. 366:259-87.

134. CristiniV.BlawzdziewiczJ.LoewenbergM. (1998). Drop breakup in three-dimensional viscous flows. Physics of Fluids. 10(8):1781-3.

135. FerrariM.AnzideiL.CristiniV.SimbolottiG. (1995). Impact of the passive stabilization system on the dynamic loads of the ITER first-wall/blanket during a plasma disruption event. Fusion Eng and Design 1995; 27:507-14.

Papers Submitted

1. Kabil NNBayraktar RIvan CKahraman NHamada AMokhlis HACaner AWang ZCristini VRam PTSiddik ZHCalin GALopez-Berestein GOzpolat B. MicroRNA-484 acts as an “Onco-miR” by targeting HOXA5 in Triple Negative Breast Cancer. Molecular Cancer Therapeutics. Under review.

2. Peláez MJ†Goel SCristini VWang ZDogra P*†. “Mechanistic modelling and machine learning to establish structure-activity relationship of nanomaterials for improved tumour delivery” (Invited Book chapterUnder Review Cancer Systems Biology and Translational Mathematical OncologyOxford University Press) 3. Migliaccio GFerraro RWang ZCristini VDogra PCaserta S. Cellular Automata Modelling Reveals Dynamics of Wound Healing Assay. SSRN. 2022 Sep 26. url: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4227003 (Research articleUnder review)

4. Rizvi SAwasthi APeláez MJWang ZCristini VNguyen HVDogra P. Deep learning-derived optimal aviation strategies to control pandemics. arXiv. 2022 Oct 12. doi: 10.48550/arXiv.2210.10888. (Research article preprint)

5. Amereh MShojael SWalsh TDogra PCristini VNadler B. “Unveiling the role of metabolic rates variation in driving tumor heterogeneity and controlling growth and invasion: insights from an integrated multiscale in-vitro in-silico framework.” Research Square. 2023 May 22. doi: 10.21203/rs.3.rs-2828746/v1 (Research articleUnder review)

Papers in Preparation (selected)

1. Nizzero SSchiavone CCristini VDogra P. Mathematical model of Covid-19 mRNA vaccines in pregnancy and lactation: unraveling the fetus response. In preparation.

2. Nizzero SP OertleM WasleyG SrivastavaM KimAppenzeller TBarsoumian HLoparic MWang ZA CortezN PueblaP DograCristini VM Plodinec MWelsh J. Nanomechanics predicts PD1 resistance in lung adenocarcinoma. To be submitted to Nature.

3. Nizzero SZhang LXu LPeláez Soní MJDogra PMenegaz BAJordan LBPurdie CAQuinlan PRNagiSepulveda KOertle PAppenzeller TChen SHLoparic MWang ZCristini VPlodinec MThompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. To be submitted to Nature.

4. Ferrari RAscione FDogra PCristini VGuido SCaserta S. Diffusion induced anisotropic cancer invasion: a novel experimental method based on tumour spheroids. To be submitted to Cancer Research.

5. Dogra PButner JDRuiz-Ramirez JCristini VCalin GAOzpolat BWang Z. A mathematical model for predicting treatment efficacy based on miR-155 in lung cancer. To be submitted to Science Translational Medicine.

6. Dogra PChuang YLHanson JAButner JDCristini VBrinker CJWang Z. A multiscale hybrid model to study nanomedicine delivery in tumors. To be submitted to ACS Nano.

7. Nizzero SRuiz-Ramirez JGoel SKim MTong SQLi FCristini VBlanco ELi ZWang ZFerrari M. A quantitative approach to discover predictors of biodistribution reveals the synergistic role of myeloid-derived cells on the in vivo biodistribution of injectable inorganic particles. To be submitted to Nanomedicine.

8. Dodoo GJacobson GGrandgenett PHollingsworth MCristini VWang ZKoay Eand Butner JD. A mathematical model for predicting CA19-9 normalization and patient survival in pancreatic ductal adenocarcinoma. To be submitted to Journal of Clinical Oncology.

9. J.D. ButnerM. FarhatV. CristiniJ. WelshC. Chungand Z. Wang. Hybridizing mechanistic mathematical model with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy. To be submitted to Nature Computational Science.

10. Dodoo GJacobson GGrandgenett PHollingsworth MCristini VWang ZKoay Eand Butner JD. Predicting CA19-9 normalization and patient survival in pancreatic ductal adenocarcinoma using a combination of mathematical modeling and deep learning. To be submitted to Nature Biomedical Engineering.

11. Butner JDDogra PChung CCristini VWang Z. Mathematical Modeling of Cancer Immunotherapy: Towards Individualized Treatment. To be submitted to npj Precision Oncology. (invited) 12. Amereh MShojael SWalsh TDogra PCristini VNadler B. “Unveiling the role of metabolic rates variation in driving tumor heterogeneity and controlling growth and invasion: insights from an integrated multiscale in-vitro in-silico framework.” Research Square. 2023 May 22. doi: 10.21203/rs.3.rs-2828746/v1 (Research articleUnder review)

13. Cave JWang ZCristini VDogra PFujita M. “Modeling the transport kinetics of 11C-ER176 PET ligand to study the role of blood-CSF barrier in neuroinflammation.” (Research articleUnder preparation)

14. B DeP DograM ZaidD ElganainyK SunAM AmerC WangMK RooneyE ChangHC KangZ WangP BhosaleBC OdisioTE NewhookCD TzengHST CaoYS ChunJ VautheySS LeeA KasebK RaghavM JavleBD MinskySS NoticewalaEB HollidayCM TaniguchiGL SmithAC KoongP DasV CristiniEB LudmirEJ Koay. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. (Research articleUnder preparation)

15. Cave JSchiavone CNguyen HVCampen MStaquicini DBrinker CJCristini VWang ZNoureddine ADogra P*. Modeling for rational design of nanoparticles: enabling safer and targeted nanomedicines. (Review articleIn preparation)

16. Schiavone CCave JCaserta SCristini VAdelman MWang JWang ZDogra P*. A quantitative guide to vaccine immunology: enabling model-informed vaccine development. (Review articleIn preparation)

Invited ReviewsEditorialsetc. in Journals and Magazines

1. Butner JDDogra PChung CPasqualini RArap WLowengrub JCristini VWang Z. Mathematical Modeling of Cancer Immunotherapy for Personalized Clinical Translation. Nature Computational Science 2785–796 (2022 Dec). https://doi.org/10.1038/s43588-022-00377-z

2. Open Access GovernmentApril2021. Is the Pandemic Obeying the Elliott Wave Principle of Financial Markets? (with P Dogra). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=4bc1adac-723d-4261-a012-f8ebe5f8ad14

3. Open Access GovernmentJanuary 2021. Personalized prediction of immunotherapy efficacy: improving clinical approaches via mechanistic mathematical modeling (with JD Butner and Z Wang). Open Access Government2021: p. 116-117. https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=abe4b9c2-2198-40d4-9b41-c05d7aaff94f

4. Open Access GovernmentMay2020. Modeling the whole-body dynamics of SARS-CoV-2 to investigate treatment strategies for effective management of COVID-19 (with P DograK SinhaZ Wang). https://www.openaccessgovernment.org/body-dynamics-of-sars-cov-2-treatment-of-covid-19/86929/

5. Open Access GovernmentMarch 102020. Graph theory in the study of Alzheimer’s disease progression (with M PelaezP DograZ Wang). https://www.openaccessgovernment.org/graph-theory-in-the-study-of-alzheimers-disease-progression/83621/

6. Open Access GovernmentDecember 62019. Giving oncology its power back: A clinical technology revolution is conquering the US from Texas (with S NizzeroM PlodinecZ Wang). https://www.openaccessgovernment.org/oncology/78946/

7. Open Access GovernmentOctober 12019. Profile: Ductal Carcinoma in Situ: Gaining new Biological Insights from Multiscale Mathematical Modeling (with J ButnerZ Wang). https://www.openaccessgovernment.org/wp-content/uploads/2019/10/OAG24-WEB.pdf

8. Open Access GovernmentJuly 92019. In vivo imaging and mathematical modelling in nanoparticle pharmacokinetics (with P DograMJ PelaezZ Wang). https://www.openaccessgovernment.org/mathematical-modelling-nanoparticle-pharmacokinetics/68801/

9. Open Access GovernmentOctober 112018. Regenerative medicine to trump cancer (with B CorradettiP DograM Ferrari). https://www.openaccessgovernment.org/regenerative-medicine-to-trump-cancer/53150/

10. Open Access GovernmentProfile: Towards Precision Oncology in Breast Cancer: Predicting Response to Neoadjuvant Chemotherapy Using Tumor Vasculature Characteristics (with U Brown-GlabermanTA BrocatoR SelwynZ Wang). https://www.openaccessgovernment.org/precision-oncology-breast-cancer/60456/.

11. Open Access GovernmentMay 12018. Profile: Non-invasive radiofrequency hyperthermia (with S CurleyP DograJD ButnerZ Wang). https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=558600cb-8de9-4616-9242-f8f3b41da315&pnum=78

12. Open Access GovernmentAug 312017. Health & Social Care Reports: Targeting stem cell trans-differentiation could eradicate glioblastoma (with J Lowengrub and Chris Hughes) https://www.openaccessgovernment.org/stem-cell-transdifferentiation/36169/

13. Open Access GovernmentJuly 262017Health & Social Care News: The dilemma of over diagnosis of pancreatic cysts (with A Maitra and E Koay) https://www.openaccessgovernment.org/dilemma-diagnosis-pancreatic-cysts/35088/

14. Open Access GovernmentJune 262017Health & Social Care News: Identifying pancreatic cysts that might turn into cancer (with A Maitra and E Koay) https://www.openaccessgovernment.org/identifying-pancreatic-cysts-might-turn-cancer/34409/

15. Open Access GovernmentMay 182017,Health & Social Care Reports: Multimodal feedback control can lead to self-organizing morphogenesis (with J Lowengrub and Arthur Lander). https://www.openaccessgovernment.org/multimodal-feedback-control-can-lead-self-organizing-morphogenesis/34429/

16. WangZ.CristiniV. Research Profile: Tissue-scale factors in predicting cancer treatment outcome. Open Access Government. March 82017. https://www.openaccessgovernment.org/tissue-scale-factors-predicting-cancer-treatment-outcome/32302/

17. WangZ. SenS.CristiniV. Special Report: Development of Integrated Non-Invasive Methods for Cancer Diagnosis and Treatment. Open Access Government Special Report January 232017. https://www.openaccessgovernment.org/integrated-non-invasive-cancer-diagnosis/31174/

18. CorrS.J.S CurleyS.WangZ.CristiniV. Development of Integrated Non-Invasive Methods for Cancer Diagnosis and Treatment. Open Access Government Special Report. April152016. https://www.openaccessgovernment.org/cancer-diagnosis-and-treatment/25598/

19. KoayE.J.FlemingJ.B.WangZ.CristiniV. Understanding cancer through physics. Open Access Government May 42016. https://www.openaccessgovernment.org/understanding-cancer-physics/25938/

20. WangZ.CristiniV. A Spatio-temporal Mathematical Model for Predicting Cancer Treatment Outcome. Open Access Government March 92016. https://www.openaccessgovernment.org/spatio-temporal-mathematical-model-cancer/28963/

21. KoayE.J.CristiniV.WangZ.. Profile: Mathematical pathology in determining surgical volume for breast cancer treatment. Open Access Government Feb 12016. https://www.openaccessgovernment.org/profile-mathematical-pathology-determining-surgical-volume-breast-cancer-treatment/23968/

22. MartinG.V.KoayE.J.CristiniV. The Mathematical Relationship between the Immune System and Cancer and its Implications for Cancer Therapy. Open Access

Government Report. November 112015. https://www.openaccessgovernment.org/mathematical-relationship-immune-system-cancer-implications-cancer-therapy/22262/

23. KoayE.J.WangZ.CristiniV. Profile: Combining biology with physics to solve the cancer problem. Open Access Government November 112015. https://www.openaccessgovernment.org/profile-combining-biology-physics-solve-cancer-problem/22371/

24. CristiniV.KoayE.J.WangZ. Prediction of Cancer Treatment Outcome using Physics. Open Access Government. Special Report. September 302015. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics/21432/

25. CristiniV.KoayE.J.WangZ. Prediction of Cancer Treatment Outcome using Physics. Open Access Government. Special Report. Oct 62015. https://www.openaccessgovernment.org/prediction-cancer-treatment-outcome-using-physics-2/21536/

26. CristiniV.KoayE.J.WangZ. Taking cancer out of the equation. International Innovation. 2015. 191: 38-40.

27. BrocatoT.DograP.Koay,E.J.DayA.ChuangY.L.WangZ.CristiniV. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. Current Breast Cancer Reports. 2014. 6(2): 110-120. [PMC4039558]

28. SinekJ.SangaS.ZhengX.FerrariM.CristiniV. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulations. J of Mathematical Biology. April 2009. 58(4-5):485-510.

29. LiX.CristiniV.NieQ.LowengrubJ.Nonlinear three-dimensional simulation of solid tumor growth. Discrete and Continuous Dynamical Systems B. 2007. 7(3):581-604.

30. SangaS.Frieboes,H.ZhengX.GatenbyR.BearerE.CristiniV. Predictive oncology: a review of multidisciplinarymultiscale in-silico models connecting phenotypemorphology and growth. NeuroImage; 37S 1. 2007. S120-S134.

31. SangaS.SinekJ.FrieboesH.FerrariM.FruehaufJ.CristiniV. Mathematical modeling of cancer progression and response to chemotherapy: towards the development of a multiscale computer simulator. Expert Review of Anticancer Therapy. 2006. 6(10):1361-76.

32. CristiniV.RenardyY.Scalings for droplet sizes in shear-driven breakup: non-microfluidic ways to monodisperse emulsions. Fluid Dynamics and Materials Processing. 2006. 2(2):77-94.

33. CristiniV.KassabG.S. Computer modeling of red blood cell rheology in the microcirculation: A brief overview. Annals of Biomedical Engineering. 2005. 33(12):1724-7.

34. CristiniV.TanY.-C. Theory and numerical simulation of droplet dynamics in complex flows-A review. Lab on a Chip. 2004. 4(4):257-64.

35. SinekJ.FrieboesH.ZhengX.CristiniV. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles. Biomed Microdev. 2004. 6(4):297-309.

Book Chapters

1. Butner JDDogra PCristini VDeisboeck TSWang Z. Computational approaches in multiscale modeling. In Encyclopedia of Cell Biology (Second Edition)R.A. BradshawG.W. Hartand P.D. StahlEditors. 2023Academic Press: Oxford. p. 251-260.

2. Noureddine AButner JDZhu WNaydenkov PPeláez MJGoel SWang ZBrinker CJCristini VDogra P. Emerging lipid-coated silica nanoparticles for cancer therapy. In: Saravanan M.Barabadi H. (eds) Cancer NanotheranosticsVol 1. Nanotechnology in the Life Sciences. SpringerCham. 2021 Oct 6; pp 335-361. doi: 10.1007/978-3-030-74330-7_12

3. WangZ.CristiniV.DeisboeckT.S. (2016). Computational approaches for multiscale modeling. In R.A. Bradshaw & P.D. Stahl (Eds.)Encyclopedia of Cell Biology. Vol. 4 (pp. 80-85). Elsevier.

4. WangZ.CristiniV. (2013). Integration of Molecular Signaling into Multiscale Modeling of CancerMultiscale Computer Modeling in Biomechanics and Biomedical Engineering. In A. Gefen (Ed.)Studies in MechanobiologyTissue Engineering and Biomaterials Volume 14. (pp. 381-394). Springer.

5. HatzikirouH.ChauviereA.LowengrubJ.De GrootJ.CristiniV. (2012). Effect of vascularization on glioma tumor growth. In L. TrachetteJackson (Eds.) Modeling Tumor Vasculature: MolecularCellularand Tissue Level Aspects and Implications. (pp. 237-259). Springer.

6. FrieboesHermann B.LowengrubJ.CristiniV. (2011). Diffusional Instability as a Mechanism of Tumor Invasion. In T.S. Deisboeck & G.S. Stamatakos (Eds.)Multiscale Cancer Modeling. (pp. 193-21). Boca Raton: CRC Press: Taylor & Francis Group.

7. ChaplainM.A.J.MacklinP.McDougallS.AndersonA.R.A.CristiniV.LowengrubJ. (2011). Multiscale Mathematical Modeling of Vascular Tumor Growth: An Exercise in Transatlantic Cooperation. In In T.S. Deisboeck & G.S. Stamatakos (Eds.)Multiscale Cancer Modeling. (pp. 253-308). Boca Raton: CRC Press: Taylor & Francis Group.

8. MacklinP.KimJ.TomaiuoloG.EdgertonM.CristiniV. (2009). Agent-Based Modeling of Ductal Carcinoma in Situ: Application to Patient-Specific Breast Cancer Modeling. In T. Pham (Ed)Computational Biology: Issues and Applications in Oncology. (pp. 77-112). New York: Springer.

9. LowengrubJ.CristiniV.FrieboesH.LiX.MacklinP.SangaS.WiseS.ZhengX. (2009). Nonlinear tumor growth: Modeling and simulation. In B.C. KhooZ. Li&P. Lin (Eds.)IMS Lecture Notes SeriesVol 17: Interface Problems and Methods in Biological and Physical Flows. (pp. 69-134).

10. FrieboesH.DecuzziP.SinekJ.FerrariM.CristiniV. (2008). Computational Modeling of Tumor Biobarriers: Implications for Delivery of Nano-based Therapeutics. In M. Zhang & N. Xi (Eds.)Nanomedicine: A Systems Engineering Approach. (pp. 201-243). Pan Stanford Publishing. (invited)

11. CristiniV.FrieboesH.B.LiX.LowengrubJ.S.MacklinP.SangaS.WiseS.M.ZhengX. (2008). Nonlinear modeling and simulation of tumor growth. In N. BellomoM.A.J. Chaplain& E. de Angelis (Eds.)Selected topics in cancer modeling: Genesisevolutionimmune competitionand therapy. Modelling and Simulation in

ScienceEngineeringand Technology. (pp. 113-82). BirkhäuserBostonMA USA. (invited)

12. SangaS.FrieboesH.SinekJ.CristiniV. (2006). A multiscale approach for computational modeling of biobarriers to cancer chemotherapy via nanotechnology. In T. Webster & H. S. Nalwa (Eds.)Cancer Nanotechnology. (pp. 1-21). American Scientific Publishers. (invited)

13. SinekJ.FrieboesH.SivaramanB.SangaS.CristiniV. (2006). Mathematical and computational modeling: Towards the development and application of nanodevices for drug delivery. In C Kumar (Ed.)Series: Nanotechnologies for the Life Sciences; Vol. 4: Nanodevices for the Life Sciences. (pp. 29-66) Wiley-VCH. (invited)

14. FrieboesH.SinekJ.NalciogluO.FruehaufJ.CristiniV. (2006). Nanotechnology in cancer drug therapy: a biocomputational approach. In A.P. LeeL.J. Lee (Eds.)BioMEMS and Biomedical Nanotechnology 2006; Vol. 1: ProspectusBiological and Biomedical Nanotechnology. (pp. 435-460). Springer-Verlag. (invited)

BOOKS (MONOGRAPHIES)

1. CristiniV.LowengrubJ.WangZ. Biophysical Modeling of Cancer in Silico. Springer. To be published in July 2024.

2. Vittorio CristiniEugene KoayZhihui Wang. An Introduction to Physical Oncology. CRC PressTaylor & Francis Group. July 2017. https://www.crcpress.com/An-Introduction-to-Physical-Oncology-How-Mechanistic-Mathematical-Modeling/Cristini-Koay-Wang/p/book/9781466551343

ISBN-13: 978-1466551343

3. CristiniV.LowengrubJ. (2010). Multiscale Modeling of Cancer: an Integrated Experimental and Mathematical Modeling Approach. Cambridge University Press. ISBN-13: 978-0521884426

E-Books

1. Invited e-book: “Mathematical Pathology” in Global Health & Pharma 2016www.ghp-magazine.com

2. WangZ.CristiniV. (2016) Mathematical Modeling of Drug Delivery via Nanoparticles in Cancer Treatment. Open Access Government. eBook. https://www.openaccessgovernment.org/mathematical-modeling-drug-delivery-via-nanoparticles-cancer-treatment/27830/

3. CristiniV.KoayE.J.WangZ. (2016). The Clinical Application of Mathematical Pathology. Open Access Government. eBook: http://www.adjacentgovernment.co.uk/wp-content/uploads/2016/01/Uni-of-Texas-ebook-web.pdf

Other Professional Communications

Selected: Presentation and Lecture Invitations (mentee involved)

• Cave JWang ZCristini VDogra P. Machine learning-based rational design of nanoparticles for improved safety in biomedical applications. Weill Cornell Graduate School of Medical Sciences RetreatWeill Cornell MedicineNov 22023New YorkNYUSA. (PosterPresenter: Cave J)

• Dogra PCave JButner JCristini VWang Z. Multiscale Modeling-Identified Synergistic Combinations of Anti-microRNA-155 and Standard-of-Care Drugs for Improved Outcomes in Non-small Cell Lung Cancer. American Association of Pharmaceutical Scientists PharmSci 360 ConferenceOctober 22-252023OrlandoFLUSA. (Presenter: P Dogra)

• Banerjee D*Cave JCristini VWang ZDogra P. Machine Learning-Based Feature Selection to Identify the Determinants of Tumor Delivery Efficiency of Nanoparticles. 6th Annual MAPTA Summer Science SymposiumHouston Methodist Research InstituteAug 3-42023HoustonTXUSA. (Poster)

• Christiono A*Cave JCristini VWang ZDogra P. Predicting Nanoparticle Toxicity Through Machine Learning Models. 6th Annual MAPTA Summer Science SymposiumHouston Methodist Research InstituteAug 3-42023HoustonTXUSA. (Poster)

• “Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer”. 45th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. SydneyAustralia. July 24-272023. (Presenter: Z Wang)

• “Mechanistic modeling for optimal design of dissolvable microneedle-based patches for transdermal drug delivery”. 45th Annual International IEEE Engineering in Medicine and Biology Society (EMBC) ConferenceSydneyAustraliaJuly 24-272023. (Presenter: P Dogra)

• “Mechanistic model-based simulator to support clinical vaccine development”Infectious Diseases Journal ClubDivision of Infectious DiseasesHouston Methodist HospitalHoustonTXUSAJul 182023. (Presenter: P Dogra)

• “Artificial intelligence in research”Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) Seminar SeriesHouston Methodist Research InstituteHoustonTXUSAJul 172023. (Presenter: P Dogra)

• Capuani SHernandez NPaez-Mayorga JDogra PWang ZCristini VChua CYXNichols JEGrattoni A. Local Delivery of Drugs in a 3D Bioengineered Subcutaneous Niche: Biodistribution and Pharmacokinetics. 8th Nano Today Conference. April 22-252023. San DiegoCaliforniaUSA. (Presenter: Capuani S)

• Dogra PShinglot VCave JCristini VWang Z. Muliscale Mechanisic Modeling of Nanoparticle-Delivered Anti-microRNA-155 Therapy and Its Combination with Standard-of-Care Drugs in Lung Cancer. 17th U. S. National Congress on Computational MechanicsAlbuquerqueNMUSA. July 23-272023.

• Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: “The Receiver Operator Characteristic Plot: the rest of the story,” Houston Methodist Research InstituteHoustonTXUSA4/26/2023 (Presenter: JD Butner).

• “Mechanistic modeling-based first-in-human predictions of cancer remission with a novel microRNA therapy”Expanding Texas Leadership in Computational Oncology Throughout the Cancer Continuum: A CPRIT SymposiumThe University of Texas at AustinAustinTXUSAApr 202023. (Presenter: P Dogra)

• “Characterizing the systemic and brain pharmacokinetics of TSPO radioligand 11C-ER176” Department of NeurologyHouston Methodist HospitalHoustonTXUSAApr 182023. (Presenter: P Dogra)

• “Mathematical Modeling of Biological Systems for Oncology Applications: From Basic Science to Clinically Translatable Methods,” The Image Guided Cancer Therapy Research Program and the Department of Radiation OncologyMD Anderson Cancer CenterHoustonTXUSA4/13/2023 (Presenter: JD Butner).

• “Modeling and simulations to support vaccine development”Vaccine Research Center Baylor College of MedicineHoustonTXUSAApr 112023.

• “Navigating the valley of death with mathematical modeling”Dr. Mary and Ron Neal Cancer CenterHouston Methodist HospitalHoustonTXUSAFeb 92023. (Presenter: P Dogra)

• “Mathematical modeling applications in cancer treatment optimization”Gordon Research Seminar (Physical Science of Cancer)GalvestonTXUSAFeb 42023. (Presenter: P Dogra)

• “Predicting Personalized Immunotherapy Outcomes using Mathematical Biomarkers,” Houston Methodist Cancer Center Working GroupHouston Methodist Research InstituteHoustonTXUSA2/2/2023 (Presenter: JD Butner).

• “Navigating the valley of death with computational medicine”Department of Chemical and Biological Engineering Seminar SeriesUniversity of New MexicoAlbuquerqueNMUSADec 142022. (Presenter: P Dogra)

• “Navigating the valley of death with computational medicine”Centre for BioSystems Science and EngineeringIndian Institute of ScienceBengaluruIndia (Virtual)Oct 262022. (Presenter: P Dogra)

• “Crossing the valley of death with mathematical modeling and simulation”The Department of Electrical & Computer Engineering Speaker SeriesCullen College of EngineeringUniversity of HoustonHoustonTXUSA (Virtual)Sep 122022. (Presenter: P Dogra)

• Dogra PSchiavone CCaserta SWang ZCristini V. “Mathematical modeling identifies optimal dosing schedules for COVID-19 vaccines to minimize breakthrough infections”. American Association of Pharmaceutical Scientists PharmSci 360 ConferenceOctober 16-192022BostonMAUSA. (Presenter: P Dogra)

• Weill Cornell Medical CollegeCornell UNYC 2022

• Birur RMPeláez MJPuri AWang ZCristini VDogra P. “Mathematical modeling of microneedle-based transdermal drug delivery for immediate- and extended-release applications” 5th Annual MAPTA Summer Science SymposiumHouston Methodist Research InstituteAug 4-52022HoustonTXUSA. (Presenter: R Birur)

• Butner JZ WangV Cristini. “Development of Mathematical Biomarkers for Predicting Cancer Immunotherapy Outcome” The Society for Industrial and Applied Mathematics (SIAM) Conference on Life Sciences (LS22)PittsburghPennsylvaniaJuly 11-142022. (Presenter: J Butner)

• Mathematical Modeling in Drug Discovery and Development”Guest lecture at Strategic Consideration for Healthcare Informatics CourseMaster in Clinical Translation ManagementUniversity of St. ThomasHoustonTXUSA06/27/2022 – 07/01/2022. (Presenter: P Dogra)

• Nizzero SPelaez MJZhang LXu YZheng JMenegaz BADogra PButner JJordan LBPurdie CAQuinlan PRNagi CSepulveda KAOertle PAppenzeller TALoparic MChen SWang ZCristini VPlodinec MThompson AM. Spatial patterns of microenvironmental biomarkers drive long-term breast cancer outcome. American Association of Cancer Research Annual Meeting 2022. April 8-132022New OrleansLAUSA. (Presenter: S Nizzero)

• “From bench to bedside with mathematical modeling”Neuroscience Seminar SeriesThe University of Oklahoma Health Sciences CenterOklahoma CityOKUSA (Virtual)Apr 222022. (Presenter: P Dogra)

• “Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: R Coding BootcampDay 4: Importing & fitting data with built-in and user-defined equations”Houston Methodist Research InstituteHoustonTXUSAJan 242022. (Presenter: J Butner)

• “Navigating the valley of death with mathematical modeling and simulation”30th University Grants Commission-Networking Resource Center training course: New Era Technologies in Formulation Design SpaceUniversity Institute of Pharmaceutical SciencesPanjab UniversityChandigarhIndia (Virtual)Jan 192022. (Presenter: P Dogra)

• “Houston Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) presents: R Coding BootcampDay 3: Boolean logicloopsand writing functions”Houston Methodist Research InstituteHoustonTXUSAJan 172022. (Presenter: J Butner)

• Weill Cornell Medical CollegeCornell UNYC 2021

• Universita’ degli studi di Napoli “Federico II” 2021NaplesItaly

• Dompe’ PharmaL’AquilaIT 2021

• “Modeling transport phenomena in diseases to support the development of drugs and drug delivery systems”Università degli Studi di Napoli Federico IIItaly (Virtual)Dec 152021. (Presenter: P Dogra)

• “Bench to Bedside with Mathematical Modeling”Methodist Association for Postdoctoral and Trainee Affairs (MAPTA) Seminar SeriesHouston Methodist Research InstituteHoustonTXUSADec 82021. (Presenter: P Dogra)

• “Modeling and simulation in clinical translation”Guest lecture at Clinical Translation Management ProgramUniversity of St. ThomasHoustonTXUSANovember 152021. Instructors: JD ButnerP Dogra.

• Dogra PRuiz Ramírez JButner JDPeláez MJCristini VWangZ2021. A Multiscale Model to Identify Limiting Factors in Nanoparticle-Based miRNADelivery for Tumor Inhibition. Proceedings of the 2021 43nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society;2021 Oct-Nov; GuadalajaraMexico. Oral presentation (Wang Z).

• “Interfacing Mathematics and Medicine: Predicting Cancer Patient Response to Checkpoint Inhibitor Immunotherapy” The Wolfram Virtual Technology Conference 2021Wolfram AlphaOct 12-152021 (Presenter: JD Butner).

• “Modeling and Simulation of Human BiologyDiseaseand Treatment”PhysiologyBiophysics & Systems Biology Faculty Research PresentationsWeill Cornell Medical College (Virtual)Sep 212021. (Presenters: P DograJD Butner)

• Dogra P.Peláez J. M.RamirezJ.R.SinhaK.ButnerJ.D.CristiniV.Wang Z. “Investigating the role of innate immunity in the control of SARS-CoV-2 infection using a mathematical model” American Association of Pharmaceutical Scientists PharmSci 360 ConferenceOct 17-202021PhiladephiaPA. Poster presentation (Dogra P)

• DelkJ.MessinaL.TerraccianoR.FilgueiraC.WangZ.CristiniV.DograP. “Mathematical Modeling Identifies the Mechanism for Variable Intratumoral Distribution Patterns of Nanoparticles” 4th Annual MAPTA Summer Science SymposiumHouston Methodist Research InstituteAug 5-62021HoustonTXUSA. Poster presentation (Delk J.)

• Gordon Research ConferenceGalveston TX 2020

• Dompe’ PharmaL’AquilaIT 2020

• “Alzheimer’s disease progression and treatment modeling”Presentation at NeuralCODR Fall 2020 CourseHouston Methodist Research InstituteHoustonTXUSADec 142020. (Presenter: P Dogra)

• DograP.Peláez J. M.RamirezJ.R.ButnerJ.D.CristiniV.Wang Z. “Identifying parameters to improve the pharmacokinetics and tumor delivery efficiency of nanomedicine”. Special poster presentation session at the American Association of Pharmaceutical Scientists PharmSci 360 Conference. Oct 26-Nov 52020 (Virtual). Poster presentation (Dogra P)

• Physical targeting strategies for enhanced therapeutic efficacy: bridging physics and biology through rational design’. 11th Annual Symposium "Physics of Cancer"September 22 - 242020University of LeipzigGermany. Invited talk (Nizzero S)

• “Investigating the Effect of Aging on the Pharmacokinetics and Tumor Delivery of Nanomaterials using Mathematical Modeling.” 42nd Annual International IEEE Engineering in Medicine and Biology Society (EMBC) Conference. MontrealCanada. July 20-242020. Oral presentation (Z Wang)

• “Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical bio-physics”. American Physiological Society (APS) Interface of Mathematical Models and Experimental Biology: Role of the Microvasculature Conference 2019. September 11-142019. Oral presentation (Butner JD)

• Mathematical Modeling and Radiation OncologyMD Anderson Cancer CenterSeptember2019.

• Seminar“Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical biophysics”Houston Methodist Research InstituteMarch 2019.

• Gordon Research ConferencePhysical Sciences of CancerGalvestonTX (February 2019). Poster presentation. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Gordon Research SeminarPhysical Sciences of CancerGalvestonTX (February 2019). Poster presentation. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Rice University Smalley-Curl InstituteRice UniversityHoustonTX (February 2019). Selected talk. “Unraveling synergistic biological transport barriers for injectable inorganic delivery systems.” (Nizzero S)

• Workshop on silicon nanoparticlesBertinoroItaly (October 2018). Selected talk. “Mathematical design of iNPG silicon vectors for site-selective vascular targeting.” (Nizzero S)

• Lecture“Emerging mechanistic biomarkers of cancer chemo-radiation and immunotherapy from mathematical biophysics,” November2018; December 2018

• Rutgers Cancer Institute of NJJune 2018

• The Fields InstituteTorontoMay 2018

• Moffitt Cancer CenterTampaFLJune 2018

• MIT Engineering Mechanics Institute Conference (EMI)May 29th-June 1st2018. Mini-Symposium MS42 “Mechanics of growth in biology and engineering”

• “Come Alla Corte di Federico II,” (transl.: Like at the Court of King Federico II) symposium organized by the University of NaplesItaly 2018. http://www.comeallacorte.unina.it

• Symposium: MULTISCALE IN-SILICO MODELLING OF CANCER BIOPHYSICS AND THERAPY6th European Conference on Computational Mechanics and 7th European Conference on Computational Fluid DynamicsGlasgow UK 2018

• Symposium on “Imaging in Tumor Modeling,” American Association of Physicists in Medicine (AAPM) Annual Meeting (Nashville TN | July 29 - August 22018)

• Houston Methodist Research Institute2/26/2018

• Keynote presentationHouston Methodist Research Institute Center for Immunotherapeutic Transport Oncophysics (CITO) Winter Symposium on “Patient Advocacy and the Physical Sciences for Cancer Immunotherapy” February 202018

• Symposium: Ductal Carcinoma In Situ of the Breast (DCIS) @ MDAnderson – a multidisciplinary approach16th February 2018

• MD Anderson Cancer CenterDepartment of Systems Biology 2018

• Keynote speaker“International Conference and Expo on Nanotechnology,” April 19-212018DubaiUAE

• Universidade de Sao Paulo Brazil 2018Instituto de Química - Dept. Bioquímicaand Medical GenomicsAC Camargo Cancer Center

• The University of Naples Federico IIItalyDepartment of Chemical and Biomedical Engineering. November 20172018.

• CNR (National research Center)Naples Italy. November 20172018. Institute for Experimental Endocrinology and Oncology

• Division of GI CancerMoffitt Cancer CenterTampaFLOctober 20172018

• UC IrvineDept. of Mathematics September 20172018

• American Society for Radiation Oncology (ASTRO) Annual Meeting. Presidential Symposium I - The Scientific State of the ArtSan Diego Convention CenterSept 242017. “Cutting Edge Translational Science: Early Lessons from RT-Immunotherapy combinations.” (J Welsh)

• 6th International Conference on Tissue Engineering and Regenerative MedicineAugust 23-242017San Francisco. “Importance of Tissue Engineering and Regenerative Medicine for the Future of Health Care”.

• 2017 NCI PreCancer Atlas Think Tank Meeting – “Bridging genotypes to phenotypes”Discussion Session I: Technologies and Standardized MethodologiesRockvilleMD (E Koay)

• SMB Minisymposium "Agent-based modeling as a tool to represent and understand complex multi-scale biological systems". Annual Meeting of the Society for Mathematical BiologySalt Lake City 7/17-20 2017 (J Lowengrub)

• 2017 NRG Semi-Annual meeting – “Changes in mass transport as a biomarker of response in pancreatic cancer”HoustonTX (E Koay)

• Drug Discovery & Therapy World Congress 2017. "Mechanistic Patient-Specific Predictive Correlation of Tumor Drug Response with Microenvironment and Perfusion Measurements," BostonJuly 10-13th. (Invited by Renata Pasqualini)

• Gordon Research Conference on Cancer Nanotechnology - Multimodal Nano-Therapies Against Cancer. "Mechanistic Patient-Specific Predictive Correlation of Tumor Drug Response with Microenvironment and Perfusion Measurements," Mount Snow in West DoverVermont 6/18-23 2017

• Astrazeneca Immuno-Oncology Tumor Modeling Advisory Board Meeting5/12 2017The Loews Philadelphia HotelPhiladelphiaPennsylvania

• Gordon Research Conference on Physical Science of Cancer. "Patient-Specific Mechanistic Modeling of Drug Response," 02/05/2017-02/10/2017Hotel Galvez in Galveston TX

• Society for Brain Mapping & Therapeutics (SBMT) - World Brain Mapping World CongressSilicon ValleyCA 2017 (Babak Kateb).

• 2016 NCI Alliance for Pancreatic Cancer Consortia – “Imaging biomarkers of pancreatic cancer: we see themso now what?”RockvilleMD (E Koay) * Delaware Valley Drug Metabolism Discussion Group (www.dvdmdg.org) at Bucks CountyPA. September 192016. Symposium on Mechanistic PK/PD Modeling and Bio-imaging.

• 2016 MDACC Imaging Physics Research RetreatLa Torretta Lake Resort & SpaMontgomeryTx. 9/16/2016 (invited by J Hazle)

• The University of Naples Federico IIItaly. 1998200020012005200720152016.

• Mount Sinai Cancer Center. 2016.

• BostonMA. May 19-202016. “Cancer Immunotherapy Congress”.

• Systems Biology of Mammalian CellsMunichGermany. April 6-82016.

• MD Anderson Imaging Physics invited seminar. Dec 152015.

• Stanford University. 2015.

• CNR (National research Center)Naples Italy. 20152017. Institute for Experimental Endocrinology and Oncology

• Wolfgang Pauli InstituteViennaAustria. July 2-32015. Meeting on mathematics and cancer.

• King Abdulaziz UniversityDepartment of Mathematics. 2015-2016.

• University of New Mexico Cancer Center. June 262015. Joint Los Alamos National Lab/UNM Cancer Center research retreat on Biotechnology & Bioengineering in Science and Medicine.

• The University of New Mexico 50th Anniversary of the Department of Pathology. 2014.

• Sandia National LaboratoriesAlbuquerqueNM. 2014. “Mechanistic mathematical modeling to understand intra-tumoral heterogeneity”,

• University of New Mexico. August 2014. Q-Bio Summer School: guest lecture in the “Cancer Dynamics Course”.

• Q-Bio conferenceSanta FeNM. 2014. Special lecture.

• The Methodist Hospital Research InstituteHouston TX. 2014.

• The University of ArcavacataCalabriaIT. 2014-2016.

• King Abdulaziz UniversityKing Fahad Medical Research Center. 20142015 (2).

• Universita’ della Calabria – Arcavacata. November 222014. Keynote lectureEvent: “I quattro matematici italiani più influenti al mondo incontrano gli studenti calabres” (The 4 Most Influential Italian Mathematicians World-Wide Meet in Calabria).

• The University of Texas Health Science CenterHoustonTX. 2014.

• Baylor College of MedicineHoustonTX. 2014.

• ColumbusOH. 2014. Mathematical Biosciences Institute (MBI) Workshop: Metastasis and Angiogenesis.

• Los Alamos National LabsNew Mexico Consortium Workshop to launch NMC/LANL joint initiatives in Biomedical Technology. May 92013. “Diffusion properties limit effectiveness of chemotherapy in cancer”.

• 4th Annual NCI PS-OC Network Investigators’ MeetingScottsdaleAZ. April 17-192013. Keynote talk“Clinical Applications” session. “Mathematical Models of Tumor Microenvironment Transport Accurately Predict Limitations to Chemo/Radiation Delivery and Outcome”.

• Duke University. 2013.

• The University of Texas Health Science CenterSan AntonioTX. February 7-9 2013. Cancer Systems Epigenomics workshop“Diffusion properties limit effectiveness of chemotherapy in cancer”.

• Advances in Computational MechanicsSan DiegoCA. February 24-272013.

• NIH. December 2012. New Frontiers in Physical Sciences and Oncology Symposium.

• 9th Annual Computational & Theoretical Biology SymposiumBiophysical Approaches to Systems and Synthetic BiologyBiomedical EngineeringRice UniversityHoustonTX. November 30-December 12012. “Mathematical modeling of Transport Onco-Physiscs”.

• Department of Biomathematics Seminar Series: Frontiers in Systems and Integrative BiologyUCLA. November 2012. “Modeling Tumor Growth in an Evolving Organ: A Diffuse Domain Approach”. (Y.-L. Chuang).

• CTO-Physical Sciences in Oncology Annual Site VisitThe Methodist Hospital Research InstituteHouston. 2012. “Project 3: Identification of cancer biomarkers using mathematical modeling”. (E. Koay).

• CTO-Physical Sciences in Oncology Annual Site VisitThe Methodist Hospital Research InstituteHoustonTX. 2012. “Mathematical Core 1: Integrated Computational/Experimental Modeling of Mass Transport in Tumors”.

• The Methodist Hospital Research InstituteDepartment of NanomedicineHoustonTX. October 2012. “Mathematical Modeling of Drug Delivery to Tumors”. (J. Pascal)

• Center for Transport Oncophysics Seminar SeriesThe Methodist Hospital Research InstituteHoustonTX. 2012. Prediction of Tumor Growth and Treatment Response using Integrated Computational/Experimental Modeling. (H.B. Frieboes).

• University of New Mexico. 2012. The Art of Lecturing and Making Presentations. (J Pascal).

• University of New Mexico. 2012. Problem Based Learning workshop. (J Pascal).

• Physical Sciences in Oncology Annual Site VisitUniversity of Southern CaliforniaLos AngelesCA. 2012. “RP3: Integrated Computational/

• University of New Mexico Cancer Center biotechnology program meeting. 2012. Experimental Modeling of Lymphoma Growth.“Mathematical modeling of mass transport in tumors.”

• University of New Mexico Cancer Center retreat. October 272012. “Identification of cancer biomarkers using mathematical modeling.”

• University of New Mexico Center for Biomedical Engineering. September 52012. “A novelpatient-specific mathematical pathology approach for assessment of surgical volume: Application to ductal carcinoma in situ of the breast,”

• Tennessee Technological UniversityDepartment of Chemical EngineeringCookevilleTN. August 2012. “Multi-scale Modeling of Biological Systems.” (J. Pascal).

• SIAM conference on the life sciencesSan DiegoCA. August 7-102012. “A NovelPatient-Specific Physical Pathology Approach for Prediction of Tumor Growth and Chemotherapy Outcome”.

• KnoxvilleTN. July 2012. Communication in Collaboration: Leading Collaborative Groups Workshop. (J Pascal).

• Spring SchoolSaint FlourFrance. June 2012. ”Societe Francophone de Biologie Theorique”. (A. Chauviere).

• Northwestern UniversityBostonMA. June 2012. NSF Future Faculty Workshop. (J Pascal).

• University of New MexicoAlbuquerqueNM. April 2012. DAMSIG group of the SpatioTemporal Modeling Center. (A. Chauviere).

• Meeting of the American Physical SocietyBostonMA. March 2012. “Dynamic Density Functional Theory of Solid Tumor Growth: Preliminary Models.” (A. Chauviere).

• The New Mexico Center for Translational Science (CTSC)University of New Mexico. February 2012. “Mathematical Modeling of Diabetes.”. Invited presentation.

• Present Challenges of Mathematics in Oncology and Biology of Cancer: Modeling and Mathematical AnalysisMarseille (CIRMLuminy). March 2012. “A NovelPatient-Specific Mathematical Pathology Approach for Prediction of Tumor Growth.”

• University of New MexicoDepartment of Physics Colloquium. September 162011. “Multiparameter Computational Modeling of Tumor Invasion”.

• University of New MexicoSpatio-Temporal Modeling Center (STMC) External Advisory Board. August 2011. Mathematical modeling of intracellular motor-cargo dynamics. (E. Bearer).

• Conference Abstract: 5th Annual q-bio Conference on Cellular Information Processing. Santa FeNew Mexico. 2011. “A NovelPatient-Specific Mathematical Pathology Approach for Accurate Prediction of Tumor Growth”.

• Sandia/University of New Mexico Cancer Center Symposium on “Nanoparticle Human Interactions”. June 2-32011. Multiscale in-silico modeling of drug/nanoparticle transport barriers and tumor response.

• University of New Mexico Computer Science Colloquium. May 2011. “Multiparameter computational modeling of tumor invasion”.

• University of New Mexico Cancer CenterCancer Biology and Biotechnology Program Mini-Retreat. April 302011. Topic: Prediction of Breast Surgical Volumes using Computational Modeling.

• University of New MexicoMath Department. April 282011. CNTC presentationMultiparameter Computational Modeling of Tumor Invasion.

• Special Topics in Computational BiologyBIOM 505Org.: S SteinbergUNM Mathematics and Statisticsand E Bearer. March 102011. Path: Multiscale breast cancer modeling and development.

• University of New Mexico Center for Biomedical Engineering (CBME) Seminar Series. March 232011. Multiparameter Computational Modeling of Tumor Invasion.

• University of New Mexico Department of Pathology Resident Journal Club. March2011. Predicting breast tumor surgical volume using mathematical modeling.

• University of New Mexico Cancer Center Ovarian Cancer Focus Working Group. February 2011. Topic: Multiscale Modeling of Ovarian Cancer Spread

• University of New Mexico Cancer Center Breast Cancer Focus Working Group. February 242011. Topic: Prediction of Breast Surgical Volumes using Computational Modeling.

• University of Southern CaliforniaNCI PS-OC Annual Site Visit. 2010-2013.

• World Congress on Computational MechanicsSydneyAustralia. 2010. Mini-symposium on Tumor Growth Modeling. “Multiscale Multiparameter Modeling of Tumor Growth and Response to Treatment”.

• University of New MexicoSpatiotemporal Modeling Center. 2010. “Multi-parameter computational Modeling of Tumor Invasion”.

• MDACC institutional grand rounds. September 2010. Session: Innovativenoveltranslational imaging methods in breast cancer. “Novel mathematical methods for measuring breast cancer size”.

• Los Alamos National LabsCenter for Nonlinear Studies. 2010. “Multi-parameter computational Modeling of Tumor Invasion”.

• The Methodist Hospital Research InstituteNCI PS-OC Center for Transport OncophysicsAnnual Site Visit. 2010-2013.

• University of New Mexico Department of Pathology. 20102011.

• University of Southern California. 20042005200920102011.

• Scottish Universities Life Sciences Alliance Annual SymposiumUniversity of St AndrewsScotlandUK. 2010. “Multiscale Multi-parameter Computational Modeling of Tumor Growth”.

• Physical Science in Oncology Centers (NIH-National Cancer Institute) first all investigator annual meetingMaryland. April 2-52010. “Multiparameter Multiscale Physical Modeling of Delivery of Nanotherapeutics to Tumors and Tumor Response”.

• ASME 2010 First Global Congress on NanoEngineering for Medicine and BiologyHouston TX. 2010. Symposium on Multiscale Modeling in Biological Systems. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• European Union Marie Curie Conferences and Training Course Program. 2010.

• Rutgers University. 2010

• The University of Texas Health Science Center at Houston200620092010.

• Methodist HospitalTexas Medical CenterHoustonTX. 2009. “Multi-parameter multiscale computational Modeling of Tumor Growth and Response to Treatment”.

• Biocomplexity X Conference on Quantitative Tissue Biology and Virtual TissuesIndiana University. October 27- November 12009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• Cellular Behavior Ontology WorkshopNational Cancer InstituteBethesda. 2009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• Accelerate Brain Cancer Cure Annual Scientific RetreatSausalitoCA. October 1-22009. “Computer Simulation of Glioma Growth and Response to Treatment”.

• NCI/EU 1st Transatlantic Workshop on virtual tissues. 2009. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”.

• European Conference on Complex SystemsWarwickUnited Kingdom. September 21-252009. Keynote speaker.

• Oberwolfach Workshop on Mathematical Biology. May 3-9 2009.

• International Academy of Nano Medicine annual meeting. 2009.

• The University of Texas School of Health Information Sciences Center at HoustonTX. 2009. From the Lab to the Marketplace: Highlights in Entrepreneurial Research. “Capitalizing on Computation – New Frontiers in DiagnosticsTreatmentsApproaches toward Cures”. Keynote Lecture.

• University of DundeeUnited Kingdom200620082009. Plenary TalkCancer Modeling WorkshopEU Marie Curie Conferences and Training Course Program.

• The University of Minnesota. 1998200020012002200420072009.

• Vanderbilt University. 2008.

• The University of Texas Health Science Center at San Antonio. 2008. “Virtual Cancer- Reducing Cancer Recurrence and Progression: New Paradigms in Cancer Diagnostics and Treatment Through Computational Modeling of Biological Systems”. Keynote Lecture.

• The University of Texas Health Science Center at HoustonTX. 2008. The World’s Best: The Willerson Years- 2001-2008 celebrating the progress of the health science center during the presidency of James T. WillersonMD.

• The University of Texas at Austin’s Institute for Computational Engineering & Sciences (ICES)2008

• The University of Texas at Austin2008. “Multi-scale Modeling and Non-Linear Simulation of Vascular Tumor Growth”

• The University of Houston2008

• University of California Cedars-Sinai Medical Center2008. “Multi-parameter Computational Modeling of Tumor Invasion”

• University of California IrvineSymposium on Mathematical Systems Biology2008. “Multi-parameter Computational Modeling of Tumor Growth and Drug Response”

• Society of Mathematical Biology 2008. “Non-linear Simulation of Tumor NecrosisNeo-vascularization and Tissue Invasion”

• NCI/EU 1st Transatlantic Workshop on multi-scale cancer modelingBrussels 2008. “Multi-parameter Computational Modeling of Tumor Growth and Response to Treatment”

• Gordon Research Conference on Theoretical Biology and Biomathematics2008. “Modeling of ductal carcinoma in situ: application to patient-specific breast cancer modeling”.

• Pennsylvania State University. 19992008.

• MD Anderson Cancer Center Grand RoundsHouston20072010. “Multi-parameter computational Modeling of Tumor Invasion”

• MD Anderson Cancer CenterHouston 200720082009. “Computer Simulation of Glioma Growth and Morphology”

• Alliance for Nanohealth2007.

• Roche2007.

• 9th U.S. National Congress on Computational Mechanics2007. “Multi-DisciplinaryMulti-scale In-Silico Models Connecting PhenotypeMorphology and Growth”.

• Rice University Keck Seminar Series2007. “Multi-disciplinarymulti-scale In-Silico Models Connecting PhenotypeMorphology and Growth”.

• Asia UniversityTaiwan2007.

• International Brain Mapping and Intra-operative Surgical Planning Society Annual Meeting. 200420052007.

• American Academy of Nanomedicine2006. “Mathematical Modeling of Cancer Progression and Response to chemotherapy: Towards the Development of a Multi-scale Computer Simulator”.

• University of California Irvine. 200120022003200420052006.

• New Jersey Institute of Technology. 2005.

• University of Arizona. 20042005.

• University of California Los Angeles 200320042005

• The University of NottinghamUnited Kingdom. 2004.

• Stanford University2004. “Non-linear Simulation of Tumor Growth”

• California State UniversityNorthridge. 2004.

• Biofluid SymposiumCaltech2003. “Computer Modeling of Red Blood Cell Rheology in the Micro-Circulation,”

• National Cancer Institute. 2002. “Non-linear Simulation of Tumor Growth”

• AMO-Advanced Medical Optics. 2002.

• University of California Davis. 2002.

• Medtronic. 20012002.

• Virginia Tech. 2000.

• Texas Tech University. 2000.

• PPG Industries. 2000.

• Novartis Pharmaceutics. 2000.

• University of Technology at CompiegneFrance. 1999.

• Harvard University. 1998.

• Yale University. 1998.

Invention Disclosures

• P DograZ WangV CristiniY-L ChuangB WilsonEL BearerCJ Brinker. Invention No. 2018-051“Multiscale mathematical model to study nanomedicine delivery to solid tumors,” STC Ref. no. 2018-051University of New Mexico 2018.

• J FreyerA ShreveV Cristini. Invention No. 2013-086“A 3D Tissue Model for Spatially Correlated Analysis of BiochemicalPhysiological and Metabolic Microenvironments,” STC Ref. no. 2013-086University of New Mexico 2013.

• E KoayV CristiniJ FlemingP BhosaleC CraneH ShenM FerrariInvention No. 2013-031titled “System and methods for quantitatively describing biophysical markers.” University of New MexicoUT HealthMD Anderson Cancer CenterUS

Poetry and Other Writings

Il mattino

Forse perché della vera realtà
tu sei ombra fedelea me sì
dolce mi sorprendimattino
ancor giovane e scuro.

Quando ti corteggian d’ansia piene
le coseche dell’essere ancor
voglion sentir la pena;
e quando nell’incerto aere ancor
disfattiframmenti di esperienze
tu mi menimescolati nell’onde
dell'universo tenebrose e lunghe;
sempre scendi caroe le segrete
vie del mio cor soavemente tieni.

Ma poi l’occhio dei miei pensier si apre:
e ritornan dal nulla senza tempo
la scrivania amata e l’altre cose
familiari; e intanto fugge
la verità profonda;
e si compongon senza lei
le illusioni delle cure
onde meco ognun si strugge.

E mentre io sento ancora la tua pacedorme quello spirto guerrier
ch'entro mi rugge.

Un sogno di ombre

Nel tempo pieno
di dolcezza inquieta,
quando nel libro della vita,
con mani esitanti,
ancor poche pagin’io voltavo;

in quell’ora della notte
sì tarda e buia,
prima del mattino,
che la familiare realtà nostra
quasi si frantuma
nell’anima che dorme;

come l’aere
agitato e minaccioso
in grandi altezze scuote
un piccolo aquilonecosì
un sogno gettò la mente mia:

sì come in folla persona si vede,
e come in voce voce si
discernequando una è ferma,
e l’altra va e riede,
io stupito con terrore seguitavo
ombre sole nella stanza oscura:
il vuoto intorno a me;
e nulla all’ombre
dando formanon io persino;
e non cosa pesante ne’ parete.

Poi di colpocome
al risveglio del padrone
distratti servitoriinnumerabili
le indaffarate particelle
si lanciaron tra l’imposte; e
al posto giusto ritornaron
la lampadal’armadio
e la scrivania amata,
compagna de’ miei faticosi studi:
incomincio’
l’incantesimo del giorno.

Ma fu troppo tardi.
E col mio segreto
me ne andai zitto,
tra gli uomini che non vedono
per troppa luce
che nasconde l’ombre.

Il Paradiso

La gattina che zompetta intorno
intornodentro’l cespuglio amato
era posata a nutrir li dolci nati;
ma già previene il tempo
della nova famee va cercando
per trovar lo cibo ancora onde li pasca;
in che gravi labor le sono aggrati
per legge universal che non perdona!

Scende la sera intanto. E a gruppetti,
fuor dalle biblioteche e dalle aule
si ritrova la gioventùe mira ed
è miratae’n cor s’allegradiscorrendo
del giorno che muore e quell’altro
che viene novità promette.
Mi va così il pensier ai nostri padri
che nella primavera della vitae
del secolo buio che già è passato,
così di vita lor il tempo ignoto
ancor che fosse tardi immaginaron.
Tornata e’ la stagion più bellama quell’anime nopiù non ritornano,
fuor se nei sogni il cor
ombre care mi scuotono.

Ma quando sento il pianto dei suoi nati
io penso a tutte quante le innumerevoli
generazioni del passatoe a questa
miacui oggi è dato vedere il giorno
e passeggiar in rumorosi viali.
Allora io un altro mondo m’immagino
diverso; e mentre quasi vedotra
colli e boschi e calme acquepiù felici
genti e famiglie di animali un più
benigno sole irraggiare: in questo
vaneggiar la mente mia si perde;
e al fin sfamatotra quei natinel
grembo della madre mi addormento.

A una giovane morta

Gettando la lenza
nello stagno de’ ricordi,
che taglia ahimè per acque
immobili e scuret’ho ritrovato
anima fragileimmagine cara
d’infinita bontà.

Il tuo amor per lo mondo,
più forte di me,
fu come l’umile albero
chetra tempeste e siccità
sempr’al ciel puntando,
schivo del rumor del mondo,
ma conscio e sicuro del proprio valorguarda passar della storia
le stagione in fin muorecon coraggio
in piedi restandoal contrario di noi.

Derubata del giorno,
che la sorte ci die’
tropp’ancor che sera fosse,
impronta sol pur rimani
silenziosa e forte.

Ne’ sogni della notte
ombra frequente e amata
due figlie tue t’abbraccian;
l’occhi lor di giovani donne
ancor ti portano il sol.

Alla luna

Cara luna gentiletu assomigli
al grigio deserto della mente mia
che splende sulla notte del mondo.

Da quei luoghia tutte le genti
familiarionnipresenti eppur
dal mondo abbandonati;
ove se non di dolor,
abusi e violenza cieca,
malanni ed abbandono,
muor a poco a poco,
non solo il vecchio
ma ancor di più il bambino
per lo cibo che manca,
e piange lacrime morendo
che pesan di più che tutta la terra;

lor con te via portio luna
quando tramonti e quando sorgi
come scaglia dopo scaglia
scolpite dall’artista chelevando,
della materia rivela vera forma;
infino ai fortunati pochiche
un amor e qualcos’hanno!
A lor l’amate cose e i dolci cari
pur togliche perdutiancor stanno:
impronte fisse nell’anima
com’in tua polvere antica.

Forse nelle tue vaste valli silenti
si raggruppano infine,
a far la guardia all’eterno,
vecchigiovani e infanti
nei reggimenti come’l mondo antichi
di quel temuto general
che mai un soldato perse?

E sulle secche tue spiagge,
ridotte in sabbia fina da mani
di roccia gittate nell’oscurità:
s’abbracceranno ancora,
quando nessuno vede,
quelli che se ne sono andati?

Non so: però sul tuo corrugato
volto anticocon vetri e strumenti
che la faticosa ragion ci die’,
crateri solo deserti io vedo uscir
dal limitar dell’ombra.

La luna e la stellina

Tu la luna seied io
della sera
la stella piccolina.

Sorgiamo insieme
quando’l giorno tramonta;
e’l mondo tutto si scolora.
Poi nella notte t’inseguo
che le cose ci nasconde.

Nell’oscurità io spingo
i bracci esili di luce:
ma mai io ti raggiungo;
solo mirarti posso
di lontano.

Society

• https://youtu.be/mfIlqoNcpDs?si=sVbtNROZTyHIFmC4

References